

CURRICULUM VITAE

Prof. Aleix Prat

Jefe del servicio de Oncología Médica
Hospital Clínic de Barcelona

Profesor Titular
Universitat de Barcelona

Jefe de grupo “Genómica Translacional y Terapias dirigidas a Tumores sólidos”
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)



ÍNDICE

Presentación

Datos personales

Formación

Posiciones actuales

Actividades de carácter científico o profesional

Distinciones y Premios

Patentes

Sociedades Médicas y Científicas

Consejos Editoriales y asesor de revistas

Conferencias

Publicaciones

Participación em congresos

Actividad Docente

Dirrección de tesis

Libros y Capítulos

Experiencia en técnicas de laboratório

Investigador principal (IP) y Co-IP en multi-centro y/o ensayos clínicos internacionales

Presentación

Desde el 2014 soy Jefe del Servicio de Oncología Médica del Hospital Clínic de Barcelona (España), Profesor titular de la *Universitat de Barcelona* y lidero mi propio Laboratorio de « Genómica Traslacional y Terapias Dirigidas a Tumores Sólidos » en IDIBAPS. Un 25% de mi tiempo lo dedico a la actividad asistencial, la educación y la formación, y el 75% restante a la investigación.

Médico Oncólogo con una alta formación médica, como así lo demuestra la posición número 17 de los 8,000 presentados en el MIR, obtenido en 2003 y los 15 artículos publicados en los que participé activamente durante mi residencia en oncología médica en el Hospital Vall d'Hebron (España), bajo la supervisión del Dr. Josep Baselga (2004-2008).

Como coordinador científico de la Junta Científica del Grupo Español de Investigación Cooperativa del Cáncer de Mama (SOLTI) que realiza ensayos clínicos de excelencia en oncología, fui nombrado miembro de la Junta Ejecutiva de The Breast International Group (BIG) en 2018, una organización internacional sin ánimo de lucro que incluye más de 56 grupos cooperativos de todo el mundo, más de 10,000 expertos y está vinculada a más de 3,000 hospitales. Desde mayo de 2019 abandoné la coordinación científica para asumir la Presidencia de la Junta de Gobierno de SOLTI. Además, soy el Jefe de la Unidad de cancer de mama en IOB-Quirón Salud así como Directivo y co-fundador de la reciente creada spin-off Reveal Genomics.

A lo largo de mi carrera obtuve un prestigio mundial como investigador científico en el campo de la genómica del cáncer de mama y el desarrollo de biomarcadores. Mi interés en el campo genómico creció durante mi beca y después de completar el Master en Oncología Molecular en el Centro Nacional de Investigación del Cáncer, CNIO (Madrid, 2008). Durante mi beca en Vall d'Hebron, publiqué 15 artículos, incluyendo 2 estudios publicados en *Annals of Oncology* (IF: 7.040), donde establecí el valor de un biomarcador conocido como CA-125 para predecir el riesgo de recurrencia tumoral en pacientes con cáncer de ovario. En 2008, inicié mi formación post-doctoral (2008-2012) en el Centro Integral de Cáncer Lineberger (Universidad de Carolina del Norte en Chapel Hill, EE. UU.), concretamente en el Laboratorio del Prof. Charles M. Perou, un investigador traslacional de mama de renombre mundial. Durante esta experiencia postdoctoral, descubrí y caractericé un nuevo subtipo molecular de cáncer de seno, conocido como Claudin-low (Prat et al. *Breast Cancer Research* 2010; Citas: 1,518). Además, participé en el proyecto de cáncer de mama The Cancer Genome Atlas (*Nature* 2012; Citas: 4,661), que es el estudio de caracterización molecular más importante que se haya realizado en cáncer de mama.

Desde 2007, he participado activamente en un total de 215 publicaciones (46 como primer autor y 35 como autor principal. 60 † autor correspondiente) con un factor de impacto total de 2.276.606 y un Índice-H de 59 con 21.349 citas y 160 comunicaciones en congresos internacionales. He sido invitado a dar conferencias en todo el mundo como experto en genómica del cáncer de mama. En 2013, presenté la tesis doctoral en la Universidad Autónoma de Barcelona (UAB) titulada "Caracterización molecular de los subtipos intrínsecos de cáncer de mama "(calificación cum laude), por la cual la UAB me otorgó en 2015, el Premio Extraordinario de Doctorado en el campo de la Medicina. También recibí el Premio Internacional de Investigación del Cáncer de Mama (Padova, Italia) por mis descubrimientos científicos sobre la caracterización y el valor clínico de los subtipos intrínsecos.

He recibido financiación competitiva de fuentes nacionales e internacionales. Por ejemplo, gracias a la beca Susan Komen Career Catalyst (\$ 450,000), dirigí el ensayo clínico PAMELA como investigador principal, y mi laboratorio realizó todos los análisis científicos correlativos. Los principales resultados fueron presentados en diciembre de 2016 en una de las Sesiones plenarias de SABCS donde fui invitado y publicados en 2017 (Llombart-Cussac et al *Lancet Oncol* 2017; IF: 26.509; Citas 32). Uno de los Premios mas importantes recibidos fué el otorgado por la Fundación de Investigación del Cáncer de Mama-AACR *Career Development Awards* para la Investigación Traslacional del Cáncer de Mama (150,000 USD) que me permitirá liderar el proyecto "Tailoring systemic treatment of Luminal B breast cancer".

Formo parte del *Guardant Health Clinical Advisory Committee*, una de las principales compañías actuales focalizadas en el análisis de la biopsia líquida como herramienta para detectar y monitorizar el cáncer, tanto en sus formas tempranas como avanzadas. También soy miembro de la Junta Consultora de Future and Emerging Technologies (FET) Open (Horizon 2020), un programa para apoyar la investigación

científica y tecnológica basada en ideas novedosas sobre nuevas tecnologías que desafíen los paradigmas actuales. Por otro lado, soy codirector del Comité científico de eHAP – eHealth Advanced Program, plan que tiene como objetivo establecer un sistema de eSalud interoperable en Europa proporcionando una hoja de ruta para la colaboración de los Estados miembros de la UE. Desde el año 2021 formo parte del Comité Científico de Oncología de Precisión de Catalunya perteneciente al CatSalut y desde 2019 soy miembro del consorcio Breast Cancer GeoMx de la empresa tecnológica Nanostring. Formo parte del comité científico consultor de diversas empresas biotecnológicas/farmacéuticas como Oncolytics Biotech, Lilly o Daiichi Sankyo.

Como profesor titular de la Universidad de Barcelona, estoy particularmente interesado en la educación y la formación. En 2008, publiqué un libro de autoevaluación para becarios de oncología médica y médicos conocidos como "OncoQuest". Este libro fue un éxito inmediato con más de 1,000 copias vendidas hasta la fecha. He dirigido 5 tesis doctorales y actualmente superviso las tesis de 3 estudiantes.

Mis áreas de interés son el diagnóstico y el tratamiento del cáncer de mama y los subtipos de cáncer de mama intrínseco (Luminal A, Luminal B, enriquecido con HER2 y de tipo basal). Mi investigación líder se basa en el uso de datos genómicos para guiar el diseño de ensayos clínicos y el desarrollo de biomarcadores con el fin de identificar tratamientos más óptimos para pacientes con cáncer. Específicamente, sus principales líneas estratégicas son: ayudar a implementar y desarrollar plataformas genómicas aplicables en la práctica clínica diaria; Participar en estudios prospectivos y retrospectivos donde los científicos analizaron genómica de tumores; Validar biomarcadores y/o pronósticos genómicos predictivos en ensayos clínicos y evaluar los datos de expresión génica como una herramienta para identificar nuevos mecanismos de sensibilidad/resistencia a los medicamentos y/o nuevos objetivos terapéuticos como inmunoterapia.

Nombre: Aleix PRAT
Fecha de Nacimiento: 1/03/1979
Lugar: Barcelona (España)
Nacionalidad: Español
Dirección Profesional: Servicio de Oncología Médica,
Instituto Clínic de
Enfermedades Hematológicas y Oncológicas
(ICMHO), www.hospitalclinic.org
Hospital Clínic de Barcelona, Calle Villarroel 170
08036-Barcelona, España

Teléfono: (+34) 93 227 54 00 Ext. 2203
Movil: (+34) 646 847 709
E-mail: alprat@clinic.cat



Orcid: [0000-0003-2377-540X](https://orcid.org/0000-0003-2377-540X)
Scopus Author ID: 22980672400
Researcher ID: P-8561-2014

Formación

PhD 2013. Doctor en Medicina. "Magna Cum Laude". *Universitat Autònoma de Barcelona*, España.
DEA 2008. Diploma de Estudios Avanzados (DEA). *Universitat Autònoma de Barcelona (UAB)*, España.
Especialización 2008. Oncología Médica. *Ministerio de Sanidad y Consumo*. España.
Residencia Médica 2004-2008. Hospital Universitario de la Vall d'Hebron, Servicio de Oncología Médica. *Universitat Autònoma*. Director: Dr. José Baselga. España.
Exámen 2004. USMLE. STEP 2 Clinical Knowledge (CK) Score: 99.
Exámen 2004. Examen de acceso a la Residencia (MIR) del Ministerio de Sanidad y Consumo; Posición obtenida: 7 de 8,000 candidatos (aprox). Global: 17.
Licencia Médica 2003. Barcelona, Licencia Médica Num. # 38,578.
Exámen 2002. United States Medical Licensing Examination (USMLE). Grado 1 Nota: 97.
MD 1997-2003. Facultad de Medicina- *Universitat de Barcelona (UB)*. BCN, España.

Posiciones actuales

2021 Director de la Cátedra de Innovación en Oncología de Precisión. *Universitat de Barcelona (UB)*.
2020 Miembro del Consejo Científico Asesor del "Programa de Oncología de Precisión en el Sistema Sanitario público de Cataluña". Plan Director de Oncología. *Servei Català de la Salut*. Cataluña, España.
2020 Director Científico y Co-fundador de la *spin-off* Reveal Genomics, SL.
2020 Director de la Unidad de cáncer de mama de IOB-Quirón salud. Instituto Oncológico IOB. Barcelona, España.
2020 Profesor Titular Médico. Universidad de Barcelona (UB), Facultad de Medicina, Barcelona, España.
2019 Miembro del Consejo Científico Asesor (SAB). Peptomyc S.L. Compañía enfocada al desarrollo de una nueva generación de péptidos penetrantes de células (CPP) dirigidos a la oncoproteína Myc para el tratamiento del cáncer. Barcelona, España.
2019 Presidente de la Junta Directiva de SOLTI. Grupo Cooperativo Español para la Investigación del Cáncer de Mama. Barcelona, España.
2019 Director del Master de patología mamaria. Sinología. Facultad de Medicina y Ciencias de la Salud. Universidad de Barcelona (UB).

- 2018 Miembro de la Junta provincial de la Asociación Española contra el Cáncer (AECC). Barcelona, España.
- 2017 Coordinador de la asignatura optativa de Oncología Médica y radioterapia. Grado de medicina. Facultat de Medicina y ciencias de la Salud. Universidad de Barcelona (UB). Barcelona, España.
- 2017-2021 Miembro del Comité ejecutivo de *The Breast International Group (BIG)*.
- 2015 Co-Responsable de l'Àrea de Investigación de Oncología y Hematología. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Hospital Clínic de Barcelona. Barcelona, España.
- 2014 Jefe del Servicio de Oncología Médica. Hospital Clínic de Barcelona, Barcelona, España.
- 2014 Jefe del Grupo de Genómica Translacional y Terapias Dirigidas a Tumores Sólidos. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Hospital Clínic de Barcelona. Barcelona, España.
- 2014 Profesor Asociado Médico. Universidad de Barcelona (UB), Facultad de Medicina, Barcelona, España.
- 2014 Evaluador de proyectos de investigación. Agencia Nacional de Evaluación y Prospectiva, ANEP (Ministerio Español de Economía y Competitividad).

Actividades de carácter científico o profesional

- 2015 - 2019 Coordinador Científico de la Junta Directiva de SOLTI. Grupo Cooperativo Español para la Investigación del Cáncer de Mama. Barcelona, España.
- 2014 - 2018 Coordinador de Investigación del Instituto Clínic de Enfermedades Hematológicas y Oncológicas (ICMHO). Hospital Clínic de Barcelona, Barcelona, España.
- 2012 - 2017 Jefe del Grupo de Genómica Translacional. Instituto de Oncología de la Vall d'Hebron (VHIO). Hospital Universitari de la Vall d'Hebron, Barcelona, España.
- 2012 - 2014 Facultativo especialista. Hospital Universitari de la Vall d'Hebron, Barcelona, España.
- 2011 - 2013 Programa PhD en medicina, Universitat Autònoma de Barcelona (UAB), España.
Director de tesis: Dr. Joan Albanell Mestres (Hospital del Mar, Barcelona).
- 2010 - 2012 Investigador a tiempo parcial, Instituto de Oncología del Valle de Hebron (VHIO). Hospital Universitario de la Vall d'Hebron, Barcelona, España.
- 2008 - 2012 Investigador PhD, Lineberger Comprehensive Cancer Center [Charles M. Perou Laboratory]. University of North Carolina, NC, USA.
- 2006 - 2008 Master en Oncología Molecular. 3ª Edición. Centro Nacional de Investigaciones Oncológicas (CNIO). Escuela Europea de Oncología. Madrid, España. Nota: Matrícula de Honor.
- 2006 - 2006 Workshop in Molecular Biology in Clinical Oncology. Workshop Organized by the American Association for Cancer Research (AACR). Given Institute of Colorado University, Aspen, CO, USA.
- 2004 - 2008 Beca en Investigación, Servicio de Oncología Médica. Director del Programa: José Baselga, MD. Hospital Universitario de la Vall d'Hebron, Universitat Autònoma de Barcelona (UAB). España.
- 2002 - 2002 Clinical Clerkship in Hematology/Oncology. Mayo Clinic, Rochester, MN, USA. Grade: Honors.

Distinciones y Premios: Personales

- 2021 **CRIS Research Excellence Programmes 2021.** Dissecting and overcoming mechanisms of resistance to CDK4/6 inhibition in advanced hormone receptor-positive/HER2-Negative HER2-Enriched breast cancer. (1,249,999.70€)
- 2021 **XXI Edición de las Becas FERO en Investigación Oncológica Traslacional.** "Identification of biomarkers to immunotherapy in hormone receptor-positive/HER2-negative breast cancer". (80.000€).
- 2020 **ASEICA Young Investigator Award 2020.** Reconocimiento al esfuerzo de los investigadores españoles en los avances contra el cáncer. ASEICA.
- 2020 **Fundació La Marató TV3.** Identificación de mecanismos de respuesta a los inhibidores de CDK4/6 en cancer de mama receptor hormonal positivo. 400.000€ (150.000€ IDIBAPS).
- 2020 **Horizon 2020 Research and Innovation Framework Programme.** 952103-EuCanImage. A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology. (467.500€).
- 2020 **Horizon 2020 Research and Innovation Framework Programme.** RESCUER: Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer. (400.000€).
- 2020 **I Premio M. Chiara Giorgetti.** Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama. (50.000€).
- 2019 **Ayudas Fundación Científica Asociación Española Contra el Cáncer (AECC) a Proyectos de Investigación en cáncer, Grupos coordinados.** Treatment of Breast cancer with adoptive transfer of CD8-Positive/PD1-Positive tumour-Infiltrating Lymphocytes (TILS). (442.062,28 €).
- 2019 **Instituto de Salud Carlos III – FIS (Ministerio de Ciencia e Innovación-MICINN).** PI19/01846. Identificación de nuevas dianas terapéuticas para el tratamiento del fenotipo molecular HER2-enriched en cáncer de mama receptor hormonal positivo. (177.265€).
- 2019 **Premio al mejor poster presentado ESMO Breast Cancer.** "ERBB2 mRNA as a predictor of response to antiHER2 antibodydrug conjugates in breast cancer". ESMO Breast Cancer 2019.
- 2019 **Premio al artículo publicado más citado en 2017.** Cancer Research by American Association for Cancer Research (AACR).
- 2019 **Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research.** "Tailoring systemic treatment of Luminal B breast cancer". (150.000 USD).
- 2019 **Premio "La Vanguardia de la ciencia"** por el proyecto "La Inmunoterapia del càncer" La Vanguardia y la Fundació Catalunya-La Pedrera.
- 2019 **Ayudas de la Fundación Merck Salud.** Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched. (30.000€).
- 2019 **Beca "Dolna Compromiso"** en cancer de mama. Laboratorios Adamed. (13.920€)
- 2018 **Breast Cancer Now Catalyst Grant.** "Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer". (320.878€).
- 2018 **Terapia de amigos - Premios Fundación Quirónsalud a la Investigación en cáncer de**

- mama.** Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk (21.000€).
- 2018 **XV Convocatoria de Ayudas a la Investigación en Salud de la Fundación Mutua Madrileña.** Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS. (120.000€).
- 2017 **Reconocimiento como grupo de investigación por la Generalitat de Catalunya (SGR 2017-2019).** AGAUR_SGR17: 01554. Translational Genomics and Targeted Therapeutics in Solid Tumors. Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS).
- 2017 **Premio Jóvenes Investigadores 2017.** Categoría de Oncología. Fundación AstraZeneca. (20.000€)
- 2017 **Acreditación de Investigación avanzada** (catedrático) por la "Agencia per a la Qualitat del Sistema Universitari de Catalunya (AQU)".
- 2016 **Instituto de Salud Carlos III – FIS.** (Ministerio de Ciencia y Innovación-MICINN). Dual Her2 Blockade without Chemotheray in early Her2+ Breast Cancer. (180.000€)
- 2015 **Fundación Eugenio Rodríguez Pascual – FERP.** Ayudas de Investigación Biomédica 2015. "Construcción y evaluación de linfocitos T con un receptor quimérico antigénico (CART) anti-HER2 para el tratamiento de tumores sólidos HER2-positivos". (18.000€).
- 2015 **Premio Extraordinario de Doctorado (2013).** *Universitat Autònoma de Barcelona.* UAB.
- 2014 Sociedad Española de Oncología Médica (SEOM) Beca. Proyectos de investigación en salud (€40.000).
- 2013 **Susan G. Komen Career Catalyst Grant** (\$450.000).
- 2013 Programa Estatal de Fomento de la Investigación Científica y Tecnológica. Proyectos de investigación en salud. Validación de un predictor genómico en Cancer de mama triple negativo (€205.000).
- 2012 Beca ROCHE en Investigación Oncológica (€77.000).
- 2012 Travel Grant from IMPAKT 2012 Breast Cancer Meeting.
- 2012 Premio Internacional de Investigación en Cáncer de mama. Accademia Nazionale di Medicina. Padova, Italia.
- 2011 Nominated for BioMed Central Open Data Award.
- 2011 Merit Award. American Society of Clinical Oncology (ASCO) Annual Meeting.
- 2011 Beca en investigación traslacional de la Sociedad Española de Oncología Médica (SEOM) (€70.000).
- 2010 Premio al estudiante. American Association for Cancer Research (AACR).
- 2009 Premio al mérito. American Society of Clinical Oncology (ASCO) Annual Meeting
- 2003 Primer Premio. Medical Graduate Academy Award ('Curso Intensivo MIR Asturias'). Oviedo, España. 1,200 candidatos

Distinciones y Premios: Institucionales

- 2021 World's Best Specialized Hospitals in Oncology 2121 by Newsweek. Based on Global Board of medicals experts: recommendations overall reputation Score.

Patentes

- **Title:** Methods for breast cancer treatment and prediction of therapeutic response.
Application No.: WO/2021/232057
Country priority: USA, Europa, Asia, Africa.
Holder entity: SCHIFF, Rachel; RIMAWI, Mothaffar; VEERARAGHAVAN, Jamunarani; OSBORNE, C. Kent; GUTIERREZ, Carolina; HILSENBECK, Susan; PRAT, Aleix; REIS-FILHO, Jorge.
Extension: [PCT/US2021/070543](#)
- **Título:** HER2DX breast cancer
Num. De solicitud: 20 382 679.7
Pais prioritario: Europa
Fecha de prioridad: 2020
Inventores: Aleix Prat
Extensión: pendiente
- **Título:** HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.
Num. de solicitud.: PCT/EP2016/080056
Pais prioritario: Europe.
Fecha de prioridad: 7 December 2016.
Inventores: Aleix Prat, Javier Cortés, Antonio Cussac.
Extensión: PCT/EP2016/080056.
- **Título:** CES: un índice quimioendocrino basado en PAM50 para el cáncer de mama con receptores hormonales positivos con un riesgo intermedio de recidiva.
Num. de solicitud: [WO/2018/096191](#)
Pais prioritari Europa.
Fecha de prioridad: 28 noviembre, 2016
Inventores: PRAT, Aleix; PEROU, Charles M. y EMILIO, Alba.
Extensión: PCT/ES2017/000148.

Sociedades Médicas y Científicas

- | | |
|---------|---|
| 2018 | ASEICA. Asociación Española de Investigación sobre el Cáncer. |
| 2020-21 | Miembro de la Junta Directiva. |
| 2018 | AECC. Miembro del Consejo Provincial de la Junta Provincial de Barcelona de la Asociación Española Contra el Cáncer. |
| 2016 | 1st Annual European Congress on Immunotherapies in Cancer™. European Planning Committee and faculty. Immuno-oncology in the Clinic-II. Barcelona, España. http://www.gotoper.com/conferences/ecic/meetings/1st-annual-european-congress-on-immunotherapies-in-cancer |
| 2012 | AIBCC. Miembro del Comité Científico de la reunion annual “The Professor Advanced International Breast Cancer Course” (AIBCC - https://meettheprofessor.acmed.org/). Accademia Nazionale di Medicine. University of Padua. Padua. Italia. |
| 2008 | ASCO. Miembro de American Society of Clinical Oncology. (ASCO - www.asco.org). ASCO ID number: 85963. |
| 2008 | ESMO. Membership of European Society of Medical Oncology. (ESMO - www.esmo.org). ESMO ID number: 27141. <ul style="list-style-type: none">– ESMO 2021 Breast cancer, early stage Scientific Sub-Committee.– ESMO 2019 Breast cancer, early stage Scientific Sub-Committee |
| 2006 | AACR. Miembro de American Association for Cancer Research (AACR - www.aacr.org). AACR ID number: 129163. |
| 2005 | SEOM. Miembro de la Sociedad Española de Oncología Médica (SEOM - www.seom.org). |

- Miembro del Comité de becas desde 2012.

Consejos Editoriales y asesor de revistas

- Frontiers in Cancer Genetics. Member of the Editorial Board.
- Clinical Cancer Research. *Ad-hoc* reviewer.
- Lancet Oncology. *Ad-hoc* reviewer.
- Annals of Oncology. *Ad-hoc* reviewer.
- Breast Cancer Research. *Ad-hoc* reviewer.
- British Journal of Cancer. *Ad-hoc* reviewer.
- Breast Cancer Research and Treatment. *Ad-hoc* reviewer.
- Disease Markers. *Ad-hoc* reviewer.
- Clinical Breast Cancer. *Ad-hoc* reviewer.
- Cancer Research. *Ad-hoc* reviewer.
- The Breast. *Ad-hoc* reviewer.
- Cancer Treatment Reviews. *Ad-hoc reviewer*.
- The Oncologist. *Ad-hoc reviewer*.
- F1000Prime. Experto asesor. (2017)

Conferencias

- 02/22 **SPCC – ABC6 Conference**, “Discordant results between primary and metastatic sites”. Virtual.
- 02/22 **ESMO Targeted Anticancer Therapies Congress 2022 Industry Satellite Symposium**. From bench to bedside and back to bench: The evolution of antibody–drug conjugates in the treatment of cancer and Round-table discussion: Recent advances in ADC technology. Virtual.
- 01/22 **Jornada C17 d’actualització en Tumors urològics**. “Presentació i introducció”. Virtual. Servei Oncologia Mèdica Hospital Clínic de Barcelona. España.
- 01/22 **Seminario INCLIVA 2022**. “Oncología de Precisión en Cáncer de Mama: Nuevas Herramientas”. IIS INCLIVA. Valencia.
- 12/21 **Sesión del Servicio de Farmacología Clínica**. “Medicina de precisión en cáncer de mama”. Hospital Clínic de Barcelona. Virtual.
- 12/21 **IV Jornada Científica del Área del Medicamento**. “Medicina de precisión en cáncer de mama”. Virtual. Hospital Clínic de Barcelona. Barcelona, España. **I Jornades d’Innovació Campus**
- 12/21 **Clínic**. “Reveal Genomics: redefiniendo la oncología de precisión”. Virtual. Hospital Clínic de Barcelona. Barcelona, España.
- 12/21 **San Antonio Breast Cancer Symposium – SABCS21**. Translational Science Forum HER2 Heterogeneity. “Molecular heterogeneity in HER2+ breast cancer – can outcomes be predicted?”. San Antonio, Texas, USA.
- 11/21 **1st Annual Meeting of Evomet**. “The intrinsic subtypes of breast cancer in advanced HR+/HER2-neg breast cancer”. IRB. Barcelona, España.
- 11/21 **44ª edición del World Hospital Congress**. People on board: Transforming healthcare by blending agility, responsiveness and resilience. Virtual.
- 10/21 **ABC6 Sixth Advanced Breast Cancer International Consensus Conference**. Challenges on evaluating patients with ABC “How to act in discordant biomarker results (primary vs mets vs other mets)”. Live Q&A: Challenges on evaluating patients with ABC. ABC Global Alliance. **ABC6**. Virtual Conference.
- 10/21 **Congreso Nacional SEOM**. Sesión Formativa: Medicina de Precisión. “¿Cuándo puedo comenzar a usar un Biomarcador molecular para tomar decisiones?”. SEOM. Virtual.
- 10/21 **Integrating Clinical Omics in Precision Management of Breast Cancer**. “Clinical implication of

- Intrinsic subtypes in ER+HER2- tumour". Biomedical Research Center at The Royal Marsden and ICR. Virtual meeting.
- 10/21 **Jornada presencial y online Càncer de Mama.** Conferencia Magistral "Hope". Espacio de la aacc. Barcelona. España.
- 10/21 **IV Jornada C-17: Ginecología Oncológica IV Curso de Actualización en Ginecología.** Presentación y Bienvenida.
- 10/21 **II Simposio Virtual Internacional Abordaje Multidisciplinario en Cáncer de Mama. Virtual.** Hospital Vivian Pellas.
- 10/21 **AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.** Plenary Session 6: HER2-directed Therapies - Dedicated to the Memory of José Baselga. "HER2 heterogeneity implications for biology, tumor evolution, and treatment". Virtual. AACR-NCI-EORTC.
- 10/21 **"New strategies to optimize adjuvant endocrine treatment in breast cancer". Webinar.** "intrinsic subtypes in defining the response to endocrine therapy and CDK4-6 inhibitors". Virtual. EORTC and BIG.
- 10/21 **Integrating Clinical Omics in Precision Management of Breast Cancer Virtual Meeting.** "Clinical implication of Intrinsic subtypes in ER+HER2 tumour". Virtual. Team Leader, ICR CTSU Integrative Genomics Analysis in Clinical Trials Institute of Cancer Research.
- 10/21 **II ASPIC-ASEICA International Meeting - Current Trends in Precision Medicine in Cancer.** "Personalized medicine in advanced breast cancer treatment". Virtual. ASEICA.
- 10/21 **Meeting the Minds 2021 | Hematology and Oncology.** "How to apply what we know about HER2 tumor heterogeneity in the clinic?". Libbs. Virtual.
- 09/21 **17th Meet The Professor Advanced International Breast Cancer Course (AIBCC).** "Clinical impact of genomics in BC". Accademia Nazionale di Medicina. Virtual.
- 09/21 **Innovators in Breast cancer.** "Novel RNA-based approaches towards precision medicine in HR+/HER2- breast cancer". University of Piemonte Orientale (UPO), Novara. Virtual.
- 09/21 **ESMO Congress 2021.** Special symposium: Impact of breast cancer biology in the neoadjuvant setting "Impact of RNA expression".
- 09/21 **Innovators in Breast cancer.** Session: Molecular Biology. "Novel RNA-based approaches towards precision medicine in HR+/HER2- breast cancer". Aula Magna Campus Perrone-UPO, Novara. Virtual.
- 07/21 **V Jornades C17: càncer de mama.** "Podem evitar la cirurgia en un grup seleccionat de pacients: ELPIS trial". Hospital Clinic de Barcelona. Barcelona, Spain.
- 07/21 **Seed and Soil. Cancer Research.** Session 5. "From USA to Barcelona". ECUSA. Españoles Científicos en USA. Virtual
- 06/21 **ABO webinar | Management of Her2- positive Breast Cancer.** "Biomarkers of response to Her2 blockade including Her-2 low disease". Virtual
- 06/21 **2nd IGTP Retreat: Research and Networking across the Can Ruti Campus.** "Investigación Translacional y medicina de Precisión". Instituto Germans Trias i Pujol (IGTP), Badalona Business Centre (BCIN). Barcelona, España.
- 06/21 **Institute for Research in Biomedicine.** Mesa redonda: Presente y future de la investigación en càncer de mama. IRB. Barcelona, España.
- 05/21 **XXX CONGRESO NACIONAL SEAP-IAP.** Mesa Redonda: Dificultades de acceso a biomarcadores de calidad en càncer: la experiencia española. Virtual.

- 05/21 **Up-to-Date Virtual Summit Solti.** Latest advances in breast cancer: from molecular data to the clinical practice. "The HOPE experience". Virtual.
- 05/21 **VI Foro Virtual e-OM3d.** La Oncología Médica en 3 Días 2021. Inauguración y clausura, y Moderación Mesa 3: Ponencia Magistral. Ponencia: Anticuerpos monoclonales con tecnología BITE (bispecific T-cell engager monoclonal antibody) Dr. Emiliano Calvo. Mesa 6: Controversias en cáncer de mama localizado. Mesa 11: Keynote Lectures. Virtual.
- 05/21 **ESMO Breast Cancer Virtual Congress 2021.** Expert at the YO Virtual Lounge Discussion and Chair of the Educational session 1: Optimal sequence in metastatic HER2+ breast cancer. ESMO BC 2021. Virtual.
- 05/21 **I Congreso cáncer en la mujer Argentina 2021.** "Cáncer de mama: tratamiento personalizado del cáncer de mama Her2+ en los estadios iniciales". Sociedad Argentina de Cancerología. Virtual.
- 04/21 **Jornada de actualización cáncer de mama triple negativo (CMTN).** "Biología molecular del CMTN " l'Institut d'Investigació Sanitària Pere Virgili (IISPV). Reus, España.
- 04/21 **First Sicilian GOM Breast Cancer (SiGOB-1).** " the HER2-enriched molecular subtype within HR+/HER2-negative breast cancer: wath we do/don't know today ?". Virtual. Vincenzo Adamo.
- 04/21 **VII Jornadas Cáncer Mama Hereditario_2021.** Bienvenida. Geicam, Solti, SEOM. Virtual.
- 04/21 **V Edición Premios Jornada Jóvenes Investigadores: "Jóvenes Investigadores: Un silencio que salva vidas".** Mesa redonda: "Retos de la investigación del presente, éxitos médicos del futuro". Fundación AstraZeneca. Madrid, Spain.
- 04/21 **12+1 Simposio Internacional del Grupo GEICAM de Investigación en Cáncer de Mama.** "Plataformas genómicas de decisión en tratamiento adyuvante". Virtual. GEICAM.
- 03/21 **Big Scientific Virtual Meeting.** Co-chair and Speaker about RIBOLARIS. Virtual BIG.
- 03/21 **Sant Gallen Breast Cancer Conference.** Discussant: Session 2: Care for patients with HER2-positive breast cancer. Co-Chair: Session 4: Predictive and prognostic biomarkers in patients with breast cancer. Panelist: Consensus session. **SG-BCC 2021.** Virtual.
- 02/21 **LUCC - AI and Cancer Seminar.** "Predicting prognosis and treatment benefit in early-stage and metastatic HR+/HER2-negative breast cancer using RNA-based data". Virtual. Lund University Cancer Center (LUCC).
- 01/21 **VI Simposio Biopsia Líquida.** Debate de: Cáncer de mama: la traslación de la biopsia líquida a la medicina de precision. Panel discussion about: Breast cancer: the translation of liquid biopsy to cancer precision medicine. "Nuevo horizonte de la biopsia líquida en cáncer de mama". Virtual. Universidad Francisco de Vitoria (Madrid-España).
- 01/21 **7th the Hong Kong Breast Oncology Group (HKBOG) "Best of SABCS" Scientific Symposium.** "CDK4/6 inhibitors on HER2 enriched disease in the MONALEESA study". Virtual.
- 01/21 **13th BGIICC.** "Predicting prognosis and benefit from CDK4/6 inhibitors in breast cancer using biology-based data". Virtual.
- 12/20 **Guardant Health Webinar.** Challenges of Tissue Testing for Advanced Prostate and Breast Cancer Patients. "Tissue challenges in the management of advanced BC".Virtual.
- 12/20 **San Antonio Breast Cancer Symposium – SABCS20.** General Session. GS1-04. "Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies". Virtual.
- 12/20 **San Antonio Breast Cancer Symposium – SABCS20.** Educational Session. Personalized HER2 Targeted Therapy 2020 - Are We There?. "Personalized treatment for early stage HER2-positive breast cancer". chaired by Eric P. Winer. Virtual. **SABCS20.**
- 11/20 **17th ASEICA International Congress.** Sesión 4: Novel Therapies in clinical Practice: a focus on Immunotherapy.2Predicting immunotherapy benefit across cancer-types. **ASEICA 2020.** Virtual.
- 11/20 **LIVE Simposio AIOM.** The evolution of customized therapeutic options in HR+/HER2- aBC patients. "The evolution of customized therapeutic options in HR+/HER2- aBC patients. Tailoring HR Future". VyvaMed S.r.l. Virtual.

- 10/20 **Virtual Congress International Society of Liquid Biopsy 2020.** “Clinical Utility of Guardant360 Liquid Biopsy in advanced Breast Cancer”. Society of Liquid Biopsy 2020. Virtual.
- 10/20 **4ª. Edición Jornada de Tertulias Oncológicas.** Ponencia y Moderación “Cancer de mama”. IDIBELL. Virtual.
- 10/20 **65 Congreso Nacional y I Congreso Virtual de la Sociedad Española de Farmacia Hospitalaria (SEFH).** Moderador de la sesión 5: Sesión 8 Del Lab al paciente. Sociedad Española de Farmacia Hospitalaria (SEFH). Virtual.
- 10/20 **The 28th Annual Meeting of the Japanese Breast Cancer Society.** Session I. “Clinical impact of genomics for HER2+ and TNBC”. Japanese Breast Cancer Society. Virtual.
- 10/20 **16th Meet the Professor - Digital Event 2020 Advanced International Breast Cancer Course.** Live Webinar. I: Evolution in cancer Prevention and diagnosis. “Clinical impact of genomics for HER2+ and TNBC”. Accademia Nazionale di Medicina. Virtual.
- 09/20 **Workshop virtual en elaboración e interpretación de informes.** Bienvenida e introducción con “El valor de la NGS como herramienta para mejorar la medicina personalizada en el tratamiento oncológico”. Virtual. Roche.
- 07/20 **VI Jornada Cáncer Mama Hereditario.** SOLTI, SEOM, GEICAM. Virtual. Bienvenida y presentación.
- 06/20 **Educational Webinar Guardant Health.** “Utilidad clínica de la biopsia líquida en tumores sólidos”. Virtual.
- 06/20 **XXXI Curso Avanzado de Oncología Médica.** Participación en la “Mesa redonda sobre cancer de mama” y charla sobre “Situación Actual del Tratamiento Adyuvante en Cáncer de Mama”. Virtual. Doctaforum.
- 05/20 **ASCO ANNUAL MEETING 2020.** Discussant in Oral Abstract Session. Breast Cancer - Metastatic. Press: “Tailoring Therapy for HER”. ASCO 2020 Virtual.
- 05/20 **ESMO Breast Cancer Virtual Meeting.** Educational Session. “Beyond HER2: Dissecting tumour heterogeneity”. ESMO Breast Cancer 2020. Virtual Meeting.
- 05/20 **Advancing Science - A Virtual Oncology Conference.** CHAIR of Clinical Applications Scientific track. NanoString Virtual Conference. Virtual Meeting.
- 01/20 **The Genetics and Genomics of Cancer meeting.** Institute for Clinical Medicine, Faculty of Medicine, University of Oslo. “Clinical implications of the molecular classification of BC”. Institute for Clinical Medicine, Faculty of Medicine, University of Oslo. Oslo, Norway.
- 11/19 **ABC5: Advanced Breast Cancer Fourth ESO-ESMO International Consensus Conference.** “Biomarkers for new approaches: what have we been doing wrong?”. Centro de Congressos de Lisboa in Lisbon, Portugal.
- 10/19 **10 Foro de Cancer de Mama** “Protagonismo de las pacientes en la Era de la Oncología de Precisión Personalizada. Calidad de Vida”. Conferencia Magistral “Situación actual de la Oncología de Precisión Personalizada en Cáncer de Mama”. Hospital Virgen del Rocío. Sevilla, Spain.
- 10/19 **Scientific session.** “Tratamiento del cáncer en el Siglo XXI”. Institut Clínic de Medicina y Dermatología (ICMiD). Barcelona, Spain.
- 10/19 **15th MEET THE PROFESSOR Advanced International Breast Cancer Course. Coffee with Professors - Career Development: Translational research in breast cancer. Chairman:** Aleix Prat **SESSION IV – Pathology, Genomics & Molecular Biology and Speaker** “Clinical impact of genomics for HER2+ and TNBC”. Multidisciplinary Tumor Board 2. Early breast cancer: challenging cases for pathologists and clinicians. Chairman: Giancarlo Pruneri. **Panelists:** Gabriel N. Hortobagyi, Sibylle Loibl, Miguel Martin, Enrico Orvieto, Aleix Prat. Padova, Italy.
- 09/19 **Annual ESMO Congress. Poster Discussion - Breast cancer, metastatic:** Co-Chair and discussant. **Poster Display session 2 – Breast cancer, early stage:** Speaker. **Educational session -Optimal adjuvant and neo-adjuvant therapy in HER-2+ patients:** Co-chair and speaker “Dissecting the heterogeneity of HER2+ breast cancer”.

- 09/19 **Scientific Outreach SOLTI**. Avances en cáncer de mama: ¿Que haré mañana en la consulta?. Sevilla. Spain.
- 07/19 **2019 Breast cancer trials (BCT) Annual Scientific Meeting**. SCIENTIFIC SESSION 2: De-escalation Strategies. "HER2-positive early breast cancer molecular biomarkers: a guide to de-escalation?" SCIENTIFIC SESSION 5: Translational. "New breast cancer biology: supporting better treatment for our patients". SCIENTIFICA SESSION 6: Advanced Breast Cancer. "Predicting outcome and treatment benefit in HR+ve/HER2-neg metastatic Breast Cancer". Adelaide, Australia.
- 07/19 **III Jornades C17: Novedades cancer de mama**. "Innovación diagnóstica y terapéutica en cáncer de mama". Moderador: Sesión plenaria. Genomic Analysis of epithelial and immune cells for predictive oncology. Prof. Charles M. Perou. . Immunotherapy in Breast Cancer: present and future. Prof. Lisa Carey. Aula Magna. Facultad de medicina. Universdadt de Barcelona. Barcelona, España.
- 05/19 **"Medicina Personalitzada en Càncer de Mama"**. Aula d'Extensió Universitària per a la Gent Gran de Manresa. UPC Manresa. Manresa, España.
- 05/19 **VII Taller de Diseño de un Ensayo Clínico por Jóvenes Investigadores**. "Investigación traslacional en el ensayo clínico". Barcelona, España.
- 05/19 **SOLTI Inmunidad y cáncer (de mama)**. "Otros biomarcadores de predicción de respuesta a terapias inmunes". Barcelona, España.
- 05/19 **IV Foro La Oncología en 3 días**. Seminario "Biología molecular del cáncer de mama". Moderador del Bloque II: Cáncer de Mama Metastásico y Mesa 15: Cáncer de mama metastásico. Teatro Goya. Madrid, España.
- 05/19 **4th BARCELONA BREAST CANCER MEETING**. Moderador del Bloque II: Cáncer de Mama Metastásico. Auditori del Parc de Recerca Biomèdica de Barcelona. Barcelona, España.
- 04/19 **ESMO Breast Cancer**. Educational session 1 Early breast cancer: HER2 positive. "Neoadjuvant therapy in ER-negative disease". Brussels, Belgium.
- 03/19 **16th Int. St. Gallen Cancer Conference**. Session 3: Biology of breast cancer II: Prediction of response. Identifying research priorities in prediction of response in patients with early breast cancer. Viena, Austria.
- 03/19 **2019 SHE - Share HER Evolution Meeting**. Seminar "What changed in what we know about breast cancer biology". Amadora, Portugal.
- 02/19 **Fifth BiAnnual Congress of the Israel Senologic Society**. "Clinical implications of breast cancer molecular subtype: Expert perspective and experience". Zichron Yaakov, Israel.
- 01/19 Seminario "Clinical value of the intrinsic molecular subtypes of breast cancer". **Gustave Roussy**. Villejuif, Francia.
- 01/19 Seminario "Clinical Implications of the Intrinsic Molecular Subtypes of Breast Cancer". **Centro Integral Oncológico Clara Campal**. Hospital Universitario Madrid Sanchinarro. Madrid.
- 01/19 **11th Breast – Gynecological & Immunooncology International Cancer Conference**. Plenary session I: One World Against Cancer. "Dissecting the biological heterogeneity in hormonal +ve breast cancer". Adjuvant treatment in Breast cancer "Predicting outcome and treatment response in Her2 +ve early breast cancer". **11th BGICC**. Cairo, Egypt.
- 12/18 **Medical Education Program**. Cáncer de Mama: mucho ya, pero no todo aún. "El cancer de mama desde un punto de vista biológico. Entendiendo su heterogeneidad. Centro Médico Teknon. Barcelona, España.
- 12/18 **San Antonio Breast Cancer Symposium – SABCS18**. Discusor at "Spotlight Session: Next Steps in HER2+ Targeted Therapy" chaired by Ian Krop. Henry Gonzalez Convention Center. San Antonio, Texas, USA.
- 11/18 **Forum Salud Clínic**. "Medicina Personalitzada en cancer de mama". Hospital Clínic de Barcelona, Barcelona, España.
- 11/18 **II Edición tertúlias Oncológicas**. Tertuliano en la Mesa Redonda: debate de los avances del año más destacados por parte de expertos en el área terapéutica de mama. **ICO Hospital Duran i**

- Reynals.** Barcelona, España.
- 11/18 **ENVISION SUMMIT “Breast Cancer biology: Leading the Quest for New Therapies”.** Organozzer and Chair “Beyond the Tumor: Current Value and Future Potential of Liquid Biopsies (Speaker: Nicholas C. Turner)”. Madrid, España.
- 11/18 **5th Annual Metastatic Breast Cancer Conference.** “Predicting outcome in metastatic breast cancer”. Thomas B. Turner Building. Johns Hopkins University School of Medicine, Baltimore, Maryland, EUA.
- 10/18 **3rd Annual Meeting New technologies and strategies to fight cancer.** “Clinical value of the intrinsic molecular subtypes of breast cancer”. San Raffaele Congress Centre, Milano. Italia.
- 10/18 **Optimizing Immunotherapy. New Approaches, Biomarkers, Sequences and Combinations.** Table 2. Biomarkers in immunotherapy. RNA Signatures as predictive biomarker. Institut Hospital del Mar d’Investigacions Mèdiques. PRBB Auditorium, Barcelona, España.
- 10/18 **Congreso Anual ESMO.** YO Mentorship Session: Career paths in oncology. Speaker Topic 2: Translational Research. Daiichi Sankyo Symp. Industry Satellite Symposium: HER2 Expression in Metastatic Breast Cancer. “HER2 metastatic breast cancer: Biology, clinical experience and unmet medical need”. **Congreso ESMO 2018.** Munich, Alemania.
- 10/18 **Clinical implications of the intrinsic subtypes of breast cancer.** Premio el III Premio Jóvenes Investigadores de la Fundación AstraZeneca en el área de Oncología. Visita IMED, AstraZeneca. Cambridge, UK.
- 10/18 **Precision medicine today and in ten years time, with focus on Breast cancer.** “How to use different tools to best identify relevant subtypes of breast cancer”. Elite Park Avenue, Gothenburg, Suecia.
- 09/18 **Sociedad Española de Oncología Médica (SEOM).** Discursor de PLE3: La clasificación en “Integrative clusters” del cáncer de mama predice la respuesta patológica completa a quimioterapia neoadyuvante. Café con Daiichi Sankyo “Biología del Cancer de ma HER2+ y target HER2 per se”. **SEOM 2018.** Madrid, España.
- 09/18 **14th Meet The Professor Advanced International Breast Cancer Course (AIBCC).** SESSION V – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY. Speaker “Molecular stratification of HER2+ and TNBC”. Chairmen of the Session VI – NEW PATHWAYS AND NEW DRUGS. Accademia Nazionale di Medicina. Padova. Italia.
- 09/18 **Desafíos Quirúrgicos en la neoadyuvancia.** “Beneficio clínico Perjeta® - Herceptin® en la neoadyuvancia y nuevos horizontes en el CMp Her2+”. Recinto Modernista, Hospital Sant Pau.
- 07/18 **2018 Japanese Society of Medical Oncology Annual Meeting (JSMO).** “Translational research for ER+HER2- ABC/MBC”. Kobe, Japon.
- 07/18 **II Jornades C17: Novetats en cancer de mama.** “Nous biomarcadors i fàrmacs en malaltia metastàsica”. Hospital Clínic de Barcelona. Barcelona, España.
- 06/18 **Sessions científiques de l’Àrea del medicament.** “Inmuno-oncologia”. Hospital Clínic de Barcelona. Barcelona, España.
- 06/18 **Personalised Healthcare in Oncology.** “Linking Biology to Patient Benefit”. Roche Farmacèutica Química, Lda. Lisboa, España.
- 05/18 **Jornada de innovación: Diagnóstico molecular y medicina de precision.** “Diagnóstico molecular oncológico”. Hospital Clínic de Barcelona. Barcelona, España.
- 05/18 **2nd International Workshop Integrating Genomics in cancer management.** Session II Advances in Personalized Treatment of Cancer I: “Optimizing Genomic Testing in Breast Cancer”. Universidad de Navarra. Madrid, España.
- 05/18 **Third Barcelona Breast Cancer Meeting.** Moderador de la session Terapia adyuvante. Hospital de Sant Pau. Barcelona, España.

- 05/18 **Seminario Hospital de Meritxell** “Retos y desafíos de la inmunoterapia en el tratamiento del cancer. Andorra la Vella, España.
- 05/18 **III Foro la oncología médica en 3 días.** Moderador de la Mesa 12: El reto de afrontar el tumor localizado de mama. Ponente Biología molecular del cáncer de mama”. Madrid, España.
- 05/18 **Sesión Científica en la Reial Acadèmia de Medicina de les Illes Balears,** “Tratamiento personalizado en cáncer de mama”. Sala d'actes de la Conselleria de Salut i seu de la Reial Acadèmia de Medicina. Palma de Mallorca, Islas Baleares. España.
- 04/18 **XI Simposio Internrnacional Centro Parque. Cáncer de Mama de Santiago 2018.** “Prognostic and predictive biomarkers in HR+/HER2- negative advanced/ metastac breast cancer.”, “De-escalating systemic treatment in HER2+ disease”, “PARP inhibitors: Only useful for triple negative disease? Clinical data and future perspectives”, “Molecular classificaon of triple negative disease: which one is best?” - Santiago, Chile.
- 04/18 **Meeting evaluation: Milan Module. International Breast Cancer Academy 2018.** “Bridging Research and Clinical Practice in the Advanced Care Setting” In conjunction with European Institute of Oncology. “Treating metastatic breast cancer-today and tomorrow Optimising outcomes through treatment selection and enrichment vs stratification” Milan, Italia.
- 03/18 **EBCC11 - The European Breast Cancer Conference.** Chair of the Pfizer Onco. Breast Cancer Satellite Symposium “Constructing a new future in breast cancer treatment”. Barcelona, España.
- 03/18 **EBCC11 - The European Breast Cancer Conference.** Clinical Sci Symp. Should we treat differently HER-2+ER- Breast Cancer?. “Biological differences”. Barcelona, España.
- 02/18 **FOCUS Sul Carcinoma mammario. Aggiornamenti basati sull'evidenza - XV Edizione.** Lettura magistrale. Clinical Implications of the Intrinsic Molecular Subtypes of Breast Cancer. Pordenone, Italia.
- 01/18 **SABO Annual meeting Karolinska Institute** "Clinical implications of the intrinsic molecular subtypes of breast cancer". Stocolmo, Suecia.
- 01/18 **1st UK Interdisciplinary Breast Cancer Symposium.** “Predicting outcome in metastatic breast cancer”. Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital. Manchester, UK.
- 12/17 **Debates de investigación&Docencia** “Nuevas dianas terapéuticas en cáncer de mama. Hospital Universitario de La Ribera Valencia, España.
- 12/17 **San Antonio Breast Cancer Symposium – SABCS17. Discusor The Spotlight Session 3** “Spotlight on Novel Drugs / Predicting Response for HER2+ Breast Cancer”. Henry Gonzalez Convention Center. San Antonio, Texas, USA.
- 12/17 **San Antonio Breast Cancer Symposium – SABCS17. Moderador a la Sesió General 2.** San Antonio, Texas, USA.
- 11/17 **Scientific Learning.** Presentación de Caso: Manejo de una paciente postmenopáusica con un cáncer de mama precoz HER2+. Solti. Madrid, España.
- 11/17 **Curso de Inmunología tumoral y Inmunología del cáncer.** “El cáncer de mama”. Unidad de Enfermería y del Servicio de Oncología Médica. Hospital Clínic de Barcelona. Barcelona, España.
- 11/17 **B-DEBATE on Woman’s Cancer.** Lider científico y Presidente: Advances in Cancer Cure. Barcelona, España.
- 11/17 **ABC4 - Fourth ESO-ESMO.** International Consensus Conference. Management of triple negative ABC “What’s new in biology”. Lisboa. Portugal.
- 10/17 **3 Congreso Español de la mama (SESPM’17).** “Los nucleótidos y la quimioterapia”. Sociedad Española de Senología y Patología Mamaria. Madrid, España.
- 10/17 **8 Foro Cáncer de mama.** Investigación en CÁNCER de MAMA: Un espacio para la Esperanza. Oncología de precision en cancer de mama. Avances recientes. Unidad Multidisciplinar de Mama y Fundación Actitud frente al Cáncer. Hospital Virgen del Rocío. Sevilla, España.

- 10/17 **Seminario sobre cancer de mama.** “Clinical Implications of the Intrinsic Molecular Subtypes in Breast Cancer.” Instituto de Biomedicina de Sevilla. Sevilla, España.
- 09/17 **13th Meet The Professor Advanced International Breast Cancer Course (AIBCC).** Speaker “HER2+ and trastuzumab resistance”. Chairmen of the Session IV – Pathology, Genomics & Molecular and participants of the Multidisciplinary Tumor Board 2 – Challenging cases for pathologists and clinicians (including CUP syndrome, breast cancer during pregnancy) Session. Accademia Nazionale di Medicina. Padova. Italia.
- 09/17 **Congreso Anual ESMO.** Joint symposium: ESMO-SEOM Integrating biomarkers into oncology. Speaker. Sesión Educativa “Biomarkers in breast cancer”. Scientific Sub-Committee for Breast cancer, metastatic. ESMO 2017. Madrid, España.
- 07/17 **AP SUMMIT – ONCOLOGY.** “Transforming patient care through translational research for HR+ BC” and “Update and treatment strategy for HER+ \HER2- aBC”. Taipei, Taiwan, Asia.
- 07/17 **I Jornades C17: Novetats en cancer de mama.** “Noves evidències dels tests basats en expressió gènica”. Hospital Clinic de Barcelona. Barcelona, España.
- 05/17 **2017 BIG-NABCG ANNUAL MEETING PRECISION MEDICINE: SUCCESSES AND CHALLENGES.** “Precision Medicine in Breast Cancer: Challenges and Opportunities”. Chicago, IL, EUA.
- 05/17 **2nd Barcelona Breast Cancer Meeting.** “Subtipos Intrínsecos en Cáncer de mama: dónde estamos y hacia dónde vamos?”. Hospital de Sant Pau. Barcelona, España.
- 05/17 **Preceptorship I Breast Cancer.** Molecular characterization of triple negative breast cancer. Hospital 12 de octubre. Madrid, España.
- 05/17 **II Foro La Oncología Médica en 3 días.** “El papel de las plataformas moleculares”. Hospital Universitario Ramón y Cajal. Madrid, España.
- 05/17 **6th IMPAKT 2017 Breast Cancer Conference.** Session: New therapeutic strategies of endocrine dependent tumours. “The role of ESR 1 mutations”. BIG & ESMO. Bruselas, Bélgica.
- 05/17 **Master oficial en Medicina Translacional.** Ensayos clínicos y evaluación de terapias moleculares. “Desarrollo y validación de biomarcadores”. Universidad de Barcelona (UB). Barcelona, España.
- 04/17 **2a Jornada Participativa sobre Calidad de Vida y Cáncer de Mama. Entre nosotros.** Que hay de nuevo sobre el tratamiento para el cáncer de mama. Al día con los últimos avances. Hospital de la Santa Creu i Sant Pau. Barcelona, España.
- 04/17 **Preceptorship.** Nuevas estrategias para el tratamiento con inmunoterapia en el cancer de mama. Medsite. On line.
- 04/17 **Programa de Formación de Ensayos Clínicos.** “Conocer las Nuevas plataformas para la identificación de Biomarcadores en Cáncer de Mama”. SOLI. Barcelona, España.
- 03/17 **Clinical Course of Continuing Education in Obstetrics and Gynecology.** Oncology Gynecology. Genetics of cancer. New findings, new classifications. Hospital Clinic of Barcelona. Lloret de mar, Barcelona, España.
- 03/17 **SHE-Share HER Evolution meeting.** Breast Cancer Biology. “Recent advances in breast cancer biology”. Roche Farmacêutica e Química. Lisboa, Portugal, España.
- 03/17 **AMAM. Invirtiendo la historia del cáncer de mama.** Moderador. El futuro del cáncer de mama. Roche Farma, S.A. Madrid, España.
- 03/17 **ICREA-FIJC Conference.** Across Tumor Heterogeneity and Evolution in Cancer: from in silico studies to clinical impact. Chairman Session 5: Intratumor Heterogeneity in Solid Tumours II. University of Barcelona. Barcelona, España.
- 02/17 **UNC Lineberger Comprehensive Cancer Center.** The University of North Carolina at Chapel Hill School of Medicine. “Breast Cancer Genomics and its Impact in the Clinic”. Chapel Hill, EUA.
- 02/17 **Master de Medicina de Sistemas.** “Personalized medicine for breast cancer. Master de Medicina de Sistemas”. Universitat de Barcelona. Barcelona. España.
- 02/17 **Máster de uro-oncología: Biología Molecular e Investigación en Tumores urológicos.**

- “Plataformas moleculares en oncología”. Universidad de Barcelona UB. Barcelona, España.
- 02/17 **Mesa Redonda “Frente al Cáncer: un esfuerzo conjunto”**. Día Mundial del Cáncer. Colegio Oficial de Médicos. Sevilla. España.
- 01/17 **Sesión Científica del Servicio de Bioquímica y Genética Molecular**. “Implicaciones clínicas de los subtipos moleculares de cáncer de mama” Hospital Clinic de Barcelona, Barcelona, España.
- 12/16 **San Antonio Breast Cancer Symposium – SABCS16**. S3-03 Sesión Oral. “PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial”. Henry Gonzalez Convention Center. San Antonio, Texas, EUA.
- 12/16 **San Antonio Breast Cancer Symposium – SABCS16**. Sesión Educativa: Recent insights into the biology of HER2+ Breast Cancer. “Recent insights into the biology of HER2+ breast cancer”. San Antonio, Texas, EUA.
- 11/16 **I Jornada de actualización en cáncer de mama**. “Plataformas genéticas”. Cáncer de mama”. Unidad del Hospital Universitari General de Catalunya. Sant Cugat del Vallés, Barcelona, España.
- 11/16 **Máster en Medicina Translacional**. “Personalized medicine in oncology”. Universitat de Barcelona 2016/17. Barcelona, España.
- 11/16 **Máster en Medicina Translacional**. “Molecular classification of breast cancer” Universitat de Barcelona 2016/17. Barcelona, España.
- 11/16 **Seminario. The Candiolo Cancer Institute, FPO – IRCCS** “Clinical Implications of the Intrinsic Molecular Subtypes of Breast Cancer”. Candiolo, Italia.
- 11/16 **Actividades divulgativas. European Society of Radiology**. “Relación entre el oncólogo y el radiólogo”. European Board of Radiology – EBR. Barcelona, España.
- 11/16 **Translational Meeting 2016**. Grupo Español multidisciplinar de melanoma (GEM). “Nano String nCounter: predictive value for anti PD-1 drugs”. Barcelona, España.
- 10/16 **Advancing Innovative Collaborations on Metastatic Breast Cancer Research**. “International breast cancer “Omics’ research integration”. The U.S. Ambassador’s Residence, Estocolmo, Suecia.
- 10/16 **Societat Catalana d’Anatomia Patològica (SCAP)**. “Plataformes gèniques”. L’Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de balears. Barcelona, España.
- 10/16 **Sociedad Española de Oncología Médica (SEOM)**. Discusor de PLE-4: Correlación de los subtipos de Lehmann con la respuesta completa patológica en pacientes con cáncer de mama triple negativo tratadas con quimioterapia neoadyuvante con antraciclinas y taxanos +/- Carboplatinom. Madrid, España.
- 10/16 **Congreso Annual ESMO**. Challenge Your Expert (CYE) session. “What is the clinical utility of gene expression-based tests in early breast cancer?” ESMO 2016. Copenhague, Dinamarca.
- 09/16 **1st Annual European Congress on Immunotherapies in Cancer™**. European Planning Committee and faculty. Immuno-oncology in the Clinic-II. Barcelona, España.
- 09/16 **12th Meet The Professor Advanced International Breast Cancer Course (AIBCC)**. “Triple negative breast cancer”. Accademia Nazionale di Medicina. Universidad de Padova. Padova. Italia.
- 07/16 **1st Barcelona Breast Cancer Meeting (BBCM)**. Moderador: “Emerging biomarkers in advanced disease”. Roche. Barcelona, España.
- 06/16 **Jornada de actualización en Cáncer de mama para profesionales** “ La inmunoterapia: un avance en el tratamiento del cancer. Asociación Española contra el Cancer, AECC. Barcelona, España.
- 06/16 **WorkShop Focus sul Tumore metastatico della mammella**. “Metastatico HER2 – Negativo Basi molecolari”. Organizado por el Prof. S. de Placido. Nápoles, Italia.
- 05/16 **I Curso Universitario “La Oncología Médica en 3 días”**. “Plataformas genómicas en el cáncer de mama”. Hospital Universitario Ramón y Cajal, Universidad Francisco de Vitoria. Madrid, España.

- 05/16 **Simposio de Primavera: Cáncer de mama triple negativo: ¿Dónde estamos y a dónde vamos?**. “Diseción molecular del cáncer de mama triple negativo”. Solti. Hotel Hilton Barcelona. Barcelona, España.
- 04/16 **Curso “Aspectos Generales y de Investigación Básica en Cáncer de Mama”**. “Implicaciones Clínicas de los subtipos intrínsecos”. Grupo Multidisciplinario para el Estudio del Cáncer de Mama (GMECM). UAB. Facultat de Medicina Universitat de Barcelona. Barcelona, España.
- 03/16 **Sesiones de la Escuela de Hematología**. “Implicaciones clínicas de los perfiles de expresión en cáncer de mama” Facultad de Medicina, Universidad de Barcelona – UB, Barcelona, España.
- 03/16 **Máster de uro-oncología: Biología Molecular e Investigación en Tumores urológicos**. “Plataformas moleculares en oncología”. Universidad de Barcelona UB. Barcelona, España.
- 03/16 **Curso Abordaje multidisciplinar del paciente con cáncer de próstata**. *CÁNCER DE MAMA: ¿un modelo a seguir en el cáncer de próstata?*. Sanofi. Hospital Clinic de Barcelona. Barcelona, España.
- 02/16 **Nano World Cancer Day (NWCD)**, Mesa redonda “Nanomedicina aplicada al cáncer”, Plataforma Española de Nanomedicina, la Plataforma Europea de Nanomedicina (ETPN), IBEC y la UB/Hospital Clínic Universitat de Barcelona – UB. Barcelona, España.
- 02/16 **Debate: Necesitamos test genéticos para tomar una decisión terapéutica aparte de RH y HER2?**. Building the Future together. Novartis. Barcelona, España.
- 02/16 **Symposium Sysmex Europe** “Treating today's patients with tomorrow's solutions”. “Prognostic and predictive value of the intrinsic subtypes of breast cancer” Sysmex Life Science. Paris. España.
- 12/15 **Master Oficial Universitario en Medicina Translacional**. “Molecular classification of breast cancer”. Facultad de Medicina, Universidad de Barcelona – UB, Barcelona, España.
- 11/15 **Seminario en el Servicio de Radioterapia del Hospital Clinic de Barcelona**. “Clinical implications of the intrinsic molecular subtypes of breast cancer”. Barcelona, España.
- 11/15 **SOLTI Scientific Meeting: Targeting Breast Cancer in 2015** Inside and Out: from the Cell Cycle to the tumor microenvironment. Promising agents and strategies in the race for personalized breast cancer therapy. “Keynote lecture: promising agents and strategies in the race for personalized breast cancer therapy”. Madrid, España.
- 10/15 **Meeting “EMIT Project”**. “Clinical implications of intrinsic breast cancer subtypes”. Inst for Cancer Research. Oslo University Hospital. Oslo. Noruega
- 10/15 **XV ASEICA International Congress**. “Clinical implications of intrinsic breast cancer subtypes”. Sevilla. España.
- 10/15 **2º Congreso Español de la MAMA**. “Implicaciones clínicas presentes y futuras de la biología intrínseca de cáncer de mama”. SESPM. Madrid, España.
- 10/15 **Keynote COMBATing, Breast Cancer 2015**. “Current and Future Clinical Implications of the Intrinsic Subtypes of Breast Cancer”. Düsseldorf, Alemania.
- 10/15 **XV Congreso SEOM**. “Ayudas a la decisión terapéutica en tumores luminales”. Madrid, España.
- 10/15 **Medical Director’s Meeting at Celgene**. “Clinical implications of the breast cancer intrinsic subtypes: present and future”. Barcelona, España.
- 09/15 **11th Meet The Professor Advanced International Breast Cancer Course (AIBCC)** “Clinical validity versus clinical utility of genomic tests”. Accademia Nazionale di Medicina. University of Padua. Padua. Italia.
- 07/15 **Seminario In-House IDIBAPS**. “Overcoming treatment resistance in luminal breast cancer”. Esteve Auditorium IDIBAPS-CEK Building. Barcelona, España.
- 06/15 **Therapeutic and Clinical implications of the genomic landscape of breast cancer workshop**. “Therapeutic and Clinical Implications of the genomic landscape of breast cancer”. University Campus Bio-Medico of Rome. Roma, Italia.
- 06/15 **Jornada Firmas Genéticas Cáncer de mama**. “Prosigna”. Hospital Universitario Quiron-Dexeus. Barcelona, España.

- 06/15 **8º Revisión Anual GEICAM de Avances en Cáncer de Mama (RAGMA15)** *“Avances en modelos preclínicos y biología”*. GEICAM. Madrid, España.
- 06/15 **Milan Breast Cancer Conference–Webcast and Residential.** *“When to prescribe gene signature testing (as opposed to relying upon immunohistochemistry)?”* European Institute of Oncology. Milan, Italia.
- 05/15 **Simposio Internacional de Oncología Traslacional.** *“Breast cancer genetics: new findings, new classifications”*. Fundació UAB. Barcelona, España.
- 05/15 **VII Simposium Bases Biológicas del Cáncer y Terapias personalizadas.** *“Cáncer de mama y subtipos intrínsecos. Pasado, presente y future”*. Centro de Investigación del Cáncer de Salamanca. Salamanca, España.
- 05/15 **American Society of Clinical Oncology (ASCO) Annual Meeting.** *“Predicting Response in Triple-Negative and HER2-Positive Breast Cancer: Unlocking Pieces to Solve the Puzzles”*. McCormick Place, Chicago, IL, EUA.
- 04/15 **I Simposio Nacional Genómica Aplicada en Oncología.** Spanish National Cancer Research Centre (CNIO). *“¿Qué nos ofrece Nanostring (Prosigna) en el día a día? Mi experiencia”*. CNIO. Madrid, España.
- 01/15 **Foro de Actualización en Cáncer de Mama.** *“Nuevos tipos intrínsecos en cáncer de mama: aportaciones presentes y futuras de la nueva clasificación”*. Madrid, España.
- 01/15 **The Annual Meeting of the Israeli Society for Clinical Oncology and Radiation Therapy.** *“Clinical implications of the intrinsic molecular subtypes of breast cancer”*. Israeli Society for Clinical Oncology and Radiation Therapy (ISCORT) Eilat, Israel.
- 12/14 **14th St Gallen International Breast Cancer Conference-BCC 2015** *“Clinical implications of the intrinsic molecular subtypes”*. St.Gallen Oncology Conferences «SG-BCC 2015». Viena. Austria.
- 11/14 **Advanced International Breast Cancer Course.** *“Advances in Biology”*. Accademia Nazionale di Medicina. University of Padua. Padua, Italia.
- 11/14 **Symposium on Women’s Cancer.** *“The genomic landscape of HR positive breast cancer”*. Catania, Italia.
- 10/14 **Jornada de Biología Celular y Marcadores Genéticos en Oncología.** *“Marcadores genéticos de expresión en cáncer de mama”*. Izasa Scientific, Barcelona. España.
- 10/14 **IDIBELL Lecture.** *“Clinical implications of the genomic landscape of breast cancer”*. Hospitalet, Barcelona. España.
- 06/14 **American Society of Clinical Oncology (ASCO) Annual Meeting.** *“Deconstructing the Molecular Portrait of Breast Cancer”*. Poster Discussant. Chicago, USA.
- 05/14 **Sfruttare appieno le potenzialità dei farmaci anti-HER2** *“Genomics, gene expression”*. Corso Residenziale. Roma, Italia.
- 04/14 **VIII Simposio Internacional Cancer de Mama de Santiago** *“Plenary: The molecular portrait of breast cancer: Past & Future”*. Clínica Las Condes. Santiago de Chile, Chile.
- 04/14 **VIII Simposio Internacional Cancer de Mama de Santiago** *“Triple negative Breast Cancer: Molecular characterization of prediction of chemotherapy benefit”*. Clínica Las Condes. Santiago de Chile, Chile.
- 04/14 **VIII Simposio Internacional Cancer de Mama de Santiago.** *“Luminal A&B Breast Cancer: Do they benefit the same from chemotherapy?”*. Clínica Las Condes. Santiago de Chile, Chile.
- 03/14 **Advances in Oncology, Seminario series-BioDonostia.** *“Therapeutic and Clinical implications of the genomic landscape of breast cancer”*. Instituto de Investigación Sanitaria Biodonostia. San Sebastian, España.
- 03/14 **European Breast Cancer Conference.** *“This House believes that Molecular Testing has made the Pathologist Redundant”*. Glasgow, Reino Unido.
- 03/14 **10th Simposio Internacional de Oncología Traslacional.** *“Breast cancer genetics: new findings, new classifications”*. Barcelona, España.

- 02/14 **Quinto Curso de Cirugía de Cáncer de Mama.** "PAM50: Subtipos de cáncer de mama. Valor predictivo". Barcelona, España.
- 02/14 **CNIO Workshop Traslacional.** "Vía PI3K-MTOR: input, output e incorporación de datos de expresión génica en ensayos clínicos". Madrid, España.
- 11/13 **UAE Cancer Congress.** "Personalized treatment for breast cancer the long journey ahead". Dubai, UAE.
- 11/13 **UAE Cancer Congress.** "Prognostic and Predictive Significance of the Intrinsic Breast Cancer Subtypes: What the Treating Oncologist Needs to know!" Dubai, UAE
- 11/13 **Advanced International Breast Cancer Course** "The new genomic landscape of Breast cancer". Accademia Nazionale di Medicina. Accademia Nazionale di Medicina. University of Padua. Padua Italia.
- 11/13 **17Th Fritz-Bender Foundation International Symposium.** Progress towards Individualized Cancer Treatments. "The New Genomic Landscape of Breast Cancer: Clinical and Therapeutic Implications". Barcelona, España.
- 11/13 **Avances en Farmacia Oncológica.** "Biomarcadores predictivos de respuesta en cáncer de mama". Madrid, España.
- 10/13 **V Cancer Conference.** "Personalized medicine in breast cancer: the long journey". Dubai, United Arab Emirates.
- 10/13 **V Cancer Conference.** "Predictive and prognostic value of the intrinsic molecular subtypes of breast cancer: what the treating oncologist needs to know!". Dubai, United Arab Emirates.
- 10/13 **X International Breast Cancer Conference.** "From the patient to the lab: lessons learned". Madrid, España.
- 10/13 **STARGET meeting at Karolinska Institutet.** "Molecular Characterization of the Breast Cancer Intrinsic Subtypes". Estocolmo, Suecia.
- 04/13 **II Congreso Nacional AECIMA.** "Subtipos moleculares – impacto en el pronóstico". Barcelona, España.
- 04/13 **IX Simposio Internacional de GEICAM.** "Plataformas genómicas: ¿Una herramienta más?". Valencia, España.
- 02/13 **Scientific session.** "Clinical implementation of the Molecular Portraits of Breast Cancer". Hospital Clínic, Barcelona, España.
- 03/13 **ESMO Symposium on Signalling Pathways in Cancer.** "Characterization of one disease in different subtypes". Sitges, Barcelona, España.
- 11/12 **Advanced International Breast Cancer Course.** "The Molecular Portraits of Breast Cancer". Accademia Nazionale di Medicina. University of Padua. Padua, Italia.
- 11/12 **International Biedenkopf Consensus Meeting.** "The Molecular Portraits of Breast Cancer". Biedenkopf, Alemania.
- 09/12 **Conferenza Nazionale COMU.** "Clinical Implementation of the Intrinsic Molecular Subtypes of Breast Cancer". Napoles, Italia.
- 11/11 **IX Breast Cancer Conference.** "Molecular classification of triple-negative tumors". Madrid, España.
- 11/11 **III SOLTÍ Scientific Meeting: Integrating Pathways, Platforms and Partners.** "Gene expression signatures in breast cancer". Madrid, España.
- 10/11 **EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer".** "Clinical Applications and Reproducibility of Gene Expression-based Assays". Bruselas, Belgica.
- 08/11 **10th International Congress on the Future of Breast Cancer.** "Molecular classification of Triple-Negative Breast Cancers". San Diego, EUA.
- 06/11 **III Simpósio Internacional de Tratamiento Multidisciplinar de Cáncer de Mama e Ginecológico.** Seminario: "Triple-negative tumors and Basal-like tumors are unique entities?".

Sao Paulo, Brasil.

- 06/11 **III Simpósio Internacional de Tratamiento Multidisciplinar de Cáncer de Mama e Ginecológico.** Seminario: *“Clinical implementation of the intrinsic molecular subtypes of breast cancer”*. Sao Paulo, Brasil.
- 04/10 **Molecular Pathology Group. Hospital Universitario de la Vall d’Hebron.** Seminario: *“Deconstructing the Molecular Portraits of Breast Cancer”*. Barcelona, España.
- 09/09 **34th Postdoc-Faculty Research Day.** Lineberger Comprehensive Cancer Center. Title: *“Characterization of a Naturally Occurring Stem Cell-like Breast Cancer Subtype”*. University of North Carolina, EUA.
- 01/08 **Lineberger Comprehensive Cancer Center: The C. Perou laboratory.** Seminario: *“Targeting Epidermal Growth Factor Receptor Family and Beyond”*. University of North Carolina, EUA.
- 01/08 **Lawrence Berkeley National Laboratory: The Gray laboratory.** Seminario: *“Approaches to Targeted Therapy Optimization: Epidermal Growth Factor Receptor Family and Beyond”*. University of California, Berkeley, California, EUA.

Publicaciones

215 publicaciones. 46 1^{er} autor y 35 senior. 60 (*corresponding author). IF total: 2.276.606 - Indice-H : 59 con 21.349 citaciones.

2022

1. **Aleix Prat**, Valentina Guarneri, Tomás Pascual, Fara Brasó-Maristany, Esther Sanfeliu, Laia Paré, Francesco Schettini, Débora Martínez, Pedro Jares, Gaia Griguolo, Maria Vittoria Dieci, Javier Cortés, Antonio Lombart-Cussac, Benedetta Conte, Mercedes Marín-Aguilera, Nuria Chic, Joan Anton Puig-Butillé, Antonio Martínez, Patricia Galván, Yi-Hsuan Tsai, Blanca González-Farré, Aurea Mira, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Pierfranco Conte, Charles M. Perou. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. **Biomedicine**. Vol. 75, 103801, January 01, 2022. [DOI:https://doi.org/10.1016/j.ebiom.2021.103801](https://doi.org/10.1016/j.ebiom.2021.103801). *Correspondence Author.

2021

2. OnCovid Study Group et al (**Prat, A.** N 75). Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. **JAMA Oncol**. 2021 Nov 24. doi: 10.1001/jamaoncol.2021.6199.
3. Pascual T, Oliveira M, Villagrasa P, Ortega V, Paré L, Bermejo B, Morales S, Amillano K, López R, Galván P, Canes J, Salvador F, Luciforo P, Rubio I, Lombart-Cussac A, Di Cosimo S, Baselga J, Harbeck N, **Prat A.** Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. **npj Breast Cancer** AccessVolume 7, Issue 1December 2021 Article number 145. Doi : [10.1038/s41523-021-00351-4](https://doi.org/10.1038/s41523-021-00351-4).
4. Laura Díaz-Gil, Fara Brasó-Maristany, Claudriana Locatelli, Ariana Centa, Balász Gyórfy, Alberto Ocaña, **Aleix Prat**, Atanasio Pandiella. Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. **J Exp Clin Cancer Res**. 2021 Oct 7;40(1):313. doi: [10.1186/s13046-021-02098-z](https://doi.org/10.1186/s13046-021-02098-z).
5. Mercedes Marín-Aguilera, María V Pereira, Natalia Jiménez, Òscar Reig, Anna Cuartero, Iván Victoria, Caterina Aversa, Laura Ferrer-Mileo, **Aleix Prat**, Begoña Mellado. Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes. **Cancers (Basel)**. 2021 Oct 1;13(19):4960. doi: [10.3390/cancers13194960](https://doi.org/10.3390/cancers13194960).
6. Nuria Chic, Fara Brasó-Maristany, **Aleix Prat**. Biomarkers of immunotherapy response in breast cancer beyond PD-L1. **Breast Cancer Res Treat**. 2021 Oct 21. doi: [10.1007/s10549-021-06421-2](https://doi.org/10.1007/s10549-021-06421-2).
7. David J Pinato, et al (**Prat, A. Position 74**). Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid



- retrospective, multicentre registry study. **Lancet Oncol.** 2021 Nov 3;S1470-2045(21)00573-8. doi: [10.1016/S1470-2045\(21\)00573-8](https://doi.org/10.1016/S1470-2045(21)00573-8).
8. Benedetta Conte, Davide Soldato, Maria Grazia Razeti, Piero Fregatti, Evandro de Azambuja, Francesco Schettini, **Aleix Prat**, Lucia Del Mastro, Matteo Lambertini. De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence. **Clin Breast Cancer.** 2021 Oct 8;S1526-8209(21)00292-5. doi: [10.1016/j.clbc.2021.10.001](https://doi.org/10.1016/j.clbc.2021.10.001).
 9. Laia Garrigós, et al. (**Prat, A.** position 42) COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. **Ther Adv Med Oncol.** 2021; 13: 17588359211053416. Published online 2021 Nov 2. doi: [10.1177/17588359211053416](https://doi.org/10.1177/17588359211053416).
 10. Fara Brasó-Maristany, Miriam Sansó, Nuria Chic, Débora Martínez, Blanca González-Farré, Esther Sanfeliu, Lucio Ghiglione, Esther Carcelero, Javier Garcia-Corbacho, Marcelo Sánchez, Dolors Soy, Pedro Jares, Vicente Peg, Cristina Saura, Montserrat Muñoz, **Aleix Prat**, Ana Vivancos. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. **Front Oncol.** 2021 Sep 20;11:710596. doi: [10.3389/fonc.2021.710596](https://doi.org/10.3389/fonc.2021.710596). eCollection 2021.
 11. Gehan Soosaipillai, Anjui Wu, Gino M Dettorre, Nikolaos Diamantis, John Chester, Charlotte Moss, Juan Aguilar-Company, Mark Bower, Christopher Ct Sng, Ramon Salazar, Joan Brunet, Eleanor Jones, Ricard Mesia, Amanda Jackson, Uma Mukherjee, Ailsa Sita-Lumsden, Elia Seguí, Diego Ottaviani, Anna Carbó, Sarah Benafif, Rachel Würstlein, Carme Carmona, Neha Chopra, Claudia Andrea Cruz, Judith Swallow, Nadia Saoudi, Eudald Felip, Myria Galazi, Isabel Garcia-Fructuoso, Alvin J X Lee, Thomas Newsom-Davis, Yien Ning Sophia Wong, Anna Sureda, Clara Maluquer, Isabel Ruiz-Camps, Alba Cabirta, **Aleix Prat**, Angela Loizidou, Alessandra Gennari, Daniela Ferrante, Josep Tabernero, Beth Russell, Mieke Van Hemelrijck, Saoirse Dolly, Nicholas J Hulbert-Williams, David J Pinato. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. **Ther Adv Med Oncol.** 2021 Sep 2;13:17588359211042224. doi: 10.1177/17588359211042224. eCollection 2021.
 12. Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Brasó-Maristany, Zighereda Ogbah, Mireia Parés, Marta Guzmán, Judit Grueso, Olga Rodriguez, Mafalda Oliveira, Analía Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, **Aleix Prat**, Rodrigo Dienstmann, Paolo Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra. High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer. **Clin Cancer Res.** 2021 Sep 30;clincanres.CCR-21-1810-A.2021. doi: [10.1158/1078-0432.CCR-21-1810](https://doi.org/10.1158/1078-0432.CCR-21-1810). Online ahead of print.
 13. Ignacio Isola, David F Moreno, Esther Moga, Mari-Pau Mena, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Aina Oliver-Caldés, M Carmen Salgado, Fara Brasó-Maristany, Jordi Yagüe, M Teresa Cibeira, **Aleix Prat**, Laura Rosiñol, Joan Bladé, Carlos Fernández de Larrea. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. **Ann Hematol.** 2021 Aug 31. doi: [10.1007/s00277-021-04653-2](https://doi.org/10.1007/s00277-021-04653-2). Online ahead of print.
 14. Helga Bergholtz, Jodi M. Carter, Alessandra Cesano, Maggie Chon U Cheang ,Sarah E. Church, Prajan Divakar, Christopher A. Fuhrman, Shom Goel, Jingjing Gong, Jennifer L. Guerriero, Margaret L. Hoang, E. Shelley Hwang, Hellen Kuasne, Jinho Lee, Yan Liang, Elizabeth A. Mittendorf, Jessica Perez, **Aleix Prat**, Lajos Pusztai, Jason W. Reeves, Yasser Riazalhosseini, Jennifer K. Richer, Özgür Sahin, Hiromi Sato, Ilana Schlam, Therese S. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx[®] Digital Spatial Profiler. **Guideline Cancers (Basel).** 2021Sep4;13(17):4456. [10.3390/cancers13174456](https://doi.org/10.3390/cancers13174456).
 15. Adrián Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galván, Sandra Benítez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, María Teresa Soler-Monsó, Gemma Viñas, Mansour Alsaleem, Emad A Rakha, Andrew R Green, Patricia G Santamaria, Celine Mulder, Simone Lemeer, Joaquin Arribas, **Aleix Prat**, Teresa Puig, Eva Gonzalez-Suarez. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. **Breast Cancer Res.** 2021 Mar 30;23(1):42. doi: [10.1186/s13058-021-01390-2](https://doi.org/10.1186/s13058-021-01390-2).
 16. Francesco Schettini, **Aleix Prat**. Dissecting the biological heterogeneity of HER2-positive breast cancer. **Breast.** 2021 Aug 5;59:339-350. doi: [10.1016/j.breast.2021.07.019](https://doi.org/10.1016/j.breast.2021.07.019). Online ahead of print.
 17. H J Burstein, G Curigliano, B Thürlimann, W P Weber, P Poortmans, M M Regan, H J Senn, E P Winer, M Gnant, **Panelists of the St Gallen Consensus Conference**. Customizing local and systemic therapies for women

- with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. **Ann Oncol.** 2021 Jul 6;S0923-7534(21)02104-9. doi: [10.1016/j.annonc.2021.06.023](https://doi.org/10.1016/j.annonc.2021.06.023).
18. R. Reyes, R. López-Castro, E. Auclin, T. García, M.J. Chourio, A. Rodriguez, L. López, J.C. Laguna, C. Lucena, L. Molins, D. Martínez, F. Casas, M. Mayoral, C. Teixidó, **A. Prat**, N. Viñolas, N. Reguart and L. Mezquita. MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer. *J Thorac Oncol.* 2021 Mar; 16(3): S141. Published online 2021 Mar 19. doi: [10.1016/j.jtho.2021.01.219](https://doi.org/10.1016/j.jtho.2021.01.219)
 19. Valentina Guarneri, ... (**Aleix Prat** (17) at all. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. **Eur J Cancer.** 2021 Jun 18;153:133-141. doi: [10.1016/j.ejca.2021.05.018](https://doi.org/10.1016/j.ejca.2021.05.018). Online ahead of print.
 20. Leticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, Daniel G. Tiezzi, Guillermo Villacampa, Samuel Gonçalves-Ribeiro, Laia Paré, Carla Anjos Souza, Vanesa Ortega, Stephen-John Sammut, Pol Cusco, Roberta Fasani, Suet-Feung Chin, Jose Perez-Garcia, Rodrigo Dienstmann, Paolo Nuciforo, Patricia Villagrasa, Isabel T. Rubio, Aleix Prat & Carlos Caldas. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. **NPJ Breast Cancer.** 2021 Jun 7;7(1):73. doi: [10.1038/s41523-021-00282-0](https://doi.org/10.1038/s41523-021-00282-0).
 21. Nuria Chic, Francesco Schettini, Fara Brasó-Maristany, Esther Sanfeliu, Barbara Adamo, Maria Vidal, Débora Martínez, Patricia Galván, Blanca González-Farré, Javier Cortés, Joaquín Gavila, Cristina Saura, Mafalda Oliveira, Sònia Pernas, Olga Martínez-Sáez, Jesús Soberino, Eva Ciruelos, Lisa A Carey, Montserrat Muñoz, Charles M Perou, Tomás Pascual, Meritxell Bellet, Aleix Prat. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT. **EBioMedicine.** 2021 Jun 20;69:103451. doi: [10.1016/j.ebiom.2021.103451](https://doi.org/10.1016/j.ebiom.2021.103451). Online ahead of print.
 22. Olga Martínez-Sáez, **Aleix Prat**. Current and Future Management of HER2-Positive Metastatic Breast Cancer. *JCO Oncol Pract.* 2021 Jun 2;OP2100172. doi: [10.1200/OP.21.00172](https://doi.org/10.1200/OP.21.00172). Online ahead of print.
 23. Fara Brasó-Maristany, Laia Paré, Nuria Chic, Olga Martínez-Sáez, Tomás Pascual, Meritxell Mallafré-Larrosa, Francesco Schettini, Blanca González-Farré, Esther Sanfeliu, Débora Martínez, Patricia Galván, Esther Barnadas, Belinda Salinas, Pablo Tolosa, Eva Ciruelos, Esther Carcelero, Cecilia Guillén, Barbara Adamo, Reinaldo Moreno, Maria Vidal, Montserrat Muñoz, **Aleix Prat***. Gene expression profiles of breast cancer metastasis according to organ site. *Mol Oncol.* 2021 May 29. doi: [10.1002/1878-0261.13021](https://doi.org/10.1002/1878-0261.13021). *Correspondence Author.
 24. José Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, Agostina Stradella, Begoña Bermejo, Peter Schmid, Frederik Marmé, Santiago Escrivá-de-Romani, Lourdes Calvo, Nuria Ribelles, Noelia Martínez, Cinta Albacar, **Aleix Prat**, Florence Dalenc, Khaldoun Kerrou, Marco Colleoni, Noemia Afons. Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. **Lancet Oncol.** 2021 May 18;S1470-2045(21)00122-4. doi: [10.1016/S1470-2045\(21\)00122-4](https://doi.org/10.1016/S1470-2045(21)00122-4).
 25. Tomás Pascual, Mafalda Oliveira, Eva Ciruelos, Meritxell Bellet Ezquerro,, Cristina Saura, Joaquin Gavilá, Sonia Pernas, Montserrat Muñoz, Maria J Vidal, Mireia Margelí Vila, Juan M Cejalvo, Blanca González-Farré, Martin Espinosa-Bravo, Josefina Cruz, Francisco Javier Salvador-Bofill, Juan Antonio Guerra, Ana María Luna Barrera, Miriam Arumi de Dios, Stephen Esker, Pang-Dian Fan, Olga Martínez-Sáez, Guillermo Villacampa, Laia Paré, Juan M Ferrero-Cafiero, Patricia Villagrasa, **Aleix Prat***. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. **Front Oncol.** 2021 Apr 23;11:638482. doi: [10.3389/fonc.2021.638482](https://doi.org/10.3389/fonc.2021.638482). *Correspondence Author.
 26. David J Pinato... ... at all (64-**Aleix Prat**). Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. **Eur J Cancer.** 2021 Jun;150:190-202. doi: [10.1016/j.ejca.2021.03.035](https://doi.org/10.1016/j.ejca.2021.03.035).
 27. Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, Marianna Sirico, Silvia P Corona, Mario Giuliano, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Sabino De Placido, Pasquale Rescigno, **Aleix Prat**, Giuseppe Curigliano, Daniele Generali. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. **Eur J Cancer.** 2021 Apr 13;149:134-152. doi: [10.1016/j.ejca.2021.02.035](https://doi.org/10.1016/j.ejca.2021.02.035).

28. Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Pusztai, Mothaffar F. Rimawi, Rachel Schiff, Grazia Arpino, Sabino De Placido, **Aleix Prat**, and Daniele Generali. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. **Cancers (Basel)**. 2021 Mar; 13(6): 1458. Published online 2021 Mar 22. doi: [10.3390/cancers13061458](https://doi.org/10.3390/cancers13061458).
29. Ángela Quintana, Vicente Peg, **Aleix Prat**, Teresa Moliné, Guillermo Villacampa, Laia Paré, Patricia Galván, Rodrigo Dientsmann, Peter Schmid, Giuseppe Curigliano, Eva Muñoz-Couselo, José Perez-García, Merce Marti, Juan Blanco-Heredia, Carla Dos Anjos, Miguel Vazquez, Leticia De Mattos-Arruda, Javier Cortés. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. **Eur J Cancer**. 2021 Mar 17;148:134-145. doi: [10.1016/j.ejca.2021.01.037](https://doi.org/10.1016/j.ejca.2021.01.037).
30. Gino M Dettorre... at all (56-**Aleix Prat**). OnCovid study group Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. **J Immunother Cancer**. 2021 Mar;9(3):e002277. doi: [10.1136/jitc-2020-002277](https://doi.org/10.1136/jitc-2020-002277).
31. **Aleix Prat**(*), Anwasha Chaudhury, Nadia Solovieff, Laia Paré, Débora Martinez, Nuria Chic, Olga Martínez-Sáez, Fara Brasó-Maristany, Agnes Lteif, Tetiana Taran, Naveen Babbar, Fei Su. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. **J Clin Oncol**. 2021 Mar 26;JCO2002977. doi: [10.1200/JCO.20.02977](https://doi.org/10.1200/JCO.20.02977). Online ahead of print.
32. Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, Maria Vittoria Dieci, Sonia Pernas, Joaquín Gavilá, Valentina Guarneri, Javier Cortés, Patricia Villagrasa, Nuria Chic, María Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart-Cussac, PierFranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galván, Lisa A Carey, Charles M Perou, **Aleix Prat** (*). Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy. **Clin Cancer Res**. 2021 Feb 25;clincanres.4102.2020. doi: [10.1158/1078-0432.CCR-20-4102](https://doi.org/10.1158/1078-0432.CCR-20-4102).
33. Buus R, Sziogyarto Z, Schuster EF, Xiao H, Haynes BP, Sestak I, Cuzick J, Paré L, Seguí E, Chic N, **Prat A**, Dowsett M, Cheang MCU. Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®. **NPJ Breast Cancer**. 2021 Feb 12;7(1):15. doi: [10.1038/s41523-021-00216-w](https://doi.org/10.1038/s41523-021-00216-w).
34. Griguolo G, Dieci MV, Paré L, Miglietta F, Generali DG, Frassoldati A, Cavanna L, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Ficarra G, **Prat A**, Conte P, Guarneri V. Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. **NPJ Breast Cancer**. 2021 Feb 12;7(1):12. doi: [10.1038/s41523-021-00223-x](https://doi.org/10.1038/s41523-021-00223-x).
35. Martínez-Sáez O, Pascual T, Brasó-Maristany F, Chic N, González-Farré B, Sanfeliu E, Rodríguez A, Martínez D, Galván P, Rodríguez AB, Schettini F, Conte B, Vidal M, Adamo B, Martínez A, Muñoz M, Moreno R, Villagrasa P, Salvador F, Ciruelos EM, Faull I, Odegaard JI, **Prat A**. Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. **NPJ Breast Cancer**. 2021 Feb 3;7(1):8. doi: [10.1038/s41523-021-00218-8](https://doi.org/10.1038/s41523-021-00218-8).
36. Yoo Jane Han, Jing Zhang, Jung-Hyun Lee, Jennifer M Mason, Olga Karginova, Toshio F Yoshimatsu, Qinyu Hao, Ian Hurley, Laia Paré Brunet, **Aleix Prat**, Kannanganattu V Prasanth, Michaela U Gack, Olufunmilayo I Olopade. The BRCA1 Pseudogene Negatively Regulates Anti-Tumor Responses through Inhibition of Innate Immune Defense Mechanisms. **Cancer Res**. 2021 Jan 20;canres.1959.2020. doi: [10.1158/0008-5472.CAN-20-1959](https://doi.org/10.1158/0008-5472.CAN-20-1959). Online ahead of print.
37. Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerria M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, **Prat A**, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M.. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. **Lancet Oncol**. 2021 Feb;22(2):212-222. doi: [10.1016/S1470-2045\(20\)30642-2](https://doi.org/10.1016/S1470-2045(20)30642-2). Epub 2021 Jan 15.

38. Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, **Prat A**, Jerusalem G, Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. **Breast Cancer Res.** 2021 Jan 15;23(1):8. doi: [10.1186/s13058-020-01382-8](https://doi.org/10.1186/s13058-020-01382-8).
39. Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martínez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrassa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, **Prat A**. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. **NPJ Breast Cancer.** 2021 Jan 4;7(1):1. doi: [10.1038/s41523-020-00208-2](https://doi.org/10.1038/s41523-020-00208-2).

2020

40. Prat A , Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. **J Natl Cancer Inst.** 2020 Jan 1;112(1):46-54. doi: [10.1093/jnci/djz042](https://doi.org/10.1093/jnci/djz042).
41. De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, **Prat A**, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy. **Clin Cancer Res.** 2020 Feb 1;26(3):738-745. doi: [10.1158/1078-0432.CCR-19-1402](https://doi.org/10.1158/1078-0432.CCR-19-1402). Epub 2019 Oct 25
42. Díaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Gálvez F, Falcón A, Alamo MDC, Morales C, Amerigo M, Pascual J, Sanchez-Muñoz A, González-Guerrero M, Vicioso L, Laborda A, Ortega MV, Perez L, Fernandez-Martinez A, Chic N, Jerez JM, Alvarez M, **Prat A**, Ribelles N, Alba E. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. **Front Oncol.** 2019 Nov 5;9:1178. Doi: [10.3389/fonc.2019.01178](https://doi.org/10.3389/fonc.2019.01178). eCollection 2019.
43. **Prat A** , Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaña A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrassa P, Gavilá J. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, 25and randomized, 25and randomized, phase 2 trial. **Lancet Oncol.** 2020 Jan;21(1):33-43. Doi: [10.1016/S1470-2045\(19\)30786-7](https://doi.org/10.1016/S1470-2045(19)30786-7). Epub 2019 Dec 11.
44. Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, Bermejo B, Oliveira M, Morales S, Martínez N, Vidal M, Adamo B, Martínez O, Pernas S, López R, Muñoz M, Chic N, Galván P, Garau I, Manso L, Alarcón J, Martínez E, Gregorio S, Gomis RR, Villagrassa P, Cortés J, Ciruelos E, **Prat A**. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. **Nat Commun.** 2020 Jan 20;11(1):385. doi: [10.1038/s41467-019-14111-3](https://doi.org/10.1038/s41467-019-14111-3).
45. Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, Martínez O, Adamo B, Vidal M, Muñoz M, Fernández-Martínez A, Rognoni C, Griguolo G, Guarneri V, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrassa P, De Placido S, Schiff R, Veeraraghavan J, Rimawi MF, Osborne CK, Pernas S, Perou CM, Carey LA, Prat A. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. **Cancer Treat Rev.** 2020 Jan 17;84:101965. doi: [10.1016/j.ctrv.2020.101965](https://doi.org/10.1016/j.ctrv.2020.101965). [Epub ahead of print] Review.
46. Marín-Aguilera M; Jiménez N; Reig Ò; Montalbo R; Verma AK4; Castellano G; Mengual L; Victoria I; Pereira MV; Milà-Guasch M; García-Recio S; Benítez-Ribas D; Cabezón R; González A; Juan M; **Prat A**; Mellado B. Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. **Cells.** 2020 Jan 14;9(1). pii: E203. doi: [10.3390/cells9010203](https://doi.org/10.3390/cells9010203).

47. Brandão M, Caparica R, Malorni L, **Prat A**, Carey LA, Piccart M. What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?. **Clin Cancer Res.** 2020 Feb 11. pii: clincanres.2612.2019. doi: [10.1158/1078-0432.CCR-19-2612](https://doi.org/10.1158/1078-0432.CCR-19-2612). [Epub ahead of print].
48. Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzman M, Rodriguez O, Bruna A, Hirst CS, Barnicle A, de Bruin EC, Reddy A, Schiavon G, Arribas J, Mills GB, Caldas C, Dienstman R, **Prat A**, Nuciforo P, Razavi P, Scaltriti M, Turner NC, Saura C, Davies BR, Oliveira M, Serra V. Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts. **Clin Cancer Res.** 2020 Mar 27. pii: clincanres.3324.2019. doi: [10.1158/1078-0432.CCR-19-3324](https://doi.org/10.1158/1078-0432.CCR-19-3324). [Epub ahead of print].
49. Elba Marin; Cristina Teixido; Elena Carmona-Rocha; Roxana Reyes; Ainara Arcocha; Nuria Viñolas; M^ªCarmen Rodríguez-Mues; Carlos Cabrera; Marcelo Sánchez; Ivan Vollmer; Sergi Castillo; Silvia Muñoz; Ivana G Sullivan; Adela Rodriguez; Mireia Garcia; Silvia Alos; Pedro Jares; Antonio Martinez; **Aleix Prat**; Miguel Ángel Molina-Vila; Noemi Reguart. Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. **Cancers (Basel).** 2020 Apr 30;12(5):E1124. doi: [10.3390/cancers12051124](https://doi.org/10.3390/cancers12051124).
50. Olga Martínez-Sáez; Nuria Chic; Tomás Pascual; Barbara Adamo; Maria Vidal; Blanca González-Farré; Esther Sanfeliu; Francesco Schettini; Benedetta Conte; Fara Brasó-Maristany; Adela Rodríguez; Débora Martínez; Patricia Galván; Ana Belén Rodríguez; Antonio Martinez; Montserrat Muñoz; **Aleix Prat**. Frequency and Spectrum of PIK3CA Somatic Mutations in Breast Cancer. **Breast Cancer Res.** 2020 May 13;22(1):45. doi: [10.1186/s13058-020-01284-9](https://doi.org/10.1186/s13058-020-01284-9).
51. Francesco Schettini; Fabiola Giudici; Mario Giuliano; Massimo Cristofanilli; Grazia Arpino; Lucia Del Mastro; Fabio Puglisi; Sabino De Placido; da Paris; Pietro De Placido; Sergio Venturini; Michelino De Laurentis; PierFranco Conte; Dejan Juric; Antonio Lombart-Cussac; Lajos Pusztai; **Aleix Prat**; Guy Jerusalem; Angelo Di Leo; Daniele Generali. Overall Survival of CDK4/6-inhibitors-based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. **J Natl Cancer Inst.** 2020 May 14;djaa071. doi: [10.1093/jnci/djaa071](https://doi.org/10.1093/jnci/djaa071). Online ahead of print.
52. Natascha Hruschka; Maria Subijana; Osvaldo Graña-Castro; Francisco Del Cano-Ochoa; Laia Paré Brunet; Ana Sagrera; Aurelien De Reynies; David Andreu; Joe Sutton; Igor Chernukhin; SuetFeung Chin; Carlos Caldas; Ana Lluch; Octavio Burgués; Begoña Bermejo; Santiago RamónMaiques; Jason S Carroll; **Aleix Prat**; Francisco X Real; Paola Martinelli. The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. **Oncogene.** 2020 Jun 25. doi: [10.1038/s41388-020-1376-3](https://doi.org/10.1038/s41388-020-1376-3). Online ahead of print.
53. Susana Garcia-Recio, Aatish Thennavan, Michael P East, Joel S Parker, Juan M Cejalvo, Joseph P Garay, Daniel P Hollern, Xiaping He, Kevin R Mott, Patricia Galván, Cheng Fan, Sara R Selitsky, Alisha R Coffey, David Marron, Fara Brasó-Maristany, Octavio Burgues, Joan Albanell, Federico Rojo, Ana Lluch, Eduardo Martinez de Dueñas, Jeffrey M Rosen, Gary L Johnson, Lisa A Carey, **Aleix Prat**, Charles M Perou. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. **J Clin Invest.** 2020 Jun 23;130323. doi: [10.1172/JCI130323](https://doi.org/10.1172/JCI130323). Online ahead of print.
54. Ester Lozano, Mari-Pau Mena, Tania Díaz, Beatriz Martin-Antonio, Sheila León, Luis-Gerardo Rodríguez-Lobato, Aina Oliver-Caldés, Maria Teresa Cibeira, Joan Bladé, **Aleix Prat**, Laura Rosiñol, Carlos Fernández de Larrea. Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. **Clin Cancer Res.** 2020 Jun 8. doi: [10.1158/1078-0432.CCR-19-3673](https://doi.org/10.1158/1078-0432.CCR-19-3673). Online ahead of print.
55. Gaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, Tomás Pascual, Núria Chic, Tamara Saurí, Ronald Kates, Oleg Gluz, Débora Martínez, Laia Paré, Vassilena Tsvetkova, David Pesantez, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Patricia Galván, Laura Barberá, Miriam Cuatrecasas, Mathias Christgen, Hans Kreipe, Inés Monge-Escartín, Patricia Villagrasa, Dolors Soy, Tommaso Giarratano, Maria Vittoria Dieci, Pierfranco Conte, Nadia Harbeck, Valentina Guarneri, **Aleix Prat**. ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. **Cancers (Basel).** 2020 Jul 14;12(7):E1902. doi: [10.3390/cancers12071902](https://doi.org/10.3390/cancers12071902).
56. David J Pinato, Alvin J X Lee, Federica Biello, Elia Seguí, Juan Aguilar-Company, Anna Carbó, Riccardo Bruna, Mark Bower, Gianpiero Rizzo, Sarah Benafif, Carme Carmona, Neha Chopra, Claudia Andrea Cruz,

- Francesca D'Avanzo, Joanne S Evans, Myria Galazi, Isabel Garcia-Fructuoso, Alessia Dalla Pria, Thomas Newsom-Davis, Diego Ottaviani, Andrea Patriarca, Roxana Reyes, Rachel Sharkey, Christopher C T Sng, Yien Ning Sophia Wong, Daniela Ferrante, Lorenza Scotti, Gian Carlo Avanzi, Mattia Bellan, Luigi Mario Castello, Javier Marco-Hernández, Meritxell Mollà, Mario Pirisi, Isabel Ruiz-Camps, Pier Paolo Sainaghi, Gianluca Gaidano, Joan Brunet, Josep Taberbero, **Aleix Prat**, Alessandra Gennari. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. **Cancers (Basel)**. 2020 Jul 8;12(7):E1841. doi: [10.3390/cancers12071841](https://doi.org/10.3390/cancers12071841).
57. Tomas Pascual, Juan M Cejalvo, Mafalda Oliveira, Maria Vidal, Estela Vega, Sergi Ganau, Ana Julve, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Luis de la Cruz-Merino, Manel Juan, Juan M Ferrero-Cafiero, Jordi Canes, Xavier Gonzalez, Patricia Villagrasa, **Aleix Prat**. SOLT1-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. **Future Oncol**. 2020 Jul 7. doi: [10.2217/fon-2020-0246](https://doi.org/10.2217/fon-2020-0246). Online ahead of print.
 58. Manuel Ramos-Casals, Julie R. Brahmer, Margaret K. Callahan, Alejandra Flores-Chávez, Niamh Keegan, Munther A. Khamashta, Olivier Lambotte, Xavier Mariette, **Aleix Prat** & Maria E. Suárez-Almazor. Immune-related adverse events of checkpoint inhibitors. *Nature Reviews Disease Primers* volume 6, Article number: 38 (2020).
 59. David J Pinato, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher CT Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesía, Elia Segui, Federica Biello, Daniele Generali, Salvatore Grisanti, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Anna Carbó, Riccardo Bruna, Sarah Benafif, Andrea Marrari, Rachel Wuerstlein, Maria Carmen Carmona-Garcia, Neha Chopra, Carlo Alberto Tondini, Oriol Mirallas, Valeria Tovazzi, Marta Betti, Salvatore Provenzano, Vittoria Fotia, Claudia Andrea Cruz, Alessia Dalla Pria, Francesca D'Avanzo, Joanne S Evans, Nadia Saoudi-Gonzalez, Eudald Felip, Myria Galazi, Isabel Garcia-Fructuoso, Alvin J X Lee, Thomas Newsom-Davis, Andrea Patriarca, David García-Illescas, Roxana Reyes, Palma Dileo, Rachel Sharkey, Yien Ning Sophia Wong, Daniela Ferrante, Javier Marco-Hernández, Anna Sureda, Clara Maluquer, Isabel Ruiz-Camps, Gianluca Gaidano, Lorenza Rimassa, Lorenzo Chiudinelli, Macarena Izuzquiza, Alba Cabirta, Michela Franchi, Armando Santoro, **Aleix Prat**, Josep Taberbero, and Alessandra Gennari. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. **Cancer Discov**. 2020 Jul 31;CD-20-0773. doi: [10.1158/2159-8290.CD-20-0773](https://doi.org/10.1158/2159-8290.CD-20-0773). Online ahead of print.
 60. Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, Antonio Frassoldati, Luigi Cavanna, Antonino Musolino, Francesco Giotta, Anita Rimanti, Ornella Garrone, Elena Bertone, Katia Cagossi, Oriana Nanni, Federico Piacentini, Enrico Orvieto, Gaia Griguolo, Matteo Curtarello, Loredana Urso, Laia Paré, Nuria Chic, Roberto D'Amico, **Aleix Prat**, PierFranco Conte. PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype. **Clin Cancer Res** 2020 Aug 25;clincanres.1731.2020. doi: [10.1158/1078-0432.CCR-20-1731](https://doi.org/10.1158/1078-0432.CCR-20-1731). Online ahead of print.
 61. **Aleix Prat**, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, María Vidal, Fara Brasó-Maristany, Patricia Galván, Jan C Brase, Vanessa Rodrik-Outmezguine, Stephen R D Johnston, Eva M Ciruelos, Joel S Parker A. Prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer. **Clin Cancer Res** 2020 Sep 22;clincanres.2793.2020. doi: [10.1158/1078-0432.CCR-20-2793](https://doi.org/10.1158/1078-0432.CCR-20-2793). Online ahead of print.
 62. Eva M Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romaní, Luis Manso, Barbara Adamo, Eduardo Martínez de Dueñas, Javier Cortés, Silvia Vázquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez Jañez, Alvaro Montaña, Begoña Bermejo, Serafín Morales, M^a Jose Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier González Farré, **Aleix Prat**. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLT1-1303 PATRICIA trial. **Clin Cancer Res**. 2020 Sep 16;clincanres.0844.2020. doi: [10.1158/1078-0432.CCR-20-0844](https://doi.org/10.1158/1078-0432.CCR-20-0844). Online ahead of print.
 63. Rosello, I.V., Vidal-Sicart, Sánchez, Algarra, Torras, Solà, Vernet, Mollà, M. Osés, Ganau, Ubeda, Bargalló, Vidal, Muñoz, **Prat, A.** Farre, B. Marsical, A, Vargas, I. Sentinel node after NeoAdjuvancy in node-positive breast cance. **European Journal of Cancer**. Volume 138, October 2020, Page S114. doi: [10.1016/S0959-8049\(20\)30843-1](https://doi.org/10.1016/S0959-8049(20)30843-1).
 64. Lerena, I.C., Boada, D., Caparros, X., Ganau, S., Bargallo, X., Ubeda, B., Descarrega, J., Raigosa, M., Yoon, T.S., Santfeliu, E., Gonzalez, B., Muñoz, M., **Prat, A.**, Torne, A., Carmona, F., Fontdevila, J., Alonso, I.

Imaging and clinical predictors for nipple-areola complex (NAC) involvement in breast cancer patients undergoing Nipple-Sparing Mastectomy (NSM). **European Journal of Cancer**. Volume 138, October 2020, Page S118. DOI:[https://doi.org/10.1016/S0959-8049\(20\)30853-4](https://doi.org/10.1016/S0959-8049(20)30853-4).

65. **Aleix Prat**; Valentina Guarneri; Laia Paré; Gaia Griguolo; Tomás Pascual; Maria Dieci; Núria Chic; Blanca González-Farré; Antonio Frassoldati; Esther Sanfeliu; Juan M Cejalvo; Montserrat Muñoz; Giancarlo Bisagni; Fara Brasó-Maristany; Loredana Urso; Maria Vidal; Alba A Brandes; Barbara Adamo; Pierfranco Conte. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *The Lancet*. Volume 21, Issue 11, November 2020, Pages 1455-1464. [https://doi.org/10.1016/S1470-2045\(20\)30450-2](https://doi.org/10.1016/S1470-2045(20)30450-2).
66. **Aleix Prat**, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, Maria Vidal, Fara Brasó-Maristany, Patricia Galván, Jan Christoph Brase, Vanessa Rodrik-Outmezguine, Stephen Johnston Eva Ciruelos, Joel S Parker. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. **Clin Cancer Res**. 2020 Dec 1;26(23):6141-6148. doi: [10.1158/1078-0432.CCR-20-2793](https://doi.org/10.1158/1078-0432.CCR-20-2793).
67. Paolo Tarantino, **Aleix Prat**, Giuseppe Curigliano. New anti-HER2 agents for brain metastasis: histology-agnostic weapons? **Breast Cancer Res Treat**. 2020 Oct 30. doi: [10.1007/s10549-020-05982-y](https://doi.org/10.1007/s10549-020-05982-y). Online ahead of print.
68. Ana C Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, **Aleix Prat**, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L Arteaga, Ian E Krop, David B Solit, Gordon B Mills, Lewis C Cantley, Eric P Winer, Nancy U Lin, Jordi Rodon. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. *Breast Cancer Res*. 2020 Nov 2;22(1):120. doi: [10.1186/s13058-020-01354-y](https://doi.org/10.1186/s13058-020-01354-y).
69. Montserrat Muñoz, **Aleix Prat**. Implementing preoperative endocrine therapy in breast cancer. *Lancet Oncol*. 2020 Nov;21(11):1390-1392. doi: [10.1016/S1470-2045\(20\)30478-2](https://doi.org/10.1016/S1470-2045(20)30478-2).
70. Natalia Jiménez, Òscar Reig, Ruth Montalbo, Maria Milà-Guasch, Lluís Nadal-Dieste, Giancarlo Castellano, Juan José Lozano, Iván Victoria, Albert Font, Alejo Rodríguez-Vida, Joan Carles, Cristina Suárez, Montserrat Domènech, Núria Sala-González, Pedro Luis Fernández, Leonardo Rodríguez-Carunchio, Sherley Díaz, **Aleix Prat**, Mercedes Marín-Aguilera, Begoña Mellado. Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. *Front Oncol*. 2020 Nov 2;10:594023. doi: [10.3389/fonc.2020.594023](https://doi.org/10.3389/fonc.2020.594023).
71. Cristina Aguado, Cristina Teixido, Ruth Román, Roxana Reyes, Ana Giménez-Capitán, Elba Marin, Carlos Cabrera, Nuria Viñolas, Sergi Castillo, Silvia Muñoz, Ainara Arcocha, Laura López-Vilaró, Ivana Sullivan, Erika Aldegue, Sonia Rodríguez, Irene Moya, Santiago Viteri, Andrés Felipe Cardona, Ramon Palmero, Cristina Sainz, Miguel Mesa-Guzmán, María D Lozano, Andrés Aguilar-Hernández, Alejandro Martínez-Bueno, María González-Cao, Elena Gonzalvo, William P J Leenders, Rafael Rosell, Luis M Montuenga, **Aleix Prat**, Miguel A Molina-Vila, Noemi Reguart. Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer. *Mol Oncol*. 2020 Nov 25. doi: [10.1002/1878-0261.12861](https://doi.org/10.1002/1878-0261.12861). Online ahead of print.
72. Paolo Tarantino, **Aleix Prat**, Javier Cortes, Fatima Cardoso, Giuseppe Curigliano. Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. *Biochim Biophys Acta Rev Cancer*. 2020 Nov 28;1875(1):188487. doi: [10.1016/j.bbcan.2020.188487](https://doi.org/10.1016/j.bbcan.2020.188487). Online ahead of print.
73. Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, Susana Cedrés, Alex Martínez-Martí, Nuria Pardo, Nadia Saoudi-Gonzalez, Debora Martinez, Jose Jimenez, Irene Sansano, Francesco M Mancuso, Paolo Nuciforo, Luis M Montuenga, Montse Sánchez-Céspedes, **Aleix Prat**, Ana Vivancos, Enriqueta Felip, Ramon Amat. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. *Mol Oncol*. 2020 Dec 20. doi: [10.1002/1878-0261.12891](https://doi.org/10.1002/1878-0261.12891). Online ahead of print.

2019

74. Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, González X, Canes J, Paré L, Calvo I, Ciruelos E, Muñoz M, Virizuela JA, Ruiz I, Andrés R, Perelló A, Martínez J, Morales S, Marín-Aguilera M, Martínez D, Quero JC, Llombart-Cussac A, **Prat A(*)**. Safety, activity, and molecular heterogeneity following neoadjuvant non pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and

- pertuzumab in HER2-positive breast cancer (Opti-HERHEART): an open-label, single-group, multicenter, phase 2 trial. **BMC Med.** 2019 Jan 9;17(1):8. Doi: 10.1186/s12916-018-1233-1. (*) Corresponding author.
75. Ayala de la Peña, F.; Andrés, R.; Garcia-Sáenz, J.A.; Manso, L.; Margelí, M.; Dalmau, E.; Pernas, S.; **Prat, A.**; Servitja, S.; Ciruelos, E. SEOM clinical guidelines in early stage breast 29andom (2018). **Clinical and Translational Oncology.** 21(1), pp. 18-30. 25 January 2019, Pages 18-30.
 76. **Prat A**, Brase JC, Cheng Y, Nuciforo P, Paré L, Pascual T, Martínez D, Galván P, Vidal M, Adamo B, Hortobagyi GN, Baselga J, Ciruelos E. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50Intrinsic Subtype Analysis of BOLERO-2. **The Oncologist.** 2019 Jul;24(7):893-900. doi: [10.1634/theoncologist.2018-0407](https://doi.org/10.1634/theoncologist.2018-0407).
 77. Ingrid Mayer, **Aleix Prat**, Daniel Egle, Sibel Blau, Jose Alejandro Perez Fidalgo, Michael Gnant, Peter Fasching, Marco Colleoni, Antonio Wolff, Eric Winer, Christian Singer, Sara Hurvitz, Laura Garcia Estevez, Peter van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian Vogl, Dalila Sellami, and Carlos Arteaga. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). **Clin Cancer Res.** 2019.
 78. Montalbo R, Lozano JJ, Izquierdo L, Ingelmo-Torres M, Baños C, Palou J, Van der Heijden AG, Medina R, Schmidbauer J, **Prat A**, Ribal MJ, Alcaraz A, Mengual L. Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. **Transl Res.** 2019 Feb 7. Pii: S1931-5244(19)30025-8. Doi: 10.1016/j.trsl.2019.02.003. [Epub ahead of print]
 79. Guarneri V, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, Orvieto E, Urso L, Pascual T, Paré L, Galván P, Ambroggi M, Giorgi CA, Moretti G, Griguolo G, Vicini R, Prat A, Conte PF. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study. **Ann Oncol.** 2019 Jun 1;30(6):921-926. doi: [10.1093/annonc/mdz055](https://doi.org/10.1093/annonc/mdz055).
 80. Marín-Aguilera M, Reig Ò, Milà-Guasch M, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Del Alba AG, Jiménez N, Victoria I, Sala-González N, Ribal MJ, López S, Etxaniz O, Anguera G, Maroto P, Fernández PL, **Prat A**, Mellado B. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.. **Int J Cancer.** 2019 Feb 26. Doi: 10.1002/ijc.32238. [Epub ahead of print]
 81. Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, **Prat A**, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. **Ann Oncol.** 2019 Jun 1;30(6):927-933. doi: [10.1093/annonc/mdz076](https://doi.org/10.1093/annonc/mdz076).
 82. Griguolo, G.; Pascual, T.; Dieci, M.V.; Guarneri, V.; **Prat, A**. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. **Journal for ImmunoTherapy of Cancer.** Volume 7, Issue 1, 29 March 2019, Article number 90.
 83. Pascual T, Martin M, Fernández-Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, Rodríguez-Lescure Á, Perrone G, Cortés J, Morales S, Lluch A, Urruticoechea A, González-Farré B, Galván P, Jares P, Rodriguez A, Chic N, Righi D, Cejalvo JM, Tonini G, Adamo B, Vidal M, Villagrana P, Muñoz M, **Prat A**. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor Positive HER2-Negative Breast Cancer. **Front Oncol.** 2019 Apr 26;9:303. Doi: 10.3389/fonc.2019.00303.
 84. Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, **Prat A**, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. **Breast Cancer Res Treat.** 2019 Aug;177(1):103-114. doi: [10.1007/s10549-019-05284-y](https://doi.org/10.1007/s10549-019-05284-y). Epub 2019 May 27.
 85. Gluz O, Kolberg-Liedtke C, **Prat A**, Christgen M, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N. Efficacy of de-escalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. **Int J Cancer.** 2019 Jun 4. Doi: 10.1002/ijc.32488. [Epub ahead of print].

86. Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Solé A, Trinidad EM, Muñoz P, Paré L, **Prat A**, Bruna A, Caldas C, Arribas J, Soler-Monsó MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E. Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity. **Cancer Res.** 2019 Aug 15;79(16):4258-4270. doi: [10.1158/0008-5472.CAN-18-3835](https://doi.org/10.1158/0008-5472.CAN-18-3835). Epub 2019 Jun 18.
87. Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Solé A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, **Prat A**, Esteller M, González-Suárez E. The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models. **Mol Cancer Res.** *Mol Cancer Res.* 2019 Oct;17(10):2063-2076. doi: [10.1158/1541-7786.MCR-19-0040](https://doi.org/10.1158/1541-7786.MCR-19-0040). Epub 2019 Jul 18.
88. G Santamaría a, X Bargalló a, S Ganau a, I Alonso b, M Muñoz c, M Mollà d, PL Fernández e, **A Prat**. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. **European Journal of Radiology.** Volume 117, August 2019, Pages 132-139. <https://doi.org/10.1016/j.ejrad.2019.06.009>.
89. Sonia Pernas, Anna Petit, Fina Climent, Laia Paré, J. Perez-Martin, Luz Ventura, Milana Bergamino, Patricia Galván, Catalina Faló, Idoia Morilla, Adela Fernandez-Ortega, Agostina Stradella, Montse Rey, Amparo Garcia-Tejedor, Miguel Gil-Gil and **Aleix Prat** ✉. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. **Front. Oncol.**, 06 August 2019 | <https://doi.org/10.3389/fonc.2019.00707>.
90. **Prat A** ✉; Parker J. Standardized versus research-based PAM50 intrinsic subtyping of breast cancer. **Clin Transl Oncol.** 2019 Aug 21. Doi: [10.1007/s12094-019-02203-x](https://doi.org/10.1007/s12094-019-02203-x). [Epub ahead of print].
91. Lluch A, González-Angulo AM, Casadevall D, Eterovic AK, Martínez de Dueñas E, Zheng X, Guerrero-Zotano Á, Liu S, Pérez R, Chen K, Chacón JI, Mills GB, Antolín S, Blancas I, López-Serra P, Carrasco E, Caballero R, **Prat A**, Rojo F, Gonzalez-Perez A, Meric-Bernstam F, Albanell J. Dynamic clonal remodelling in breast 30andom metastases is associated with subtype conversión. **Eur J Cancer.** 2019 Oct;120:54-64. doi: [10.1016/j.ejca.2019.07.003](https://doi.org/10.1016/j.ejca.2019.07.003). Epub 2019 Sep 4.
92. Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, De Laurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, Cristofanilli M, Giordano A, Puglisi F, Pistilli B, **Prat A**, Del Mastro L, Venturini S, Generali D. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. **Lancet Oncol.** 2019 Oct;20(10):1360-1369. doi: [10.1016/S1470-2045\(19\)30420-6](https://doi.org/10.1016/S1470-2045(19)30420-6). Epub 2019 Sep 4.
93. Barbara Adamo, Meritxell Bellet, Laia Paré, Tomás Pascual, Maria Vidal, José A. Pérez Fidalgo, Salvador Blanch, Noelia Martinez, Laura Murillo, Patricia Gómez-Pardo, Ana López-González, Kepa Amillano, Jordi Canes, Patricia Galván, Blanca González-Farré, Xavier González, Patricia Villagrana, Eva Ciruelos and **Aleix Prat**. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. **Breast Cancer Res.** 2019 Sep 18;21(1):108. doi: [10.1186/s13058-019-1195-z](https://doi.org/10.1186/s13058-019-1195-z).
94. Tamara Diaz-Redondo, Rocio Lavado-Valenzuela, Begoña Jimenez, Tomas Pascual, Fernando Gálvez, Alejandro Falcón, Maria del Carmen Alamo, Cristina Morales Estevez, Marta Amerigo, Javier Pascual, Alfonso Sanchez-Muñoz, Macarena Gonzalez-Guerrero, Luis Vicioso, Aurora Laborda, Maria Victoria Ortega, Lidia Perez-Villa, Jose Manuel Jerez, Martina Alvarez, **Aleix Prat**, Nuria Ribelles and Emilio Alba. Different pathological complete response rates according PAM50 subtypes in HER2+ breast cancer patients treated with neoadjuvant Pertuzumab/Trastuzumab vs Trastuzumab plus standard chemotherapy: an analysis of Real World data. 2019. **Front. Oncol.** | doi: [10.3389/fonc.2019.01178](https://doi.org/10.3389/fonc.2019.01178).
- 2018
95. Nuciforo P; Pascual T; Cortés J; Llombart-Cussac A; Fasani R; Paré L; Oliveira M; Galvan P; Martínez N; Bermejo B; Vidal M; Pernas S; López R; Muñoz M; Garau I; Manso L; Alarcón J; Martínez E; Rodrik-Outmezguine V; Brase JC; Villagrana P; **Prat A** ✉; Holgado E. A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CeTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. **Ann Oncol.** 2018 Jan 1;29(1):170-177. Doi: [10.1093/annonc/mdx647](https://doi.org/10.1093/annonc/mdx647).

96. Laurberg T; Tramm T; Nielsen T; Alsner J; Nord S; Myhre S; Sørli T; Leung S; Fan C; Perou C; Gelmon K; Overgaard J; Voduc D; **Prat A**; Cheang MCU. Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. **Acta Oncol.** 2018 Jan;57(1):38-43. doi: 10.1080/0284186X.2017.1401735. Epub 2017 Nov 25.
97. Gawrzak S; Rinaldi L; Gregorio S; Arenas EJ; Salvador F; Urosevic J; Figueras-Puig C; Rojo F; del Barco Barrantes I; Cejalvo JM; Palafox M; Guiu M; Berenguer-Llgero A; Symeonidi A; Bellmunt A; Kalafatovic D; Arnal-Estapé A; Fernández E; Müllauer B; Groeneveld R; Slobodnyuk K; Stephan-Otto Attolini C; Saura C; Arribas J; Cortes J; Rovira A; Muñoz M; Lluch A; Serra V; Albanell J; **Prat A**; Nebreda AR; Aznar Benita A and Gomis RR. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. **Nat Cell Biol.** 2018 Feb;20(2):211-221. Doi: 10.1038/s41556-017-0021-z
98. Florosa KV, Lochmanna TL, Hub B; Monterrubio C; Hughesa MT; Wellse JD, Bernadó Morales C; Ghotra MS; Costa C; Souers AJ; Boikos SA; Levenson JD; Tan M; Serra V; Koblinski JE; Arribas J; **Prat A**; Paré L; Millere TW; Dozmorov MG; Harada H; Windle BE; Scaltritic M and Fabera AC. Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. PNAS 2018; **Proc Natl Acad Sci U S A.** 2018 Mar 13;115(11):E2594-E2603. Doi: 10.1073/pnas.1717820115.
99. Juan Miguel Cejalvo, Tomás Pascual; Aranzazu Fernández-Martínez, Fara Brasó-Maristany, Roger R. Gomis; Charles M. Perou; Montserrat Muñoz; **Aleix Prat**. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. **Cancer Treat Rev.** 2018 Jun; 67:63-70. Doi: 10.1016/j.ctrv.2018.04.015.
100. Rody A ; Ettl J ; Marmé F ; **Prat A.** Molecular Tumor Boards. **Breast Care (Basel).** 2018 Apr;13(2):141-143. Doi: 10.1159/000489138. Epub 2018 Apr 23.
101. Puig I; Tenbaum SP; Chicote I; Arqués O; Martínez-Quintanilla J; Cuesta-Borrás E; Ramírez L; Gonzalo P; Soto A; Aguilar S; Eguizabal C; Caratù G; **Prat A**; Argilés G; Landolfi S; Casanovas O; Serra V; Villanueva A; Arroyo AG; Terracciano L; Nuciforo P; Seoane J; Recio JA; Vivancos A; Dienstmann R; Tabernero J. and Palmer HG. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. **J Clin Invest.** 2018. <https://doi.org/10.1172/JCI96393>. (Ahead of print).
102. Sharma P, López-Tarruella S, Garcia-Saenz JA, Khan QJ, Gomez H, **Prat A**, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Marquez-Rodas I, Perou CM, Lehn C, Wang YY, Klemp JR, Mammen JM, Wagner J, Amin A, O'Dea AP, Heldstab J, Jensen RA, Kimler BF, Godwin AK, Martín M. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. **Clin Cancer Res.** 2018 Jul 30. Pii: clincanres.0585.2018.doi: 10.1158/1078-0432.CCR-18-0585.[Epub ahead of print]. PMID: 30061361.
103. Laia Pare, Tomas Pascual, Elia Seguí, María González-Cao, Cristina Teixidó, Adela Rodriguez, Blanca González-Farre, Miriam Cuatrecasas, Estela Pineda, Guillermo Crespo, Salvador Martin-Algarra, Elisabeth Perez Ruiz, Begona Mellado, Juan Maurel, Javier Garcia Corbacho, Miguel Angel Molina-Vila, Josep M. Llovet, Noemi Reguart, Ana M. Arance, **Aleix Prat** . Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-type. **Ann Oncol.** 2018 Oct 1;29(10):2121-2128. Doi: 10.1093/annonc/mdy335
104. Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Céspedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, **Prat A**, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R32, Brambilla E, Esteller M Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a 31randomized31, retrospective analysis. **Lancet Respir Med.** 2018 Oct;6(10):771-781. Doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

2017

105. Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; **Prat A**; AranceA. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. **Clin Transl Oncol.** 2017 Jan;19(1):119-124. Doi: 10.1007/s12094-016-1514-0.

106. **Prat A**; Cheang MCU; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. **JAMA Oncol.** 2016 Oct 1 ;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922.
107. Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor C, Gómez HL, **Prat A**, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell A, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner J, Mammen JM, McGinness M, Klemp JR, Amin A, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M. Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts. **Clin Cancer Res.** 2016 Jun 14. Doi: 10.1158/1078-0432.CCR-16-0162.
108. Samaeekia R, Adorno-Cruz V, Bockhorn J, Chang YF, Huang S, **Prat A**, Ha N, Kibria G, Huo D, Zheng H, Dalton R, Wang Y, Moskalenko G, Liu H. MicroRNA-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 pathway. **Clin Cancer Res.** 2017 Feb 15;23(4):1091-1103. Doi: 10.1158/1078-0432.CCR-16-0943.
109. M. V. Dieci* ; **A. Prat** ; E. Tagliafico ; L. Paré ; G. Ficarra ; G. Bisagni ; F. Piacentini ; D. G. Generali ; P. Conte ; V. Guarneri. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. **Ann Oncol.** 2016 Oct;27(10):1867-73. doi:10.1093/annonc/mdw262. Epub 2016 Aug 2.
110. Aya F; Gaba L; Victoria I; Fernández-Martínez A; Tosca M; **Prat A**; Arance A. Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. **Future Oncol.** 2016 Dec;12(23):2683-2688. Epub 2016 Sep 1.
111. Morancho B; Zacañas-Fluck M; Esgueva A; Di Cosimo S; **Prat A**; Cortés J; Arribas J; Rubio IT. Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. **Oncotarget.** 2016 Oct 18;7(42):67956-67965. Doi: 10.18632/oncotarget.11815.
112. **Prat A**; Lluch A; Turnbull AK; Dunbier AK; Calvo L; Albanell J; Haba-Rodríguez J; Arcusa A; Chacón JI; Sánchez-Rovira P; Plazaola A; Muñoz M; Paré L; Parker JS; Ribelles N; Jimenez B; Bin Aiderus AA; Caballero R; Adamo B; Dowsett M; Carrasco E; Martín M; Dixon JM; Perou CM and Alba E. A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. **Clinical Cancer Research.** 2017 Jun 15;23(12):3035-3044. Doi: 10.1158/1078-0432.CCR-16-2092.
113. Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; **Prat A**. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: a single-arm, 32 randomized, phase 2 trial. **Lancet Oncol.** 2017 Apr;18(4):545-554. Doi: 10.1016/S1470-2045(17)30021-9.
114. Reguart N; Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, **Prat A**. Identification of ALK, ROS1 and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. **Clin Chem.** 2017 Mar;63(3):751-760. Doi: 10.1373/clinchem.2016.265314.
115. Fernandez A; Pascual T; Perrone G; Morales S; Haba J; González-Rivera M; Galvan P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; **Prat A**; Martin M. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. **Oncotarget.** 2017 Mar 28;8(13):21930-21937. Doi: 10.18632/oncotarget.15748.
116. Cejalvo JM, Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasió O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano A; Muñoz M; Nuciforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; **Prat P**. Intrinsic subtype and gene expression changes between matched primary and metastatic samples of breast cancer patients. **Cancer Res.** 2017 May 1;77(9):2213-2221. Doi: 10.1158/0008-5472.CAN-16-2717.

117. **Prat A.** Pertuzumab Use in the Adjuvant Setting: Why Not?. **J Clin Oncol.** 2017 Apr 1;35(10):1138. Doi: 10.1200/JCO.2016.68.6212.
118. Gomez-Miragaya J; Palafox M; Pare L; Yoldi G; Ferrer I; Vila S; Galvan P; Pellegrini P; Perez-Montoyo H; Igea A; Muñoz P; Esteller M; Nebreda AR; Urruticoechea A; Morilla I; Pernas S; Climent F; Soler-Monso MT; Petit A; Serra V; **Prat A** and Gonzalez-Suarez E. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. **Stem Cell Reports.** 2017 May 9;8(5):1392-1407. Doi: 10.1016/j.stemcr.2017.03.026.
119. **Prat A;** Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Allos LI; Pardo N; Cedrés S; Fan Ch; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma. **Cancer Res.** 2017 Jul 1;77(13):3540-3550. Doi: 10.1158/0008-5472.CAN-16-3556.
120. Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, **Prat A,** Rimawi MF, Osborne CK, Schiff R. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. **Breast.** 2017 Aug;34 Suppl 1:S19-S26. Doi: 10.1016/j.breast.2017.06.022.
121. Tuca A; Gómez-Martínez M; **Prat A.** Predictive model of complexity in early palliative care: a cohort of advanced cancer patients (PALCOM study). **Support Care Cancer.** 2018 Jan;26(1):241-249. Doi: 10.1007/s00520-017-3840-3.
122. **Prat A;** Pascual T; Adamo B. Intrinsic molecular subtypes of HER2+ breast cancer. **Oncotarget.** 2017 Septiembre. **Oncotarget.** 2017 Sep 4;8(43):73362-73363. Doi: 10.18632/oncotarget.20629.
123. GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. Moreno M, Pedrosa L, Paré L, Pineda E, Bejarano L, Martínez J, Balasubramaniyan V, Ezhilarasan R, Kallarackal N, Kim SH, Wang J, Audia A, Conroy S, Marin M, Ribalta T, Pujol T, Herrerros A, Tortosa A, Mira H, Alonso MM, Gómez-Manzano C, Graus F, Sulman EP, Piao X, Nakano I, **Prat A,** Bhat KP, de la Iglesia N. **Cell Rep.** 2017 Nov 21;21(8):2183-2197. doi: 10.1016/j.celrep.2017.10.083.
124. F Cardoso E, Senkus A, Costa E, Papadopoulos M, Aapro F, André N, HarbeckB, Aguilar, Lopez C H Barrios J Bergh; L Biganzoli, CB Boers-Doets M J, Cardoso, L A Carey, J Cortés, G Curigliano, V Diéras, N S El Saghier, A Eniu, L FallowfieldP, A Francis, K Gelmon, S R D Johnston, B Kaufman, S Koppikar, I E Krop, M MayerG, Nakigudde B V, Offersen S, Ohno O, Pagani S, Paluch-Shimon F, Penault-Llorca, **Aprat,** HS Rugo, GW Sledge, Dspence, Cthomssen, DA Vorobiof, Bxu L Norton, EP Winer. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). **Ann Oncol.** 2017 Dec 1;28(12):3111. Doi: 10.1093/annonc/mdx036.

2016

125. Font C, Fernández-Avilés F, Calderon C, García-Fernández T, Arab N, Pineda E, Buxó E4, Ayora P, Carreño M, Pereira V, Viladot M, Moreno C, Gallego C, Hernando A, Creus N, Barrera C, Alcaraz R, Sanchez J, **Prat A,** Tuca A. Home management of acute medical complications in cancer patients: a prospective pilot study. **Support Care Cancer.** 2016 May;24(5):2129-37. Doi: 10.1007/s00520-015-3006-0.
126. **Prat A;** Fan C; Fernández A; Hoadley AA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MCU; Adamo B; Perou CM. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. **BMC Med.** 2015 Dec 18;13(1):303. Doi: 10.1186/s12916-015-0540-z.
127. Bonnetterre J, **Prat A,** Galván P, Morel P, Giard. Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study. **Curr Med Res Opin.** 2016 May;32(5):835-9. doi: 10.1185/03007995.2016.1146664.
128. Arques O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, **Prat A,** Espin E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase inhibition blocks Wnt/ β -catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. **Clin Cancer Res.** 2016 Feb 1;22(3):644-56. Doi: 10.1158/1078-0432.CCR-14-3081.
129. **Prat A;** Galván P; Jimenez B; Buckingham W; Jeiranian HA; Schaper C; Vidal M; Álvarez M; Díaz S; Ellis C; Nuciforo P; Ferree S; Ribelles N; Adamo B; Ramón y Cajal S; Peg V and Alba E. Prediction of Response to

Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. **Clin Cancer Res.** 2016 Feb 1;22(3):560-6. Doi: 10.1158/1078-0432.CCR-15-0630.

130. Martin M; Brase JC; Ruiz A; **Prat A**; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. **Breast Cancer Res Treat.** 2016 Feb;156(1):81-9. Doi: 10.1007/s10549-016-3725-z.
131. Reig O; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Verónica M; Fernández P; **Prat A**; Mellado B. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. **Eur Urol.** 2016 Nov;70(5):709-713. Doi: 10.1016/j.eururo.2016.02.034.
132. Gendoo DM, Ratanasirigulchai N, Schröder MS, Paré L, Parker JS, **Prat A**, Haibe-Kains B. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. **Bioinformatics.** 2016 Apr 1;32(7):1097-9. Doi: 10.1093/bioinformatics/btv693.
133. Aya, F, Ruiz-Esquide, V, Viladot, M, Font, C, Prieto-González, S, **Prat, A**, Arance. Avasculitic neuropathy induced by pembrolizumab. **Ann Oncol.** 2017 Feb 1;28(2):433-434. Doi: 10.1093/annonc/mdw613.
134. Aya F, Fernández-Martínez A, Gaba L, Victoria I, Tosca M, Carrera C, **Prat A**, Arance A. Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. **Immunotherapy.** June 2016 ,Vol. 8, No. 6, Pages 687-692, doi 10.2217/imt-2015-0025.

2015

135. Sun Z, **Prat A**, Cheang MC, Gelber RD, Perou CM. Chemotherapy Benefit for “ER-Positive” Breast Cancer and Contamination of Non-Luminal Subtypes – Waiting for TAILORx and RxPONDER. **Ann Oncol.** 2015 Jan;26(1):70-4. Doi: 10.1093/annonc/mdu493.
136. Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D’Angelo RC, Korkaya S, Baker TL, Esen ES, **Prat A**, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. **Oncogene.** 2015 Feb 5;34(6):671-80. Doi: 10.1038/onc.2014.4.
137. Anderson WF, Rosenberg PS, **Prat A**, Perou CM, Sherman ME. Response. **J Natl Cancer Inst.** 2015 Feb 24;107(4). Pii: djv029. Doi: 10.1093/jnci/djv029.
138. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, **Prat A**, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. **Sci Transl Med.** 2015 Apr 15;7(283): 283ra51. Doi: 10.1126/scitranslmed.aaa4442.
139. Cheang MC, Martin M, Nielsen TO1, **Prat A**, Voduc D1, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA. Defining breast cancer intrinsic subtypes by quantitative receptor expression. **Oncologist.** 2015 May;20(5):474-82. Doi: 10.1634/theoncologist.2014-0372.
140. Vidal, M; Peg, V; Galván, P; Cortés, J; Ramón y Cajal, S; Rubio, I; **Prat, A**. Gene Expression-based Classifications of Fibroadenomas and Phyllodes tumours of the Breast. **Mol Oncol.** 2015 Jun;9(6):1081-90. Doi: 10.1016/j.molonc.2015.01.003.
141. Martín M; González-Rivera M; Morales S; de la Haba-Rodríguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; **Prat A**. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. **Curr Med Res Opin.** 2015 Jun;31(6):1129-37. Doi: 10.1185/03007995.2015.1037730.

142. **Prat A**, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. **Breast**. 2015 Nov;24 Suppl 2:S26-35. Doi: 10.1016/j.breast.2015.07.008.
143. Triulzi T, De Cecco L, Sandri M, **Prat A**, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. **Oncotarget**. 2015 Sep 29;6(29):28173-82. Doi: 10.18632/oncotarget.4405.
144. Pavlovic M*, Arnal-Estape A*, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albeniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, **Prat A**, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis JR. *Authors contributed equally to this work. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. **JNCI J Natl Cancer Inst** (2015) 107 (12): djv256. Doi: 10.1093/jnci/djv256.

2014

145. Pedersen K, Canals F, **Prat A**, Tabernero J, Arribas J. PLO1 negatively regulates HER receptor signaling and metastasis. **Oncogene**. 2014 Feb 27;33(9):1190-7. Doi: 10.1038/onc.2013.35.
146. Montemurro F; **Prat A**, Rossi V; Valabrega G; Sperinde J; Peraldo-Neira C; Donadio M; Galván P; Sapino A; Aglietta M; Scaltriti M. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer clinical trial. **Mol Oncol**. 2014 Feb;8(1):20-6. Doi: 10.1016/j.molonc.2013.08.013.
147. **Prat A**, Bianchini G, Thomas M, Belousov A, Cheang M, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhov M, Bermejo B, Zambetti M, Vazquez F, Gianni L, Baselga J. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. **Clinical Cancer Research** 014 Jan15;20(2):511-21. Doi: 10.1158/1078-0432.CCR-13-0239.
148. Harrell JC, Pfefferle AD, Zalles N, **Prat A**, Fan C, Khramtsov A, Olopade OI, Troester MA, Dudley AC, Perou CM. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. **Clin Exp Metastasis**. 2014 Jan;31(1):33-45. Doi: 10.1007/s10585-013-9607-4.
149. Skibinski A, Breindel JL, **Prat A**, Galván P, Smith E, Rolfs A, Gupta PB, Labaer J, Kuperwasser C. The Hippo Transducer TAZ Interacts with the SWI/SNF Complex to Regulate Breast Epithelial Lineage Commitment. **Cell Rep**. 2014 Mar 27;6(6):1059-72. Doi: 10.1016/j.celrep.2014.02.038.
150. Cuenca-López MD, Montero JC2, Morales JC, **Prat A**, Pandiella A and Ocana A*. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. **BMC Cancer** 2014, 14:302 doi:10.1186/1471-2407-14-302.
151. Phillips S, **Prat A**, Sedic M, Proia T, Wronski A1, Mazumdar S, Skibinski A, Shirley SH, Perou CM, Gill G, Gupta PB, Kuperwasser C. Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. **Stem Cell Reports**. 2014 Apr 24;2(5):633-47. Doi:10.1016/j.stemcr.2014.03.008. Collection 2014.
152. Romero A, **Prat A**, García-Sáenz JA, Del Prado N, Pelayo A, Furió V, Román JM, de la Hoya M, Díaz-Rubio E, Perou CM, Cladés T, Martín M. Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. **Clin Transl Oncol**. 2014 Apr;16(4):386-94. Doi: 10.1007/s12094-013-1088-z.
153. Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, **Prat A**, Perou CM, Wolff AC, Carey LA. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. **Breast Cancer Res Treat**. 2014 Aug;146(3):557-66. Doi: 10.1007/s10549-014-3039-y.
154. **Prat A**, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. **Breast Cancer Res Treat**. 2014 Aug;147(1):185-91. Doi: 10.1007/s10549-014-3056-x.
155. Anderson WF, Rosenberg PS, **Prat A**, Perou CM and Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more?. **J Natl Cancer Inst**. 2014 Aug 12;106(8). Doi: 10.1093/jnci/dju165.

156. Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortés J, Baselga J, Perou CM, **Prat A**, Rubio IT, Arribas J. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. **J Natl Cancer Inst.** 2014 Sep 24;106(11). Doi: 10.1093/jnci/dju291.
157. **Prat A**, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodríguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. **Br J Cancer.** 2014 Oct 14;111(8):1532-41. Doi: 10.1038/bjc.2014.444.
158. **Prat A**, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM and Baselga J. Molecular Features and Survival Outcomes of the Intrinsic Subtypes within HER2-Positive Breast Cancer. **J Natl Cancer Inst.** 2014 Aug 19;106(8). Pii: dju152. Doi: 10.1093/jnci/dju152.
159. Jenkins EO, Deal AM, Anders CK, **Prat A**, Perou CM, Carey LA, Muss HB. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. **Oncologist.** 2014 Oct;19(10):1076-83. Doi: 10.1634/theoncologist.2014-0184.
160. Bockhorn J, **Prat A**, Chang YF, Liu X, Huang S, Shang M, Nwachukwu C, Gomez-Vega M, Harrell JC, Olopade OI, Perou CM, Liu H. Differentiation and loss of malignancy of spontaneous pulmonary metastases in human-in-mouse breast cancer models. **Cancer Res.** 2014 Dec 15;74(24):7406-17. Doi: 10.1158/0008-5472.CAN-14-1188.
- 2013
161. Bockhorn J, Yee K, Chang YF, **Prat A**, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. **Breast Cancer Res Treat.** 2013 Jan; 137(2): 373-382. Doi: 10.1007/s10549-012-2346-4.
162. **Prat A**, Cheang MC, Martín M, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemical-defined Luminal A breast cancer. **J Clin Oncol** 2013 Jan 10;31(2):203-9. Doi: 10.1200/JCO.2012.43.4134.
163. Bockhorn J, Dalton R, Nwachukwu C, **Prat A**, Yee K, Chang Y, Huo D, Wen Y, Huang S, Swanson KE, Qiu T, Lu J, Park S, Dolan E, Perou CM, Olopade O, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits Human Breast Tumor Chemotherapy Resistance by regulating TWF1 and IL-11. **Nat Commun** 2013 Jan 22;4:1393. Doi: 10.1038/ncomms2393.
164. **Prat A**, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of Basal-like and non-Basal-like triple-negative breast cancer. **Oncologist.** 2013;18(2):123-33. Doi: 10.1634/theoncologist.2012-0397.
165. Martín M, **Prat A**, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. **Breast Cancer Res Treat.** 2013 Apr; 138(2):457-466. Doi: 10.1007/s10549-013-2416-2.
166. Knight JF, Lesurf R, Zhao H, Pinnaduwa D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, **Prat A**, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. **Proc Natl Acad Sci U S A.** 2013 Apr 2; 110(14):E1301-1310. Doi: 10.1073/pnas.1210353110.
167. **Prat A**, Baselga J. Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Hormonal Therapy for the Treatment of Primary HER2-Positive Breast Cancer: One More Step Toward Chemotherapy-Free Therapy. **J Clin Oncol.** 2013 May 10; 31(14):1703-1706. Doi: 10.1200/JCO.2012.48.4998.
168. Serra V, Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL, Marlow S, Scaltriti M, **Prat A**, Arribas J, Hahn WC, Kim SY, Baselga J. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. **J Clin Invest.** 2013 Jun 3; 123(6):2551-2563. Doi: 10.1172/JCI66343.
169. Usary JE, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges AS, **Prat A**, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless N, Perou CM. Predicting drug

- responsiveness in human cancers using genetically engineered mice. **Clin Cancer Res.** 2013 Jul 1; 31(19):2517-1518. Doi: 10.1158/1078-0432.CCR-13-0522.
170. **Prat A**, Martin M, Nielsen TO, Perou CM. Reply to Y.Yamamoto et al. **J Clin Oncol.** 2013 Jul 1; 31(19):2517-1518. Doi:10.1200/JCO.2013.49.9061
171. Zhang X, Claerhout S, **Prat A**, Dobrolecki L, Petrovic I, Lai Q, Landis M, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua S, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick A, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen E, Zuloaga P, Shaw C, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT. A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-derived Human Breast Cancer Xenografts. **Cancer Res.** 2013 Aug 1; 73(15):4885-4897. Doi: 10.1158/0008-5472.CAN-12-4081.
172. Jordan NV, **Prat A**, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL. SWI/SNF Chromatin-Remodeling Factor Smarcd3/Baf60c Controls Epithelial-Mesenchymal Transition by Inducing Wnt5a Signaling. **Mol Cell Biol.** 2013 Aug 33(15):3011-3025. Doi: 10.1128/MCB.01443-12.
173. Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, **Prat A**, Perou CM, Earp HS, Massarweh S, Cook RS. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. **J Clin Invest.** 2013 Oct;123(10):4329-43. Doi: 10.1172/JCI66764.
174. Li S, Shen D, Shao J, Crowder R, Liu W, **Prat A**, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, Deschryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ. Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. **Cell Rep.** 2013 Sep 26;4(6):1116-30. Doi: 10.1016/j.celrep.2013.08.022.
175. Puig I, Chicote I, Tenbaum SP, Arques O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espin E, **Prat A**, Elez ME, Argiles G, Vivancos A, Tabernero J, Rojas S, Palmer HG. A Personalized Pre-clinical Model to Evaluate the Metastatic Potential of Patient-derived Colon Cancer Initiating Cells. **Clin Cancer Res.** 2013 Dec 15;19(24):6787-801. Doi: 10.1158/1078-0432.CCR-12-1740.
176. **Prat A**, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, Perou CM. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. **Breast Cancer Res Treat.** 2013 Nov;142(2):237-55. Doi: 10.1007/s10549-013-2743-3.
177. Dienstmann R, Rodon J, **Prat A**, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. **Ann Oncol.** 2013 Nov 20. Doi: 10.1093/annonc/mdt419.
178. **Prat A***, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortés J. Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. **Sci Rep.** 2013 Dec 18;3:3544. Doi: 10.1038/srep03544. *Correspondence Author.

2012

179. Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, **Prat A**, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. **Proc Natl Acad Sci U S A.** 2012 Jan 3;109(1):221-6. Doi: 10.1073/pnas.1115802109.
180. Eichhorn PJA, Rodón L, González-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, **Prat A**, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. USP15 stabilizes the TGF- β receptor I and promotes oncogenesis through the activation of the TGF- β signal in glioblastoma. **Nat Med.** 2012 Feb 19;18(3):429-35. Doi: 10.1038/nm.2619.

181. Ma CX, Cai S, Li S, Ryan CE, Guo Z, Lin L, Hoog J, Goiffon R, **Prat A**, Aft RL, Ellis MJ, Piwnica-Worms H. Targeting Chk1 in p53-Deficient Triple Negative Breast Cancer Using Human in Mouse Tumor Models. **J Clin Invest.** 2012 Apr 2;122(4):1541-52. Doi: 10.1172/JCI58765.
182. Xu K, Usary J, Kousis PC, **Prat A**, Wang D, Adams JR, Wang W, Loch AJ, Deng T, Zhao W, Cardiff RD, Yoon K, Gaiano N, Ling1 V, Beyene J, Zacksenhaus E, Gridley T, Leong WL, Guidos C, Perou CM and Egan SE. Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-Like Breast Cancer. **Cancer Cell** 2012 May 25;21(5):626-41. Doi: 10.1016/j.ccr.2012.03.041.
183. **Prat A**, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. **Breast Cancer Res Treat.** 2012 Aug;135(1):301-6. Doi: 10.1007/s10549-012-2143-0.
184. Bastien RRL, Rodríguez-Lescure A, Ebbert MTW, **Prat A**, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Ángel Seguí M, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TON, Perou CM, Astill M, Bernard PS and Martín M. PAM50 Breast Cancer Subtyping by RT-qPCR and Agreement with Standard Clinical Molecular Scoring. **BMC Med Genomics** 2012 Oct 4;5:44. Doi: 10.1007/s10549-012-2143-0.
185. The Cancer Genome Atlas Project. Comprehensive molecular portraits of human breast tumors. **Nature.** 2012 Oct 4;490(7418):61-70. Doi: 10.1038/nature11412.
186. **Prat A**, Parker JS, Fan C, Cheang MCU, Miller LD, Bergh J, Chia SKL, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. **Ann Oncol.** 2012 Nov;23(11):2866-73. Doi: 10.1093/annonc/mds080.
187. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, **Prat A**, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. **Cancer Discov.** 2012 Nov;2(11):1036-47. Doi: 10.1158/2159-8290.CD-11-0348.
188. Harrell C, **Prat A**, Parker J, Fan C, He X, Carey L, Anders C, Ewend M and Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung and liver relapse. **Breast Cancer Res Treat.** 2012 Apr;132(2):523-35. Epub 2011 Jun 14. Doi: 10.1007/s10549-011-1619-7.
189. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, **Prat A**, Perou CM, Gilmore H, Schnitt S, Naber SP, Garlick JA, Kuperwasser C. Defining the cellular precursors to human breast cancer. **Proc Natl Acad Sci U S A.** 2012 Feb 21;109(8):2772-7. Doi: 10.1073/pnas.1017626108.

2011

190. Fan C*, **Prat A***, Parker J, Liu Y, Carey LA, Troester MA and Perou CM. Building Prognostic Models for Breast Cancer Patients Using Clinical Variables and Hundreds of Gene Expression Signatures. **BMC Med Genomics** 2011 Jan 9;4(1):3. Doi:10.1186/1755-8794-4-3
191. **Prat A**, Perou CM. Deconstructing the molecular portraits of breast cancer. **Mol Oncol.** 2011 Feb;5(1):5-2. Doi: 10.1016/j.molonc.2010.11.003.
192. Scaltriti M, Eichhorn PJA, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, **Prat A**, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C and Baselga J. Cyclin E amplification/overexpression a novel mechanism of trastuzumab resistance in HER2 positive breast cancer patients. **Proc Natl Acad Sci U S A.** 2011 Mar 1;108(9):3761-6. Doi: 10.1073/pnas.1014835108.
193. Abell AN, Vincent NJ, Huang W, **Prat A**, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Magnuson T, Perou CM, Gomez SM, Li L, and Johnson GL. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. **Cell Stem Cell.** 2011 May 6;8(5):525-37. Doi: 10.1016/j.stem.2011.03.008.
194. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, **Prat A**, Parker JS, Luo J, DeSchryver K, Watson MA, Allred DC, Esserman LJ, Unzeitig GW, Babiera GV, Margenthaler J, Marcom PK, Guenther JM, Leitch M, Hunt K and Olson JA. ACOSOG Z1031, a randomized phase 2 neoadjuvant comparison between letrozole,

anastrozole and exemestane for postmenopausal women with ER rich stage 2/3 breast cancer: Clinical and Biomarker outcomes. **J Clin Oncol**. 2011 Jun 10;29(17):2342-9. Doi: 10.1200/JCO.2010.31.6950.

195. Haakensen VD, Lingjærde OC, Lüders T, Riis M, **Prat A**, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord S, Bukholm IK, Johansen T, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A. Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. **BMC Med Genomics**. 2011 Nov 1;4(1):77. Doi: 10.1186/1755-8794-4-77.
196. **Prat A**, Perou CM. Molecular classification of triple-negative tumors. **Breast Cancer Research** 2011, 13(Suppl 2):O2 (16 November 2011). Doi: 10.1634/theoncologist.2011-S1-61.
197. **Prat A**, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. **Nat Rev Clin Oncol**. 2011 Dec 6;9(1):48-57. Doi: 10.1038/nrclinonc.2011.178.
198. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, **Prat A**, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK. Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases. **Breast Cancer Res**. 2011;13(6):R125. Doi: 10.1186/bcr3071.

2010

199. Perou CM, Parker JS, **Prat A**, Ellis MJ, Bernard PS. Clinical Implementation of the Intrinsic Molecular Subtypes of Breast Cancer. **Lancet Oncol**. 2010Aug11(8):718-9. Doi: 10.1016/S1470-2045(10)70176-5.
200. **Prat A**, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM. Phenotypic and Molecular Characterization of the Claudin-low Intrinsic Subtype of Breast Cancer. **Breast Cancer Res**. 2010;12(5):R68. Doi: 10.1186/bcr2635.

2009

201. **Prat A**, Parera M, Adamo B, Peralta S, Perez-Benavente M, Garcia A, Martinez-Palones J, Gil A, Baselga J, Del Campo J. Risk of Recurrence during Follow-up for Optimally Treated Advanced Epithelial Ovarian Cancer with a Low-Level Increase of Serum CA-125 Levels. **Ann Oncol**. 2009 Feb;20(2):294-7. Doi: 10.1093/annonc/mdn601.
202. **Prat A**, Perou CM. Mammary development meets cancer genomics. **Nat Med**. 2009 Aug;15(8):842-844. Doi: 10.1038/nm0809-842.
203. Cedrés S, **Prat A**, Martínez P, Baselga J, Felip E. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients with second-third line erlotinib. **Lung Cancer**. 2009 Nov;66(2):257-61. Epub 2009 Feb 23. Doi: 10.1016/j.lungcan.2009.01.014.

2008

204. **Prat A**, Parera M, Peralta S, Perez-Benavente M, Roxana I, Garcia A, Martinez-Palones J, Gil A, Baselga J, Del Campo J. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. **Ann Oncol**. 2008 Feb;19(2):327-31. Doi: 10.1093/annonc/mdm495.
205. **Prat A**, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J; Huguet J, Del Campo J. Successful Treatment of Pulmonary Metastatic Salivary Ductal Carcinoma (SDC) with Trastuzumab-Based Therapy. **Head Neck**. 2008 May;30(5):680-3. Doi: 10.1002/hed.20714. CR.
206. **Prat A**, Parera M, Del Campo JM. Prognostic role of CA-125 nadir in stage I epithelial ovarian cancer. **J Clin Oncol** 2008;26(10):1771-1772. Doi: 10.1200/JCO.2007.15.7594.
207. Muñoz E, **Prat A**, Adamo B, Peralta S, Ramon y Cajal S, Valverde C. A Rare Case of Malignant Solitary Fibrous Tumor of the Spinal Cord. **Spine**. 2008 May 20;33(12):E397-9. Doi: 10.1097/BRS.0B013E31817343DC.
208. Del Campo JM, **Prat A**, Gil-Moreno Antonio, Pérez J, Parera M. Update of Novel Therapeutic Agents for Cervical Cancer. **Gynecol Oncol**. 2008 Sep;110(3 Suppl 2):S72-6. Doi: 10.1016/j.ygyno.2008.04.016.
209. **Prat A**, Baselga J. The Role of Hormonal Therapy in the Management of Hormonal Receptor Positive Breast Cancer with Coexpression of HER2. **Nat Clin Pract Oncol**. 2008 Sep;5(9):531-42. Doi: 10.1038/ncponc1179.
210. **Prat A**, Serrano C, Valverde C, Calvo E. Acute severe hypothyroidism induced by sunitinib. **Radiother Oncol**. 2008 Oct;89(1):124-5. Doi: 10.1016/j.radonc.2008.05.007.

2007

211. **Prat A**, Peralta S, Cuéllar H, Ocana A. Hepatic Pneumatosis As a Complication of an Abdominal Desmoid Tumor. **J Clin Oncol** 2007;25(7):897-898. Doi: 10.1200/JCO. 2006.09.6537
212. **Prat A**, Baselga J. Biologic therapy: Current and Future Applications in Oncology. **Med Clin (Barc)**. 2007 Jun 30;129(5):184-93. Doi: 10.1157/13107796.
213. Felip E, Cedrés S, Peralta S, **Prat A**. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC). **Ann Oncol**. 2007 Jul;18 Suppl 9:ix143-146.
214. **Prat A**, Casado E, Cortés J. New Approaches in Angiogenic Targeting in Colorectal Carcinoma. **World J Gastroenterol**. 2007 Nov 28;13(44):5857-5866. Doi: 10.3748/wjg.v13.i44.5857.
215. **Prat A**, Martínez P, Serrano C, Montero MA, Andreu J, Cortés J. Acute Lung Injury Associated with Docetaxel and Bevacizumab. **Clin Oncol (R Coll Radiol)**. 2007 Dec;19(10):803-5. Doi: 10.1016/j.clon.2007.08.010.

2006

216. **Prat A**, Felip E. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. **Cancer & Chemotherapy Rev** 2006; 1:5-12. Doi: 10.1093/annonc/mdm495.

(*) Corresponding Author.

Principio

Participación en congresos

1. Bellet M, Morales S, Gasol A, Amillano K, Chic N, González-Farré X, Villagrasa P, Paré L, Falato C, Nuciforo P, Martínez D, Ferrero-Cafiero JM, Pascual T, **Prat A**, Lange C, Saura C. P1-07-02 Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptorpositive/HER2-negative early breast cancer (EBC). **SABCS 2021**. San Antonio, Texas EEUU.
2. Ciruelos EM, Lerebours F, Rugo HS, Ruiz-Borrego M, Drullinsky P, **Prat A**, Bachelot T, Neven P, Park YH, Turner N, Juric D, Gu E, Arce CH, Akdere M, Chia S. P1-18-03 Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CAmutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A. **SABCS 2021**. San Antonio, Texas, EEUU.
3. Chia S, Ciruelos EM, Rugo HS, Lerebours F, Ruiz-Borrego M, Drullinsky P, **Prat A**, Bachelot T, Turner N, Gu E, Arce C, Akdere M, Juric D. P1-18-08 Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤ 6 mo or > 6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve. **SABCS 2021**. San Antonio, Texas EEUU.
4. Ciruelos E, Pascual T, Oliveira M, Escrivá-de-Romaní S, Pernas S, Paré L, Adamo B, Martínez E, Cortés J, Perelló A, Galan M, Melé M, Tolosa P, González-Farré B, Galván P, Canes J, Nuciforo P, Gonzalez X, Villagrasa P, **Prat A**. P1-18-38 Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study. **SABCS 2021**. San Antonio, Texas, EEUU.
5. Juric D, Turner N, **Prat A**, Chia S, Ciruelos EM, Ruiz-Borrego M, Drullinsky P, Lerebours F, Bachelot T, Balbin OA, Joshi M, Roux E, Arce CH, Akdere M, Rugo HS. P5-13-03 Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the

Phase II BYLieve study. **SABCS 2021**. San Antonio, Texas EEUU.

6. Òdena A, Monserrat L, Brasó-Maristany F, Guzmán M, Grueso J, Rodríguez O, Scaltriti M, Chandarlapaty S, Qiu Y, Koyama K, Oliveira M, **Prat A**, Serra V. P5-13-14 Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs). **SABCS 2021**. San Antonio, Texas USA.
7. A. Fernandez-Martinez, T. Pascual, B. Singh, P. Nuciforo, K.A. Hoadley, N.U. Rashid, P.A. Spears, N. Chic, I. Krop, D. Hillman, A. Partridge, **A. Prat**, L. Carey, C.M. Perou, Mini oral session - Breast cancer, early stage. 20/09/2021 - 17:38 - 17:43 Channel 1. 120MO - Prognostic value of immune gene-expression signatures (iGES) vs. tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: a combined analysis of CALGB 40601 (C40601) and PAMELA trials. **ESMO Congress 2021**. Virtual.
8. D. Pinato, M. Patel, M. Lambertini, E. Colomba, F. Pommeret, M. Van Hemelrijck, A. Zambelli, T. Newsom-Davis, R. Salazar, A. Bertuzzi, G. Gaidano, G. Rizzo, G. Patel, E. Felip, **A. Prat**, J. Aguilar-Company, J. Tabernero, N. Diamantis, A. Gennari, A. Cortellini. Mini oral session - SARS-CoV-2 and cancer. 21/09/2021 16:50 - 16:55 Channel 2. 1565MO - Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: an updated analysis of the OnCovid registry. **ESMO Congress 2021**. Virtual.
9. P. Schmid, T. Bachelot, G. Bianchini, N. Harbeck, S. Loi, Y.H. Park, **A. Prat**, L. Gilham, T. Boulet, N. Gochitashvili, E. Monturus, C. Lambertini, B. Nyawira, A. Knott, S.A. Hurvitz. Poster 202TiP ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy. **ESMO Congress 2021**. Virtual.
10. Vukovic, I. Meattini, M. Lambertini, E. de Azambuja, **A. Prat**, P.G. Aftimos, M. Lustberg, I. Kruljac, G. Morgan. Poster 316P - Attitudes towards the use of stereotactic body radiation therapy in oligometastatic breast cancer: Results of an OncoAlert survey P. **ESMO Congress 2021**. Virtual.
11. E.M. Ciruelos, S. Pernas, A. Perelló, A. Lopez, F.J. Salvador Bofill, J.M. Cejalvo, I. Blancas, J. Ponce Lorenzo, S. Servitja, M. Perez, J. Cruz, C. Albacar, S.I. Escrivá-de-Romaní, J.A. Guerra, S. González-Santiago, E. Sanfeliu, C. Rodriguez, P. Tolosa, J.M. Ferrero-Cafiero, **A. Prat**. 332TiP - SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+ metastatic breast cancer (MBC). **ESMO Congress 2021**. Virtual.
12. Manso, S. Pernas, M. Margelí, S. Blanch, B. Adamo, F.J. Salvador Bofill, D. Moreno, X. González, T. Pascual, J.M. Ferrero-Cafiero, C.M. Perou, **A. Prat**, M. Oliveira. 339TiP - SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer L. **ESMO Congress 2021**. Virtual.
13. SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI). ePoster. **ESMO Congress 2021**. Virtual.
14. Schettini F, Barbao P, Braso-Maristany F, Galvan P, Martinez D, Pare L, De Placido S, Prat A, Guedan S. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. **ESMO 2021** openOpen AccessVolume 6, Issue 3, Pages 1001021 June 2021.
15. A. Fernandez-Martinez, T. Pascual, B. Singh, P. Nuciforo, K.A. Hoadley, N.U. Rashid, P.A. Spears, N. Chic, I. Krop, D. Hillman, A. Partridge, **A. Prat**, L. Carey, C.M. Perou, 120MO - Prognostic value of immune gene-expression signatures (iGES) vs. tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: a combined analysis of CALGB 40601 (C40601) and PAMELA trials. **ESMO Congress 2021**. Virtual.
16. D. Pinato, M. Patel, M. Lambertini, E. Colomba, F. Pommeret, M. Van Hemelrijck, A. Zambelli, T. Newsom-Davis, R. Salazar, A. Bertuzzi, G. Gaidano, G. Rizzo, G. Patel, E. Felip, **A. Prat**, J. Aguilar-Company, J. Tabernero, N. Diamantis, A. Gennari, A. Cortellini. 1565MO - Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: an updated analysis of the OnCovid registry. **ESMO Congress 2021**. Virtual.

17. Cristina Saura, Eva Ciruelos, Maria Vidal, Laia Garrigós, Mireia Margelí, Serafin Morales, Xvier Gonzalez-Farré, Javier Salvador Bofill, Isabel Blancas, Joan M Gasent, Elena López-Miranda, Ana Godoy, Maria Iglesias, Pedro Sánchez-Rovira, Fernando Hernao, Isabel Gallegos, Catarina Pulido, Sara Alves, Diogo Branco, José Passos-Coelho, Santiago Escrivá-de-Romaní, Juan M Ferrero-Cafiero, Patricia Villagrasa and **Aleix Prat**. Abstract OT-28-05: Solti-1718 NEREA trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-Enriched (HER2-E) advanced breast cancer (BC). **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
18. Enzo Batistella, Laia Paré, Mihir Sahasrabudhe, Tomás Pascual, Maria Vakalopoulou, Patricia Villagrasa, Eric Deutsch, Núria Chic, Guillermo Villacampa, Paolo Nuciforo, Javier Cortes, Antonio Llombart-Cussac, Nikos Paragios and **Aleix Prat**. Abstract PS5-13: Holistic artificial intelligence-driven predictor in HER2-positive (HER2+) early breast cancer (BC) treated with neoadjuvant lapatinib and trastuzumab without chemotherapy: A correlative analysis from SOLTI-1114 PAMELA. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
19. Nuria Chic, Stephen Luen, Paolo Nuciforo, Roberto Salgado, Debora Fumagalli, Florentine Hilbers, Yingbo Wang, Evandro de Azambuja, Itsvan Lang, Serena Di Cosimo, Cristina Saura, Jens Huober, **Aleix Prat** and Sherene Loi. Abstract PS5-03: Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
20. Eva Ciruelos, Tomás Pascual, Nuria Chic, Montserrat Muñoz, Begoña Bermejo, Juan Antonio Virizuela, Mafalda Oliveira, Silvia Vázquez, Salvador Blanch, Laia Paré, Fernando Salvador, Patricia Villagrasa and **Aleix Prat**. Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial). **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
21. Sung Gwe Ahn, Aranzazu Fernandez-Martinez, Mei-Yin C. Polley, Soong June Bae, Seho Park, Núria Chic, Fara Brasó-Maristany, Benedetta Conte, Valentina Guarneri, Maria Vittoria Dieci, Gaia Griguolo, PierFranco Conte, Joon Jeong, **Aleix Prat**, Lisa A. Carey and Charles M Perou. Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
22. Tomás Pascual, Juan M Cejalvo, Mafalda Oliveira, Maria Vidal, Estela Vega, Sergi Ganau, Ana Julve, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Luis de la Cruz-Merino, Manel Juan, Juan M Ferrero-Cafiero, Jordi Canes, Xavier González-Farré, Patricia Villagrasa and **Aleix Prat**. Abstract OT-13-06: Solti-1503 PROMETEO: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
23. Ana Casas, Eva Ciruelos, Mafalda Oliveira, Cristina Saura, Meritxell Bellet, Sonia Pernas, Joaquín Gavilá, Montserrat Muñoz, María Vidal, Blanca Gonzalez Farré, Juan M. Cejalvo, Rafael Lopez, Ana Vivancos, Maurizio Scaltriti, Javier S. Bofill, Isabel Blancas, Emilio Alba, Valentina Boni, Susana De la Cruz, Elena Galve, Antonia Perelló, Mireia Margelí, Jordi Canes, Pamela Céliz, Helena Masanas, Rosa Olmos, Marga Fonts, Pilar Fernandez-Pascual, Patricia Villagrasa and **Aleix Prat**. Abstract OT-17-01: Solti-1903 hope: Real-world clinical practice study to assess the impact of using comprehensive genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
24. Fara Brasó-Maristany, Laia Paré, Núria Chic, Olga Martínez-Sáez, Tomás Pascual, Meritxell Mallafré, Blanca González-Farré, Esther Sanfeliu, Débora Martínez, Patricia Galván, Belinda Salinas, Barbara Adamo, Reinaldo Moreno, Maria Vidal, Montserrat Muñoz and **Aleix Prat**. Abstract PS18-11: Molecular characterization of advanced breast cancer according to site of metastasis. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
25. **Aleix Prat**, Joaquin Gavilá, Sonia Pernas, Josefina Cruz, Cristina Saura, Esteban Nogales, Maria Bermejo, Javier Salvador Bofill, Vanesa Quiroga, Laura Garcia-Estévez, Serafin Morales, Sonia

- Servitja, Rubén del Toro, Patricia Galván, Núria Chic, Débora Martínez, Fara Brasó-Maristany, Jordi Canes, Laia Paré, Juan M Ferrero-Cafiero and Patricia Villagrasa. Abstract OT-03-07: Solti-1804 HER2-PREDICT: A biomarker research study of DS8201-A-U301 -U302 and -U303 trials. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
26. Eva Ciruelos, Patricia Villagrasa, Mafalda Oliveira, Sonia Pernas, Javier Cortes, Silvia Vazquez, Noelia Martínez, Antonia Perello, Begoña Bermejo, Eduardo Martínez, Isabel Garau, Mireia Melé, Alvaro Montaña, Estela Vega, Blanca Cantos, María Jose Echarri, Tomás Pascual, Jordi Canes, Pamela Céliz, Xavier González and **Aleix Prat**. Abstract OT2-02-06: Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
 27. Joaquín Gavilá, Cristina Saura, Tomás Pascual, Cristina Hernando, Montserrat Muñoz, Laia Paré, Blanca González Farré, Pedro Fernandez, Patricia Galván, Xavier González Farré, Mafalda Oliveira, Miguel Gil Gil, Miriam Arumi, Neus Ferrer Tur, Alvaro Montaña, Yan Izarzugaza, Antonio Llombart Cussac, Raquel Bratos, Santiago González, Eduardo Martínez, Sergio Hoyos, Beatriz Rojas, Juan Antonio Virizuela, Vanesa Ortega, Rafael López, Pamela Céliz, Eva Ciruelos, Patricia Villagrasa and **Aleix Prat**. Abstract GS2-06: Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
 28. Tomás Pascual, Patricia Villagrasa, María J Vidal, Sergi Ganau, Begoña Bermejo, Ana Julve, Esther Zamora, Ignacio Miranda, Estela Vega, Cristina Marquez, Mafalda Oliveira, Juan Miguel Cejalvo, Luis de la Cruz, Manel Juan, Jordi Canes, Xavier Gonzalez and **Aleix Prat**. Abstract OT1-01-01: SOLTI-1503 PROMETEO: Combination of talimogene laherparepvec (T-VEC) with atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
 29. Nuria Chic, Blanca González Farré, Laia Paré, Tomás Pascual, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Pedro Fernandez, Patricia Galván, Xavier González Farré, Mafalda Oliveira, Miguel Gil Gil, Pamela Céliz, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá and **Aleix Prat**. Abstract P2-11-01: Immune response following neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: A correlative analysis of the SOLTI-1402CORALLEEN phase 2 randomized trial. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
 30. **Aleix Prat**, Anwasha Chaudhury, Nadia Solovieff, Laia Paré, Debora Martinez, Nuria Chic, Olga Martínez, Fara Brasó-Maristany, Karen Rodriguez-Lorenc, Tetiana Taran, Naveen Babbar and Faye Su. Abstract GS1-04: Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. **2020 SABCS Virtual Symposium**; December 8-11, 2020; San Antonio, Texas.
 31. Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romaní, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montaña, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez and **Aleix Prat**. Abstract PD3-03: Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. **2020 AACR**.
 32. **Aleix Prat**, Anwasha Chaudhury, Nadia Solovieff, Laia Paré, Debora Martinez, Nuria Chic, Olga Martínez, Fara Brasó-Maristany, Karen Rodriguez-Lorenc, Tetiana Taran, Naveen Babbar, Faye Su. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. Oral Presentation GS1-04. **SABCS 2019**. San Antonio, Texas, USA.
 33. Núria Chic; Blanca González-Farré; Laia Paré; Tomás Pascual; Cristina Saura; Cristina Hernando; Montserrat Muñoz; Pedro Fernández; Patricia Galván; Xavier González-Farré; Mafalda Oliveira; Miguel Gil; Pamela Céliz; Eva Ciruelos; Patricia Villagrasa; Joaquín Gavilá and **Aleix Prat**. P2-11-01 - Immune response following neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: A correlative analysis of the SOLTI-1402 CORALLEEN

- phase 2 randomized trial. Poster Session. SABCS 2019. San Antonio, Texas, USA.
34. J. Gavilá, C. Saura, T. Pascual, C. Hernando, M. Muñoz, L. Paré, B. González Farré, P. L. Fernandez, P. Galván, X. González Farré, M. Oliveira, M. Gil Gil, M. Arumi, N. Ferrer Tur, A. Montaña, Y. Izarzugaza, A. Lombart Cussac, R. Bratos, S. González Santiago, E. Martínez, S. Hoyos, B. Rojas, J. A. Virizuela, V. Ortega, R. López, P. Céliz, E. Ciruelos, P. Villagrasa and **A. Prat.** GS2-06 - Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study. Oral communication. SABCS 2019. San Antonio, Texas, USA.
 35. Tomás Pascual, Patricia Villagrasa, María J Vidal, Sergi Ganau, Begoña Bermejo, Ana Julve, Esther Zamora, Ignacio Miranda, Estela Vega, Cristina Marquez, Mafalda Oliveira, Juan Miguel Cejalvo, Luis de la Cruz, Manel Juan, Jordi Canes, Xavier Gonzalez and **Aleix Prat.** OT1-01-01 - SOLTI-1503 PROMETEO: Combination of talimogene laherparepvec (T-VEC) with atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy. Session OT1-01. Immunotherapy. SABCS 2019. San Antonio, Texas, USA.
 36. Eva Ciruelos, Patricia Villagrasa, Mafalda Oliveira, Sonia Pernas, Javier Cortes, Silvia Vazquez, Noelia Martínez, Antonia Perello, Begoña Bermejo, Eduardo Martínez, Isabel Garau, Mireia Melé, Alvaro Montaña, Estela Vega, Blanca Cantos, María Jose Echarri, Tomás Pascual, Jordi Canes, Pamela Céliz, Xavier González and **Aleix Prat.** OT2-02-06 - Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial. Session OT2-02. Targeted - CDK4/6. SABCS 2019. San Antonio, Texas, USA.
 37. Sara Tolaney, Guy Jerusalem, Roberto Salgado, Xiaochun Liu, Tian Chen, Hongxia Zhang, Mustimbo Roberts, Dimitrios Zardavas and **Aleix Prat.** OT2-04-02 - CheckMate 7A8: A phase 2 trial of nivolumab + abemaciclib or palbociclib + anastrozole in postmenopausal women with ER+, HER2–primary breast cancer. Poster Session. SABCS 2019. San Antonio, Texas, USA.
 38. José Manuel Pérez-García, Antonio Lombart-Cussac, Esther Holgado, Giuseppe Curigliano, Elena López Miranda, José Luis Alonso-Romero, Begoña Bermejo, Lourdes Calvo, Vicente Carañana, Susana de la Cruz Sánchez, María Gión Cortés, Raúl Márquez Vázquez, **Aleix Prat**, Manuel Ruiz Borrego, Miguel Sampayo, Miguel Àngel Seguí, Jesus Soberino, Andrea Malfettone, Peter Schmid and Javier Cortés. P3-09-03 - A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study). Poster session. SABCS 2019. San Antonio, Texas, USA.
 39. Douglas Yee, Mafalda Oliveira, Hiroji Iwata, Anthony Gonçalves, Javier García-Corbacho, Marie Paule Sablin, **Aleix Prat**, Molly Catherine Hardebeck, Marta Puig, Dennis Chin-Lun Huang, Mingchi Hsu and Patricia LoRusso. P3-11-05 - A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts. Poster session. SABCS 2019. San Antonio, Texas, USA.
 40. N. Chic, T. Pascual, F. Brasó-Maristany, P. Villagrasa Gonzalez, L. Pare Brunet, F. Schettini, B. Conte, B. Adamo, M. Vidal, M. Muñoz, O. Martínez, B. Gonzalez-Farre, J. Cortés, A. Lombart-Cussac, V. odrik-Outmezguine, M.A. Izquierdo Delso, R. Schiff, C.K. Osborne, M. Rimawi, **A. Prat** - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials. 119P - Poster session. ESMO Annual Congress 2019. Barcelona, Spain.
 41. F. Schettini, T. Pascual, N. Chic, B. Conte, O. Martínez, B. Adamo, M. Vidal, M. Muñoz, A. Fernández-Martínez, G. Griguolo, V. Guarneri, P.F. Conte, S. De Placido, L. Carey, C. Perou, **A. Prat.** PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis. 248P - Poster session. ESMO Annual Congress 2019. Barcelona, Spain.
 42. M. Mallafré-Larrosa1, T. Pascual, N. Chic, O. Martínez, P. Galvan, B. Gonzalez-Farre, M. Vidal, M. Muñoz, B. Adamo, **A. Prat.** A retrospective gene expression analysis of surgically-removed Breast Cancer brain Metastasis (BCBM). 322P – Poster sesión. ESMO Annual Congress 2019.

Barcelona, Spain.

43. Pier Franco Conte, Gaia Griguolo, Maria Vittoria Dieci, Giancarlo Bisagni, Alba Ariela Brandes, Antonio Frassoldati, Luigi Cavanna, Antonino Musolino, Francesco Giotta, Anita Rimanti, Ornella Garrone, Patricia Galvan, Fara Brasó Maristany, Enrico Orvieto, Loredana Urso, Antonino Maiorana, Sara Balduzzi, Roberto D'Amico, Valentina Guarneri, **Dr. Aleix Prat**. PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial. Abstract No: 544. Poster Session. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
44. Enrique Grande, Félix Guerrero, Javier Puente, Isabel Galante, Ignacio Duran, Javier Fuentes, Teresa Alonso-Gordoa, Javier Burgos, Albert Font Pous, Oscar Buisan, Alvaro Pinto, Mario Alvarez-Maestro, Oscar Reig Torras, Pablo Maroto, Xavier Garcia del Muro, Patricia Galvan, Nuria Malats, **Aleix Prat**, Francisco X. Real, Daniel E. Castellano. DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores. Abstract No: TPS4588. Poster Session. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
45. Aranzazu Fernandez-Martinez, Maki Tanioka, Cheng Fan, Joel S. Parker, Katherine A. Hoadley, Ian E. Krop, Javier Cortes, Antonio Llombart Cussac, Paolo Nuciforo, Patricia Galván, Tomas Pascual, Ann H. Partridge, **Aleix Prat**, Lisa A. Carey, Charles M. Perou. Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. Abstract No: 571. Poster Session. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
46. Stephen James Luen, Gaia Griguolo, Paolo Nuciforo, Christine Campbell, Roberta Fasani, Javier Cortes, Michael Untch, Suling Joyce Lin, Peter Savas, Stephen B. Fox, Serena Di Cosimo, Antonio Llombart Cussac, Evandro de Azambuja, Martine J. Piccart-Gebhart, Lajos Pusztai, Christos Sotiriou, Roberto Salgado, **Aleix Prat**, Sherene Loi. On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. Abstract No: 574. Poster Session. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
47. Miguel J. Gil Gil, Francisco Javier Perez, Teresa Soler Monso, Tomas Pascual, Patricia Galván, Laia Pare, Anna Petit, Catalina Falo, Agostina Stradella, María Jesús Pla, Ramon Salazar, **Dr. Aleix Prat**. Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up. Abstract No: 575. Poster Session. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
48. Paolo Nuciforo, Dominik Hlascsek, Cristina Saura, Evandro de Azambuja, Roberta Fasani, Patricia Villagrasa, Karoline Muehlbacher, Christos Sotiriou, **Aleix Prat**, Georg Pfeiler, Florentine Hilbers, Timothy R. Wilson, Junko Aimi, Thomas Stout, Vicente Valero, Christian Fesl, Jose Baselga, Michael Gnant, Martine Piccart, Fabrice Andre. Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial. Abstract No: 1050. Poster Session. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
49. Laura Ferrer-Mileo; Laura Ferrer-Mileo; Adela Rodriguez; Nuria González; Mayra Orrillo; Natalia Jiménez; Mercedes Marín-Aguilera; Leonardo Rodriguez-Carunchio; **Aleix Prat**; Begona Mellado; Oscar Reig. Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience. DOI: 10.1200/JCO.2020.38.6_suppl.560 *Journal of Clinical Oncology* 38, no. 6_suppl (February 20, 2020) 560-560. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
50. Veronica Pereira Diaz, Mercedes Marin, Natalia Jiménez, Oscar Reig, Iván Victoria, Francis Esposito, **Aleix Prat**, Begona Mellado. Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes. DOI: 10.1200/JCO.2020.38.6_suppl.164 *Journal of Clinical Oncology* 38, no. 6_suppl (February 20, 2020) 164-164. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
51. Mayra Orrillo, Natalia Jimenez, Oscar Reig, Giancarlo Castellano, Albert Font, Montserrat Domenech, Alejo Rodriguez-Vida, Joan Carles, Cristina Suarez, Laura Ferrer, Nuria Gonzalez, Nuria Sala, Leonardo Rodriguez-Carunchio, Sherley Diaz, **Aleix Prat**, Mercedes Marin, Begona Mellado. Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC)

- patients. DOI: 10.1200/JCO.2020.38.6_suppl.165 *Journal of Clinical Oncology* 38, no. 6_suppl (February 20, 2020) 165-165. **2019 ASCO Annual Meeting**. Chicago, IL, EUA.
52. Pascual T, Pernaut C, Tolosa P, Galvan P, Bárcena C, Vidal M, Manso L, Adamo B, Dueñas M, Muñoz M, Chic N, Gonzalez-Farre B, Villagrasa P, Ciruelos E, **Prat A**. Tumor inflammation signature (TIS), intrinsic subtypes and chemo-endocrine score (CES) in metastatic triple-negative breast cancer (mTNBC): A SOLTI biomarker program study. Poster Session 2: Prognostic and Predictive Factors: Other. Poster# P2-08-17. **SABCS 2018**. San Antonio, Texas, EUA.
 53. Pascual T, Tsai YS, Martín M, Lluch A, Cortes J, Llombart A, Conte P, Guarneri V, Rimawi MF, Alba E, Ruiz-Borrego M, Rojo F, de la Haba J, Schiff R, Adamo B, Vidal M, Paré L, Chic N, Muñoz M, Galvan P, Gonzalez-Farre B, Brauer HA, Sullivan A, Nuciforo P, Parker JS, **Prat A**. Standardized nCounter-based determination of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor status in breast cancer. Poster Session 2: Prognostic and Predictive Factors: Other. Poster# P2-08-06. **SABCS 2018**. San Antonio, Texas, EUA.
 54. Ciruelos E, Villagrasa P, Paré L, Oliveira M, Pernas S, Cortés J, Soberino J, Adamo B, Vazquez S, Martínez N, Perelló A, Bermejo B, Martínez E, Garau I, Melé M, Morales S, Galván P, Pascual T, Canes J, Nuciforo P, Gonzalez X, **Prat A**. SOLTI-1303 PATRICIA phase II trial (STAGE 1) - Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer. Spotlight Session #3. Poster# PD3-03. **SABCS 2018**. San Antonio, Texas, EUA.
 55. **Prat A**, Adamo B, Pascual T, Perez Fidalgo JA, Blanch S, Martínez N, Gomez Pardo P, Lopez Gonzalez A, Murillo Jaso L, Amillano K, Vidal M, Paré L, Canes J, Galvan P, Gonzalez Farre B, Ortega Cebrián V, Gonzalez X, Bellet Ezquerro M, Villagrasa P, Ciruelos E. Anti-proliferative effect of oral metronomic vinorelbine (mVNB) in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): A randomized, three-arm, window-of-opportunity study. Poster Session #5. Prognostic and Predictive Factors: Predictive Biomarkers for Endocrine Therapies. Poster# P5-11-04. **SABCS 2018**. San Antonio, Texas, EUA.
 56. Brasó-Maristany F, Griguolo G, Llombart-Cussac A, Pascual T, Paré L, Bermejo B, Oliveira M, Morales S, Martinez N, Vidal M, Pernas S, Lopez R, Muñoz M, Galvan P, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Cortés J, **Prat A**. Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer. Poster Session #6. Treatment: Advanced Therapy - Targeted. Poster# P6-17-07. **SABCS 2018**. San Antonio, Texas, EUA.
 57. **Prat A**, Griguolo G, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, Pascual T, Paré L, Galvan P, Urso L, Conte P, Guarneri V. Independent validation of a combined biomarker based on the PAM50 HER2-enriched subtype and ERBB2 mRNA levels following HER2 blockade without chemotherapy in the PerELISA phase II trial. Poster Session #6. Treatment: Advanced Therapy - Targeted. Poster# P6-17-05. **SABCS 2018**. San Antonio, Texas, EUA.
 58. Griguolo G, Holgado E, Cortés J, Fasani R, Pascual T, Paré L, Bermejo B, Oliveira M, Morales S, Martínez N, Vidal M, Pernas S, Lopez R, Muñoz M, Galvan P, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Llombart-Cussac A, **Prat A**, Nuciforo P. Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy. Poster Session #6. Treatment: Advanced Therapy - Targeted. Poster# P6-17-08. **SABCS 2018**. San Antonio, Texas, EUA.
 59. Pernas S, Villagrasa P, Nuciforo PG, Vivancos A, Scaltriti M, Rodón J, Burgués O, Canes J, Dueñas M, Cecchi F, Vidal M, Lluch A, Perelló A, Llombart A, Dorca J, Montañó A, Oliveira M, Ribas G, Rapado I, Paré L, Prat A, Ciruelos E. Primary and secondary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study). Treatment: Advanced Therapy - Targeted. Poster #6-18-02. **SABCS 2018**. San Antonio, Texas, EUA.
 60. Salvador J, Ciruelos EM, **Prat A**, Jiménez-Rodríguez B, de la Cruz L, Martínez N, Villanueva Vázquez R, de Toro R, Antón A, Moreno F, Alvarez I, Gavila J, Quiroga V, Vicente E, de la Haba J, González-Santiago S, Díaz N, Barnadas A, Cantos Sánchez de Ibarra B, Delgado JI, Bellet M, Gimeno A, Sanz S, Martín M. Poster Session #6. Treatment: HER2-Targeted Therapy. Poster# P6-18-07. **SABCS 2018**. San Antonio, Texas, EUA.
 61. Crown J, Sablin M-P, Cortés J, Bergh J, Im S-A, Lu Y-S, Martínez N, Neven P, Lee KS, Morales S,

- Pérez-Fidalgo JA, Adamson D, Goncalves A, **Prat A**, Jerusalem G, Schlieker L, Espadero R-M, Bogenrieder T, Chin-Lun Huang D, Schmid P. Poster Session #6. Treatment: New Drugs and Treatment Strategies. Poster #6-21-01. **SABCS 2018**. San Antonio, Texas, EUA.
62. Tamara Díaz Redondo; Rocio Lavado Valenzuela; Begoña Apellidos Jimenez; Tomas Pascual; Fernando Galvez Montosa; Alejandro Falcón; Maria del Carmen Álamo; Marta Ámerigo; **Aleix Prat**; Emilio Alba Conejo. Incremento de la tasa de respuesta completa patológica en los distintos subtipos intrínsecos moleculares de cáncer de mama HER2+ con la adición de pertuzumab al tratamiento neoadyuvante con quimioterapia y trastuzumab. Seleccionada como Póster Destacado con el número P.DEST-1. **SEOM 2018**. Madrid, España.
 63. S. Loibl; O. Metzger; S. Mandrekar; C. Mundhenke; S. Seiler; P. Valagussa; A.M. DeMichele; E. Lim; D. Tripathy; E.P. Winer; C. Huang Bartlett; L. Carey; P. Francis; K. Miller; M.P. Goetz; A. **Prat**; S. Loi; I. Krop; L. Gianni; E. Ciruelos. A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive/HER2-Positive Metastatic Breast Cancer. **ESMO 2018 Congress**, 19-23 October, Munich, Alemania.
 64. **Prat A**; De Angelis C; Pascual T; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Krop I; Pavlick AC; Bermejo B; Hilsenbeck SG; Oliveira M; Schiff R; Osborne CK; Rimawi MF. HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: a combined analysis of TBCRC006/023 and PAMELA trials. Poster discussion No: 509. **2018 ASCO Annual Meeting**. Chicago, IL, EUA.
 65. Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Curtarello M; Pascual T; Pare L; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; **Prat A** and Conte PF. De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study. Abstract #216995. **2018 ASCO Annual Meeting**. Chicago, IL, EUA.
 66. Laurentiis MD; Neven P; Jerusalem G; Bachelot T; Jacot W; Dent S; Colleoni M; **Prat A**; Martin M; Ring A; Cottu P; Lu J; Azim HA; Zhou K; Wu J; Zarate JP; Zamagni C. Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b ComPLEEment-1 trial. Poster No: 1056. **2018 ASCO Annual Meeting**. Chicago, IL, EUA
 67. Tomás Pascual, Laia Pare, Patricia Galvan, Miguel A. Izquierdo, Vanessa Rodrik-Outmezguine, Barbara Adamo, Maria Vidal, Jamunarani Veeraraghavan, Rachel Schiff, C. Kent Osborne, Mothaffar F. Rimawi, Paolo Nuciforo, Aleix Prat. PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial. Poster No: 1025. **2018 ASCO Annual Meeting**. Chicago, IL, EUA
 68. Moreno Reinaldo, Óscar Reig, Francis Esposito, Victoria Sanchez, Patricia Rodriguez, Santiago Albiol, Miriam Cuatrecasas, Eva Hernández, Maria Vila-Cadasesús, Pedro Jares, Leire Pedrosa, Estela Pineda Losada, Jordi Camps, Aleix Prat, Juan Maurel. Association between genotypes, clinical scores and survival outcome in metastatic colorectal cancer. Poster No: 3553. **2018 ASCO Annual Meeting**. Chicago, IL, EUA.
 69. **Prat A**; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi G; Baselga J; Ciruelos E. PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): a correlative analysis of the phase III BOLERO-2 trial". **11th European Breast Cancer Conference (EBCC)**. Poster. Barcelona, España.
 70. Otto Metzger Filho, Sumithra Mandrekar, Eva. Ciruelos, Sibylle Loibl, Pinuccia Valagussa, Jane Lanzillotti, Elgene Lim, Debu Tripathy, Eric Winer, Cynthia Huang Bartlett, Lisa Carey, Prue Francis, Kathy Miller, Shom Goel, Matthew Goetz, **Aleix Prat**, Ian Krop, Luca Gianni, Angela DeMichele. A Randomized, Open-Label, Phase 3 Trial to Evaluate the Efficacy and Safety of

- Palbociclib + Anti-HER2 Therapy + Endocrine Therapy Versus Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer. **SABCS 2017**. San Antonio Breast Cancer Symposium. San Antonio, Texas, EUA. Abstract No: OT3-05-07.
71. Douglas Yee; Marie Paule Sablin; Hirojilwata; Erica L. Johnston; Thomas Bogenrieder; Josep Serra; Hairui Hua; Patricia Lo Russo; **Aleix Prat**. A phase I trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy). **SABCS 2017**. San Antonio Breast Cancer Symposium. San Antonio, Texas, EUA. Abstract No: OT3-06-02.
 72. **Aleix Prat**, Dennis Slamon, Sara A. Hurvitz, Michael F. Press, Gail Lewis Phillips, Vanesa Lopez Valverde, Astrid Kiermaier, Hans-Joachim Helms, Miguel Martin, Sanne L. de Haas. Association of intrinsic subtypes with pathological complete response in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer. **SABCS 2017**. San Antonio Breast Cancer Symposium. San Antonio, Texas, EUA. Abstract No: P2-09-04.
 73. Tomás Pascual; Maki Tanioka; M. Vittoria Dieci; Sonia Pernas; Joaquin Gavila; Valentina Guarnieri; Javier Cortes; Antonio Llombart; Pierfranco Conte; Mafalda Oliveira; Laia Paré; Patricia Galvan; Charles M. Perou; **Aleix Prat**; Lisa Carey. Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive/ HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy. **SABCS 2017**. San Antonio, Texas, EUA. Abstract No: P2-09-12.
 74. Sonia Pernas; Anna Petit; Fina Climent; Laia Paré; Javier Perez-Martin; Luz Ventura; Patricia Galvan; Catalina Faló; Idoia Morilla; Adela Fernández-Ortega; Agostina Stradella; Amparo Garcia-Tejedor; Tomás Pascual; Miguel Gil-Gil and **Aleix Prat**. PAM50 intrinsic subtyping as a predictor of pathological complete response to neoadjuvant trastuzumab-based chemotherapy in early HER2-positive breast cancer. **SABCS 2017**. San Antonio, Texas, EUA. Abstract No: P2-09-11.
 75. **Aleix Prat**, Carmine De Angelis, Tomás Pascual, Carolina Gutierrez, Tao Wang, Laia Paré, Brent Rexer, Javier Cortés, Andres Forero, Antonio Llombart, Antonio C Wolff, Ian Krop, Patricia Galván, Anne C. Pavlick, Patricia Villagrasa, Susan G Hilsenbeck, Rachel Schiff, C. Kent Osborne and Mothaffar F Rimawi. Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early stage HER2-positive breast cancer. **SABCS 2017**. San Antonio, Texas, EUA. Abstract No: P2-09-12-TBCRC.
 76. Nuciforo P; Holgado E; Llombart A; Fasani R; Paré L; Pascual T; Oliveira M; Martínez N; Bermejo B; Vidal M; Pernas S; López R; Muñoz M; Grarau, I; Manso I; Alarcón J; Martínez E; Villagrasa P; Cortes J; **Prat A**. PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial. **SABCS 2017**. San Antonio, Texas, EUA. Abstract No: P2-09-14.
 77. Gluz O; Liedtke C; **Prat A**; Christgen M; Gebauer D; Kates R; Pelz E; Clemens M; Warm M; Aktas B; Kuemmel S; Krabisch P; Laia P; Wuerstlein R; Nitz U; Kreipe H; Harbeck N. Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: results from the prospective WSG PlanB trial. **SABCS 2017**. San Antonio, Texas, EUA. Abstract No: P2-10-03.
 78. Lide Larburu; Laia Paré; Ricardo Rezola; Miren Carrera; Elvira Buch; Julia Gimenez; Vanesa Quiroga; Marta Fernandez; Sofía Aragón; Tomás Pascual; **Aleix Prat** and Ander Urruticoechea. Primary endocrine therapy (PETx) induces PAM50 intrinsic subtype migration with prognostic implications. **SABCS 2017**. San Antonio, Texas, EUA. Abstract No: P4-04-05.
 79. Eva Ciruelos; Patricia Villagrasa; Laia Paré; Mafalda Oliveira; Lorena de la Peña; Sonia Pernas; Javier Cortés; Jesús Soberino; Barbara Adamo; Silvia Vazquez; Noelia Martínez; Antonia Perelló; Begoña Bermejo; Eduardo Martínez; Isabel Garau; Mireia Melé; Serafín Morales; Patricia Galvan; Tomás Pascual; Paolo Nuciforo; Xavier Gonzalez and **Aleix Prat**. PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial. **SABCS 2017**. San Antonio, Texas, EUA. Abstract No: P5-20-19.

80. **Aleix Prat**; Dennis Slamon; Sara A. Hurvitz; Michael F. Press; Gail Lewis Phillips; Vanesa Lopez Valverde; Astrid Kiermaier; Hans-Joachim Helms; Miguel Martin; Sanne L. de Haas. Association of intrinsic subtypes with pathological complete response in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer. **SABCS 2017**. San Antonio, Texas, EUA. Abstract No: PD3-06.
81. Yee D; **Prat A**; Sablin MP; Iwata H; Johnston EL; Bogenrieder T; Serra J; Hua H; Lo Russo P. A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/- endocrine therapy), or non-small-cell lung cancer (NSCLC). **ESMO 2017**. Singapur. Asia.
82. P. Nuciforo, **A. Prat**, A. Llombart, R. Fasani, L. Paré, T. Pascual, M. Oliveira, N. Martínez Jañez, B. Bermejo De Las Heras, M. Vidal, S. Pernas Simon, R. López, M. Muñoz, I. Garau, L. Manso, J. Alarcon Company, E. Martinez de Dueñas, P. Villagrasa, J. Cortes Castan, E. Holgado. **Poster Discussion**. Tumor-infiltrating lymphocytes TILs in HER2-positive HER2+ early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial. **ESMO 2017**. Madrid. España.
83. Cejalvo JM; Pascual T; Fernández A; Adamo B; Chic N; Vidal M; Rodelo L; Muñoz M; **Prat A**; Poster. Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies. **ESMO 2017**. Madrid. España
84. B. Adamo, J.A. Perez Fidalgo, E. Ciruelos, M. Vidal, S. Blanch, A. Lopez, P. Gomez Pardo, L. Murillo, K. Amillano, N. Martínez Jañez, X. Gonzalez, J. Canes, **A. Prat**. POSTER. 214TiP VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial. **ESMO 2017**. Madrid. España.
85. P. Nuciforo, **A. Prat**, **A.** Llombart, R. Fasani, L. Paré, T. Pascual, M. Oliveira, N. Martínez Jañez, B. Bermejo De Las Heras, M. Vidal, S. Pernas Simon, R. López, M. Muñoz, I. Garau, L. Manso, J. Alarcon Company, E. Martinez de Dueñas, P. Villagrasa, J. Cortes Castan, E. Holgado. POSTER DISCUSSION. Tumor-infiltrating lymphocytes TILs in HER2-positive HER2+ early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial. **ESMO 2017**. Madrid. España
86. **Aleix Prat**, Douglas Yee, Marie Paule Sablin, Hiroji Iwata, Erica L. Johnston, Thomas Bogenrieder, Josep Serra, Kathrin Stucke-Straub, Patricia Lo Russo. POSTER. A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC). **ESMO 2017**. Madrid. España.
87. Juan Miguel Cejalvo, Tomás Pascual, Aranzazu Fernández-Martínez, Barbara Adamo, Nuria Chic, Maria Vidal, Luis Rodelo, Montserrat Muñoz, **Aleix Prat**. POSTER: Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies. **ESMO 2017**. Madrid. España
88. B. Adamo, J.A. Perez Fidalgo, E. Ciruelos, M. Vidal, S. Blanch, A. Lopez, P. Gomez Pardo, L. Murillo, K. Amillano, N. Martínez Jañez, X. Gonzalez, J. Canes, **A. Prat**.POSTER. 214TiP VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial. **ESMO 2017**. Madrid. España.
89. S. Pernas Simon, P. Villagrasa Gonzalez, A. Vivancos, **A. Prat**, M. Scaltriti, O. Burgues, J. Rodon, J. Canes, A. Lluch, A. Llombart, J. Dorca, A. Perelló Martorell, M. Oliveira, A. Montañó, L. Garcia-Estevez, P. Nuciforo, G. Ribas, I. Rapado, L. de la Pena, E. Ciruelos. POSTER. 315TiP AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain. **ESMO 2017**. Madrid. España.
90. P. Villagrasa Gonzalez, **A. Prat**, M. Oliveira, L. de la Pena, X. Gonzalez, J. Cortes Castan, J. Rios, J. Vázquez, N. Martínez Jañez, A. Perelló Martorell, I. Garau, E. Martinez de Dueñas, S. Morales, M. Melé, B. Bermejo De Las Heras, E. Ciruelos. POSTER. 321TiP SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer. **ESMO 2017**. Madrid. España.

91. O. Metzger, S. Mandrekar, E. Ciruelos, S. Loibl, P. Valagussa, A.M. Demichele, E. Lim, D. Tripathy, E.P. Winer, C. Huang, M. Khoeler, L. Carey, P. Francis, K. Miller, S. Goel, M.P. Goetz, **A. Prat**, S. Loi, I. Krop, L. Gianni. POSTER. 324TiP PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer. **ESMO 2017**. Madrid. España.
92. B. Adamo J. Perez Fidalgo E. Ciruelos M. Vidal S. Blanch A. Lopez P. Gomez Pardo L. Murillo K. Amillano N. Martínez Jañez X. Gonzalez J. Canes Ruiz **A. Prat**. 214TiP - VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial. **ESMO 2017**. Madrid. España.
93. S. Pernas Simon P. Villagrasa Gonzalez A. Vivancos **A. Prat** M. Scaltriti O. Burgues J. Rodon J. Canes Ruiz A. Lluch A. Llombart J. Dorca A. Perelló Martorell M. Oliveira A. Montañó L. Garcia-Estevez P. Nuciforo G. Ribas I. Rapado L. De la Pena E. Ciruelos 315TiP - AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain. **ESMO 2017**. Madrid. España.
94. P. Villagrasa Gonzalez; **A. Prat**; M. Oliveira; L. De la Pena; X. Gonzalez; J. Cortes Castan; J. Rios; J. Vázquez; N. Martínez Jañez; A. Perelló Martorell; I. Garau; E. Martinez de Dueñas; S. Morales; M. Melé; B. Bermejo De Las Heras; E. Ciruelos. 321TiP - SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer. **ESMO 2017**. Madrid. España.
95. O. Metzger; S. Mandrekar; E. Ciruelos; S. Loibl; P. Valagussa; A. Demichele; E. Lim; D. Tripathy; E. Winer; C. Huang; M. Khoeler; L. Carey; P. Francis; K. Miller; S. Goel; M. Goetz; **A. Prat**; S. Loi; I. Krop; L. Gianni. 324TiP - PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer. **ESMO 2017**. Madrid. España.
96. N. Jiménez; M. Marín-Aguilera; O. Reig; P. Fernández; S. García-Recio; M. Pereira; **A. Prat**; B. Mellado Gonzalez. 1680P - Reversion of epithelial-mesenchymal transition (EMT) as a mechanism of action of cabazitazell in castration-resistant prostate cancer. **ESMO 2017**. Madrid. España.
97. Teixidó C; Giménez-Capitán A; Meredith G; Martinez D; Mashadi-Hosseini A; Hernan C; Ross PM; Arcocha A; Galván P; Vilariño N; Lopez-Padres S; Rodriguez S; Bertran-Alamillo J; **Prat A**; Molina-Vila MA; Reguart N. Simultaneous Gene Profiling of Advanced NSCLC: Single-Molecule Quantification of DNA and RNA by nCounter3D™ Technology. IASLC 18th World Conference on Lung Cancer (**IASLC WCLC 2017**).
98. Vilariño N; Puig-Butille, JA; Reyes R; Victoria I; Arcocha A; Jares P; Viñolas N; González De Aledo JM; Molina R; Teixido C; **Prat A**; Reguart N. Correlation of EGFR Mutation Detection in CtDNA by Two Different Platforms in Advanced NSCLC. Patients from a Single Institution. Poster # 9475. IASLC 18th World Conference on Lung Cancer (**IASLC WCLC 2017**).
99. Douglas Yee; **Aleix Prat**; Marie Paule Sablin; Hiroji Iwata; Erica L. Johnston; Thomas Bogenrieder; Josep Serra; Hairui Hua; Patricia Lo Russo. Phase Ib trial of xentuzumab and abemaciclib in advanced or metastatic solid tumors, including advanced NSCLC. Poster presentation 1280.18. **WCLC 2017** (World Conference on Lung Cancer). 15–18 October 2017, Yokohama, Japan. Teixidó C; Giménez-Capitán A; Meredith G; Martinez D; Mashadi-Hosseini A; Hernan C; Martin P; Arcocha A; Galván P; Vilariño N; Lopez S; Rodriguez S; Bertran-Alamillo J; **Prat A**; Molina-Vila MA; Reguart N. Simultaneous Gene Profiling of Advanced NSCLC: Single-Molecule Quantification of DNA and RNA by nCounter3D™ Technology. IASLC 2017 18th World Conference on Lung Cancer. Yokohama, Japan.
100. Pascual T; Gávila J; Pérez J; Calvo I; Ciruelos E; Muñoz M; Paré M; Martínez D; Oliveira M; **Prat A**; Subtipos intrínsecos como factor predictivo de respuesta completa patológica (RCp) tras tratamiento neoadyuvante de cáncer de mama HER2positivo con quimioterapia y bloqueo dual con trastuzumab y pertuzumab. Estudio OPTIHERHEART (OHH). Comunicación Oral # O-35.

SEOM 2017. 24 al 27 de octubre. Madrid, España.

101. O. Metzger; S. Mandrekar; E. Ciruelos; S. Loibl; P. Valagussa; A. Demichele; E. Lim; D. Tripathy; E. Winer; C. Huang; M. Khoeler; L. Carey; P. Franci; K. Miller; S. Goel; M. Goetz; **A. Prat**; S. Loi; I. Krop; L. GianniPATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer. Abstract No 324TiP. **Congreso Anual ESMO 2017.** Madrid, España.
102. Gluz O; Liedtke C; **Prat A**; Christgen M; Gebauer D; Kates RE; Grischke EM; Forstbauer H; Braun MW; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kummel S; Wuerstlein R; Pelz E; Nitz U; Kreipe HH; Harbeck N. Molecular subtype, proliferation and immune genes are associated with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): results of the randomized WSG ADAPT-TN trial. **ASCO Annual Meeting.** Abstract #188021. 2-6 Junio, 2017. Chicago, IL, USA.
103. Gavilá J; Saura C; Oliveira M; Ortega V; Lopez R; Ciruelos EM; Gonzalez X; Zaragoza K; Pelaez Rivas A; de La Pena L; **Prat A.** CORALLEEN: A Phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer. **ASCO Annual Meeting.** Abstract #189618. 2-6 Junio, 2017. Chicago, IL, USA.
104. Marín-Aguilera M; Reig O; Jiménez N; Gaba L; López S; Prato J; Pereira MV, Vilella T; Domenech M; Porquet M; Font A; García-Mosquera JJ; Etxaniz O; Carrato C; Racc F; Suárez C; Fernández PL; **Prat A**; Mellado B. 2TMPRSS2_ERG predictive value for taxanes resistance according to prior second_line hormonal manipulations in metastatic castration resistant prostate cancer. 17-A-4794-AACR. **AACR Annual Meeting 2017.** 2 Abril, 2017. Washington, DC. EUA.
105. Reig O; Marín-Aguilera M; Jimenez N; Pare L; Galvan P; Mallofre C; **Prat A**; Mellado B. Molecular profile of sunitinib resistance in clear-cell renal cell carcinoma. Poster#: 5865. **AACR Annual Meeting 2017.** 2 Abril, 2017. Washington, DC. EUA.
106. Garcia-Recio S; Parker JS; Fan C; **Prat A**; Siegel M; Duronio GN; Perou CM. Identification of Genetic Drivers in HER2 Enriched/HER2negative Breast Cancer. Poster. **AACR Annual Meeting 2017.** 2 Abril 2017. Washington, DC. EUA.
107. Lydia Gaba, Ivan Victoria, Francisco Aya Sr., Gustavo Ruiz Sr., Estela Pineda, Oscar Reig, Aranzazu Fernandez-Martinez, **Aleix Prat**, Ana Arance. Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies Poster #178641. **ASCO-SITC Clinical Immuno-Oncology Symposium 2017.**Febrero, 2017. Orlando, FL, EUA.
108. Adamo B, Vidal M, Gomez Pardo P, Zaragoza K, Ciruelos E, Virizuela JA Antonio, Blanch Tormo S, Pérez-Fidalgo JA, Murillo L, Lopez-Gonzalez A, Amillano Parraga K, Martinez Jañez N, González Farré X and **Prat A.** VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial". OT1-01-04. **SABCS 2016.** San Antonio, Texas, EUA.
109. **Prat A**, Ortega V, Villagrana P, Paré L, Galván P, Oliveira M, Nuciforo P, Lluch A, Morales S, Amillano K, Lopez R, Gonzalez R, Manso L, Martinez J, Llombart A, De la Peña L, Di Cosimo S, Rubio IT T, Harbeck N, Baselga J and Cortés J. Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. P1-09-09. **SABCS 2016.** San Antonio, Texas, EUA. **SABCS 2016.** San Antonio, Texas, EUA.
110. **Prat Aparicio A**, Cortes Castan J, Pare L, Galvan P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Fasani R, Morales S, Oliveira M, de La Peña L, Peláez A and Llombart A. PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial. S3-03. **SABCS 2016.** San Antonio, Texas, EUA. **SABCS 2016.** San Antonio, Texas, EUA.
111. JM Cejalvo; E Martínez; P Galván; O Burgués; L Paré; Á Guerrero; F Rojo; J Albanell; A Lluch y **A Prat.** Cambios en el subtipo molecular intrínseco y expresión de genes entre tumor primario y metástasis en cáncer de mama. Comunicación Oral No. 021. **SEOM 2016.** Madrid, 26 Octubre

2016.

112. David Eduardo Posadas; Patricia Galván; Debora Martínez; Laia Paré; Jordina Munrós; Gorane Santamaría; Pedro Fernández; Irene Vives; Meritxell Mollà; Xavi Caparrós; Montserrat Muñoz; Aureli Torné; **Aleix Prat**; Inmaculada Alonso. Caracterización genómica del epitelio y estroma del CDIS correlación con los subtipos intrínsecos de cáncer de mama. 35º Congreso de la Sociedad Española de Senología y Patología Mamaria. **SESPM 2016**. Castellón, España.
113. N. Reguart, L. Paré, A. Giménez-Capitán, C. Teixidó, P. Galván, S. Viteri, S. Rodríguez, V. Peg, E. Aldeguer, E. Ovalle, N. Viñolas, S. Merkelbach-Bruse, F. Lopez-Rios, R. Rosell, M.Á. Molina-Vila, **A. Prat**. Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC). Poster, Abstract No 3348. NSCLC, metastatic. **ESMO 2016**. Copenhagen. 2016.
114. M.R. Chica-Parrado, A. Santonja, A. Lluch-Hernandez, J. Albanell, A. Sanchez-Muñoz, I. Chacón, L. Calvo, P. Sanchez-Rovira, J. De la Haba, L. Vicioso, M. Martin, A. Plazaola, **A. Prat**, N. Ribelles, M. Sánchez-Aragó, J. M. Jerez, M.J. Escudero, R. Caballero, E. Carrasco, E. Alba Conejo. Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer. Abstract No 187P. **ESMO 2016**. Copenhagen, Dinamarca.
115. J. de la Haba, A. Ruiz, M. Pollan, **A. Prat**, F. Rojo, M. Martin, E. Alba Conejo, J.A. Perez-Fidalgo, J. Gavilá, C. Morales, B. Navarro, A. Hernández-Blanquissett, I. Porras, A. Rodriguez-Lescure, B. Jiménez-Rodríguez, N. Martín, L. Pérez-Ramos, R. Caballero, E. Carrasco, A. Lluch-Hernandez. Gestational breast cancer: distinctive molecular and clinico-epidemiological features. GEICAM/2012-03 study. Abstract No 154PD. **ESMO 2016**. Copenague, Dinamarca.
116. I. Echavarría Diaz-Guardamino, S. Lopez-Tarruella, J.A. García-Sáenz, H. Gomez Moreno, F. Moreno, Y. Jerez, H. Fuentes, I. Marquez-Rodas, M. Cebollo, M. Del Monte-Millan, A. Picornell, T. Massarrah, A. Barnadas, **A. Prat**, A. Ballesteros García, R. Colomer Bosch, B. Pelaez, M. González-Rivera, C.M. Perou, M. Martin. Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC). Abstract No 188P. **ESMO 2016**. Copenhagen, Dinamarca.
117. N. Chic, G. Bruixola, O. Reig, R. Diaz- Beveridge, E. Buxo, E. Pineda, **A. Prat**, J. Aparicio, J. Maurel. Neutrophil-to-lymphocyte ratio as a biomarker for prognosis in localized colorectal carcinoma. Abstract No 597P. **ESMO 2016**. Copenague, Dinamarca.
118. Aya F, Gaba L, Victoria I, Fernandez-Martinez A, Ruiz-Esquide V, Pineda E, Tosca M, Viladot M, Pereira V, Malveyh J, **Prat A**, Arance A. Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. **ESMO 2016** Feb 8;1(1):e000032. DOI: 10.1136/esmooopen-2015-000032.
119. Cristina Teixido, Noemí Reguart, Ana Giménez-Capitán, Miguel Ángel Molina-Vila, Patricia Galván, Sonia Rodriguez, Laia Paré, Santiago Viteri, Vicente Peg, Zaira Yeste, Núria Viñolas, Rafael Rosell, **Aleix Prat**. Comparison of nCounter, immunohistochemistry, RT-PCR and FISH to detect ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC). ORAL, Abstract No 4344. **AACR 2016**. New Orleans, USA. 2016.
120. Y. Jane Han, Jing Zhang, Jennifer M. Mason, **Aleix Prat**, Toshio Yoshimatsu, Charles M. Perou, John Kwon, Prasanth Kannanganattu and Olufunmilayo I. Olopade. Long noncoding RNAs generated from the BRCA1 pseudogene regulate genomic instability and homologous recombination repair. Doi: 10.1158/1538-7445.AM2016-994 AACR 107th Annual Meeting 2016; April 16-20, 2016; **AACR 2016**. New Orleans, LA
121. Alejandro Navarro*; **Aleix Prat***; Ana Arance; Laia Paré; Patricia Galván; Alex Martínez; Paolo Nuciforo; Nuria Pardo; Susana Cedrés; Lydia Gaba; Ivan Victoria; Nuria Viñolas; Ana Vivancos; Noemí Reguart; Enriqueta Felip. Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types. **ASCO 2016**. Annual Meeting. McCormick Place, Chicago, IL, USA. 2016 (suppl; abstract No 3038).
122. Elia Seguí, Laia Paré; Ana Arance; Patricia Galván; Barbara Adamo; Estela Pineda; Mercedes Marin; Cecilia Orbegoso; Oscar Reig; Elvira Buxó; Javier Garcia; Montserrat Muñoz; Manel Juan; Victoria Sánchez; Margarita Viladot; Carme Font; Daniel Benítez; Cristina Nadal; Nuria Viñolas;

- Nuria de la Iglesia; Begoña Mellado; Joan Maurel; Noemí Reguart and **Aleix Prat**. Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: a TCGA pan-cancer analysis. **2016 ASCO Annual Meeting**. McCormick Place, Chicago, IL, 2016 (abstract No 3033).
123. Anderson WF, Rosenberg PS, **Prat A**, Perou CM, Sherman ME. Response. *J Natl Cancer Inst.* 2015 Feb 24;107(4). pii: djv029. doi: 10.1093/jnci/djv029. Print 2015 Apr. No abstract available.
124. Jimenez B; Lavado AI; Ribelles N; Sanchez-Rovira P; Vicioso L; Alvarez M; de Luque V; Ramirez C; Buckingham W; Schaper C; Jeiranian A; Dowidar N; Ferree S; Villar E; Zarcos I; Sanchez-Muñoz A; Gonzalez-Hermoso C; Llacer Perez C; **Prat A**; Alba E. Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients. *ASCO Annual Meeting*. McCormick Place, Chicago, IL. *J Clin Oncol* 33. **ASCO 2015**. (suppl; abstr 11049).
125. Villagrasa P; Gonzalez X; Oliveira M; Vazquez J; De La Pena L; Llobet-Canela M; **Prat A**; Ciruelos E. PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer. *ASCO Annual Meeting*. McCormick Place, Chicago, IL. *J Clin Oncol* 33. **ASCO 2015**. (suppl; abstr TPS642).
126. **Prat A**, Jimenez B, Sánchez P, Alvarez M, Vicioso L, De Luque V, Fernandez-Sousa C, Chica MR, Santonja A, Ramirez C, Lavado AI, Perez E, Gonzalez-Hermoso C, Buckingham W, Dowidar N, Ferree S, Jeiranian A, Schaper C, Ribelles N, Alba E. Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC). *ASCO Annual Meeting*. McCormick Place, Chicago, IL *J Clin Oncol* 33. **ASCO 2015**. (suppl; abstr 569) Gaba L; Victoria I; Pineda E; Fernandez A; Aya F; **Prat A**; Ana M Arance. Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. *ASCO Annual Meeting*. McCormick Place, Chicago, IL. *J Clin Oncol* 33. **ASCO 2015**. (suppl; abstr 9069).
127. F. Aya1, N. Viñolas, M. Sanchez, M. Benegas, O. Reig, A. Sosa, I. Vollmer, A. Arcoha, A. Martinez, M. Boillos, M. Viladot, **A. Prat**, N. Reguart. Early Predictive Value of Perfusion-Computed Tomography (pCT) in Advanced NSCLC Patients Treated with Bevacizumab: IMPACT Trial. 16th World Conference on Lung Cancer. **WCLC 2015**. (Abstr 2268).
128. N. Reguart, M. Gabasa, M. Puig, J. Ramirez, O. Busnadiago, F. Rodríguez-Pascual, **A. Prat**, P. Gascon, J. Alcaraz; Tumor-Associated Fibroblasts Increased Density in Non-Small Cell Lung Cancer Is Mediated by Microenvironment Through β 1/FAK Signaling. 16th World Conference on Lung Cancer. **WCLC 2015**. (Abstr 2250).
129. N. Reguart, A. Gimenez-Capitan, M.A. Molina, P. Galvan, L. Pare, S. Viteri, C.Teixidó, S. Rodriguez, J. Castellví, E. Aldeguer, N. Viñolas, R. Rosell, **A. Prat**. Detecting ALK, ROS1 and RET Fusion Genes in Advanced Non-Small Cell Lung Cancer (NSCLC) Using a Novel Multiplexed NCounter-Based Assay. ORAL, Abstract# 2254. Biology, Pathology, and Molecular Testing. 16th World Conference on Lung Cancer. **WCLC 2015**. Denver, Colorado, USA. 2015.
130. Eichhom, PJA; Serra, V; Garcia-Garcia, C; Ibrahim, YH ; Prudkin, L ; Parra, JL; **Prat, A**; Hahn, WC; Kim, SY; Baselga, J. p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer. **AACR 2015**. *Molecular Cancer Therapeutics*. Vol. 14, Núm: 7, Supo: S. Abstr B38.
131. **Prat A**, Cheang MCU, Galván P, Nuciforo P, Paré L, Adamo B, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S. Prognostic and predictive abilities of intrinsic subtype in hormone receptor-positive metastatic breast cancer from the EGF30008 phase III clinical trial. 2015 San Antonio Breast Cancer Symposium. **SABCS 2015**. (Abstract No P2-08-16).
132. **Prat A**, de la Haba-Rodriguez J, Guerrero Á, García-Sáenz JA, Morales S, Antón A, Muñoz M, Ramos M, Martínez-Jáñez N, Margelí M, Servitja S, Rojo F, Galván P, González S, Cruz J, Sánchez-Rovira P, Perelló A, Rodríguez-Martin C, Casas M, Carrasco E, Caballero R, Martín M. Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA Phase III clinical trial (GEICAM/2006-11_GBG 051). 2015 San Antonio Breast Cancer Symposium. **SABCS 2015**. (Abstract No P3-07-42).

133. **Prat A**, Ortega V, Paré L, Galván P, Oliveira M, Nucíforo P, Lluch A, Morales S, Amillano K, Lopez R, González R, Manso L, Martínez J, Llombart A, de la Peña L, di Cosimo S, Rubio IT, Harbeck N, Baselga J, Cortés J. Efficacy and gene expression results from eribulin SOLT11007 neoadjuvant study. 2015 San Antonio Breast Cancer Symposium. **SABCS 2015**. (Abstract No P3-07-66).
134. **Prat A**, Martínez de Dueñas E, Galván P, Garcia S, Burgués O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero Á, Muñoz M, Nuciforo P, Vidal M, Pérez RM, Chacón JI, Caballero R, Gascón P, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Lluch A. Intrinsic subtype and gene expression changes between primary and metastatic breast cancer. 2015 San Antonio Breast Cancer Symposium. **SABCS 2015** (Abstract No P6-05-02).
135. **Prat A**, Galván P, Buckingham W, Vidal M, Díaz S, Nuciforo P, Ferree S, Adamo B, Ramón y Cajal S and Peg V. Feasibility of the PROSIGNA® multigene test in core biopsies and comparison to corresponding surgical breast cancer sections. **SABCS 2014**. San Antonio Breast Cancer Symposium (SABCS). Abstract No: P10-02-04.
136. Eichhorn P JA;Serra V; Garcia-Garcia C; Ibrahim YH; Prudkin L; Parra JLI; **Prat A**; Hahn WC, Abstract B38: p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer, Abstracts: **2014 AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer**; September 14-17, 2014; Philadelphia, PA.
137. Bockhorn J; **Prat A**; Chang YF; Liu, X; Huang SM; Gomez-Vega, MJ; Harrell, JC; Olopade, OI; Perou, CM; Liu, HP. Differentiation and Loss of Malignant Character of Spontaneous Pulmonary Metastases in Patient-Derived Breast Cancer Models. Dec 15. **2014 AACR**. 74(24), 7406-7417. DOI: 10.1158/0008-5472.CAN-14-1188.
138. **Prat A**, Adamo B, Fan C, Peg V, Vidal M, Galvan P, Dawood S, Rodon J, Ramon y Cajal S, Del Campo JM, Felip E, Tabernero J, Cortés J. Identification of Gene Expression Commonalities across Six Cancer Types. **2013 ASCO Annual Meeting**. Abstract No: 1011.
139. Grushko T. A, Gomez-Vega M. J, **Prat A**, Mueller J, Coyle M, Perou Ch. M, Santa Cruz Guindalini R, Obeid E, Irie H, Olufunmilayo I. Olopade Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+ breast cancer as a mechanism of HER2 resistance. **J Clin Oncol** 31, 2013 (suppl; abstr 11021).
140. **Prat A**, Carey LA, Adamo BA, Vidal M, Perou CM, Baselga J, Cortés J, Fan C, Perou CM. PAM50 Molecular Features and Survival Outcomes of the Intrinsic Subtypes of Breast Cancer based on HER2 Gene Amplification. 2013 San Antonio Breast Cancer Symposium. **SABCS 2013**. Abstract No: P4-12-01.
141. Liu H, Bockhorn J, Dalton R, Nwachukwu C, **Prat A**, Yee K, Huang S, Swanson K, Perou CM, Olopade OI, Clarke MF, Greene GL. MicroRNAs regulate breast cancer stem cells and spontaneous metastases in orthotopic xenograft models. American Association for Cancer Research. **AACR 2012**. Annual Meeting 2012. Abstract No: 3331.
142. **Prat A**, Cheang MC, Martín M, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemical-defined Luminal A breast cancer. **IMPAKT 2012 Breast Cancer Conference 2012**. Abstract No: 126.
143. **Prat A**, Lluch A, Albanell J, Fan C, Lopez-Muniz JIC, Parker JS, Calvo L, Plazaola A, Lanza AA, Seguí-Palmer MA, Burgues O, Vicioso L, Sanchez-Simon R, Bermejo R, Ribelles N, Asensio BM, Caballero R, Carrasco EM, Perou CM, Alba E. Gene expression-based predictors of chemotherapy response in basal-like breast cancer. **ASCO 2012 Annual Meeting**. Abstract No: 10500.
144. Cheang MCU, Martin M, Nielsen TO, **Prat A**, Rodriguez-Lescure A, Ruiz A, Chia SKL, Shepherd LE, Voduc D, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. **2012 ASCO Annual Meeting**. Abstract No: 1008.
145. **Prat A**, Karginova O, Parker JS, Fan C, He X, Roman E, Bixby L, Harrell CJ, Troester M and Perou CM. Characterization of Cell Lines Derived from Breast Cancers and Normal Mammary Tissues for the Study of the Intrinsic Molecular Subtypes. American Association for Cancer Research (**AACR 2011**) annual meeting 2011. Abstract No: 1141.

146. **Prat A**, Parker JS, Fan C, Cheang MCU, Nielsen TO, Chia SKL, Bernard PS, Ellis MJ, Carey LA, Perou CM. Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. **2011 ASCO Annual Meeting**. Abstract No: 502.
147. Voduc D, Cheang MC, **Prat A**, He X, Tyldesley S, Snider J, DeSchryver K, Davies S, Ellis MJ, Perou CM, Nielsen T. The other triple-negative breast cancer: immunohistochemical and clinicopathological characterization of the claudin-low subtype. **2011 ASCO Annual Meeting**. Abstract No: 1129
148. **Prat A**, Bianchini G, Pickl M, Belousov A, Semiglazov V, Manikhas A, Eiermann W, Tjulandin S, Byakhov M, Lluch A, Zambetti M, Vazquez F, Gianni L, Baselga J. PAM50 intrinsic subtyping and pathological responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. **2011 ASCO Annual Meeting**. Abstract No: 554
149. Bianchini G, **Prat A**, Pickl M, Belousov A, Koehler A, Semiglazov V, Eiermann W, Tjulandin S, Biakhov M, Lluch A, Zambetti M, Vazquez FJ, Baselga J and Gianni L. Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis. **ASCO 2011 Annual Meeting**. Abstract No: 529.
150. Cheang M, **Prat A**, Fan C, Perou CM. PAM50 HER2-enriched subtype enriches for tumor response to neoadjuvant anthracyclines/taxane and trastuzumab/taxane containing regimens in HER2-positive breast cancer. 2011 San Antonio Breast Cancer Symposium. **SABCS 2011**. Abstract No: S5-2.
151. Cheang M, Parker JS, He X, Zhao W, Fan C, **Prat A**, Carey L, I-SPY Investigators and Perou CM. Hypoxia (VEGF) signature and CRYAB predict response to neoadjuvant anthracycline/taxane containing chemotherapy within triple negative and unselected breast tumors. **2010 SABCS San Antonio Breast Cancer Symposium**. Abstract No: 850401.
152. **Prat A**, Karginova O, Fan C, Perou CM. Notch-associated expression profiles in basal-like and claudin-low breast cancer molecular subtypes. **2009 ASCO Annual Meeting**. Abstract No: 11017.
153. Parker JS, **Prat A**, Cheang M, Lenburg. ME, Paik S, Perou CM. Breast cancer molecular subtypes predict response to antracycline/taxane-based chemotherapy. 2009 San Antonio Breast Cancer Symposium. **SABCS 2009**. Abstract No: 2019.
154. **Prat A**, Parker JS, Fan C, Karginova O, Livasy Chad L, Herschkowitz J, He X, Perou CM. Molecular characterization of the claudin-low intrinsic subtype of breast cancer. **AACR 2009 Special Conference in EMT and Cancer Progression and Treatment, Arlington, VA, USA**.
155. **Prat A**, Parera M, Adamo B, Peralta S, Martínez P, Pérez-Benavente MA, Gil-Montero A, Garcia A, Martínez-Palones JM, Baselga J, Del Campo JM. Prognostic significance of elevated pretreatment serum CA-125 in patients with epithelial ovarian cancer treated with platinum/taxane-based chemotherapy. **2008 ASCO Annual Meeting**. Abstract No: 22011.
156. Cedrés Pérez S, **Prat A**, Felip E, Peralta S, Perez J, del Campo J, Sala S, Andreu J, Pallisa E, Baselga J. Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlotinib in previously treated advanced non-small cell lung cancer (NSCLC). **2008 ASCO Annual Meeting**. Abstract No: 19125.
157. Tabernero J, Macarulla T, Capdevila J, **Prat A**, Ramos FJ, Elez E, Baselga J. Biopsy-driven biomarker development: pharmacodynamic studies in early clinical trials. The 14th European Cancer Conference (**ECCO 2007**), Barcelona, 2007. Abstract No: 160.
158. **Prat A**, Del Campo JM, Peralta S, Cedrés S, Perez A, Gil A, Garcia A, Martinez JM and Baselga J. Validation of CA-125 concentration nadir within the normal range following primary treatment as a predictor of survival for epithelial ovarian cancer (**EOC 2007**). **2007 ASCO Annual Meeting**. Abstract No: 16007.
159. **Prat A**, Cedrés S, Peralta S, Felip E. Cutaneous Rash as a Surrogate Marker for Tumor Progression in Patients with Non-Small Lung Cell Lung Cancer treated with Erlotinib. Sociedad Española de Oncología Médica (**SEOM 2007**). Spanish National Cancer Conference, Madrid, 2007.
160. Cedrés S, Felip E, **Prat A**, Rojo F, Majo J, Pallisa E, de Gracia J, Vilar E, Parera M, Baselga J. Comparison of epidermal growth factor receptor (EGFR) and downstream markers expression in samples from non-small-cell lung cancer (NSCLC) patients, at diagnosis and after progression

following platinum-based chemotherapy. 31st European Society for Medical Oncology Congress (**ESMO 2006**), 2006. Abstract No: 832PD.

Actividad Docente

- 2021- Coordinador del curso "Molecular Tumor Board". Cátedra UB de Innovación en Oncología de Precisión. España.
- 2019- Director del Master en Patología Mamaria- Senologia. Universitat de Barcelona. España
- 2018- Coordinador del Master en Patología Mamaria- Senologia. Universitat de Barcelona. España
- 2017-21 Coordinador de la asignatura optativa de Oncología Médica y radioterapia. 5 Curso del Grado de medicina. Facultad de Medicina y ciencias de la Salud. Universidad de Barcelona (UB). España.
- 2017-18 Profesor del Master de Urología Oncológica. Universidad de Barcelona. España.
- 2017- Profesor del Curso de Cursos Clínic de Formación Continuada en Obstetricia y Ginecología. Modulo de Ginecología oncológica. Hospital Clínic de Barcelona. España
- 2015-17 Profesor del Master de Medicina Translacional. Modulo 9: Clinical Trials design and evaluation of Molecular Therapies. Universidad de Barcelona. España.
- 2017- Professor of Clinical Research Master' degree: Systems Medicine. Faculty of Medicine and Health Sciences. University of Barcelona (UB). Spain.
- 2015- Profesor del Master de Medicina Translacional. Modulo 3: Medicina Translacional. Universidad de Barcelona. España
- 2015 VIII Curso Biología y Patología moleculares para médicos. Hospital Clínic de Barcelona. España.
- 2014- Profesor de la asignatura de Oncología médica y radioterápica. Grado en Medicina. Universidad de Barcelona (UB). España.
- 2014- Profesor del Màster de Recerca Clínica. Universidad de Barcelona. España.
- 2014- Profesor del Master en Patología Mamaria- Senologia. Universidad de Barcelona. España.
- 2014- Profesor del Master de Biomedicina. Bloque de cáncer de mama. Universidad de Barcelona. España.

Dirección de tesis

- Título: Uncovering the molecular and cellular mechanisms of metastatic dormancy in luminal breast cancer.
Autor: Juan Miguel Cejalvo
Defensa: 2020
Calificación: Magna Cum Laude
Universidad: Universitat de Barcelona
- Título: Caracterización de la expresión de ácido ribonucleico mensajero en distintos subtipos histológicos de carcinoma basocelular.
Autor: Patricia Bassas
Defensa: 25.10.2018
Calificación: Magna Cum Laude
Universidad: Universitat Autònoma de Barcelona
- Titulo: Implicació pronòstica de la infecció per virus del papiloma humà en tumors d'orofaringe i cavitat oral localment avançats irreseccables.

Autor: Victor Rodriguez Freixinos
Defensa: 27 de septiembre 2017
Calificación: Magna Cum Laude
Universidad: Facultad de Medicina. Universidad Autònoma de Barcelona

- Título: Marcadores predictivos de respuesta a quimioterapia primaria + trastuzumab en cáncer de mama HER2-positivo.
Autor: Sonia Pernas simon
Defensa: 17 de mayo 2017
Calificación: Magna Cum Laude
Universidad: Facultad de Medicina. Universidad de Barcelona

- Título: Caracterización Molecular de los Tumores Fibroepiteliales de la glándula mamaria.
Autor: Maria J. Vidal Losada
Defensa: 21 de enero 2016
Calificación: Magna Cum Laude
Universidad: Facultad de Medicina
Departamento de Medicina, Psiquiatría y Dermatología
Universidad de Zaragoza

Libros y Capítulos

1. **Prat A.** Capítulo 142. Introducción a la oncología médica. Volumen II. Sección VIII de **Oncología Médica. Rozman C. Farreras – Rozman. XIX Edición 2020.** Medicina Interna. Elsevier Spain. 2020. ISBN: 978-84-9113-545-6.
2. Muñoz M. **Prat A.** Reguart, N. Maurel J., Arance A. Capítulo 144. Tratamientos médicos en Oncología. Volumen II. Sección VIII de **Oncología Médica. Rozman C. Farreras – Rozman. XIX Edición 2020.** Medicina Interna. Elsevier Spain. 2020. ISBN: 978-84-9113-545-6.
3. Muñoz Mateu. Adamo B. Vidal M. **Prat A.** Grrau J. Reguart N. Viñolas N. Maurel J. Saurí T. Mellado B. Arance A. Gaba L. Capítulo 145. Diagnóstico y tratamiento de los principales tumores. Volumen II. Sección VIII de **Oncología Médica. Rozman C. Farreras – Rozman. XIX edición 2020.** Medicina Interna. Elsevier Spain. 2020. ISBN: 978-84-9113-545-6.
4. Núria Chic. Tomás Pascual. **Aleix Prat.** Actualizacion en oncologia ginecologica. Unidad de Ginecologia Oncologica. Capitulo 32. GENÓMICA Y TRATAMIENTO ONCOLÓGICO PERSONALIZADO. Editores: Aureli Torné, Jaume Pahisa, Pere Fusté ISBN 978-84-09-18567-2 Depósito legal. DL B 5261-2020.
5. **Prat A,** Pascual A. Capítulo DNA Circulante Tumoral Monografía “Factores pronósticos y predictivos en cáncer de mama. Una visión evolutiva de la morfología a la genética”. Fundación Española de Senología y Patología Mamaria. 2017. ISBN: 978-84-697-5070-4.
6. **Prat A,** Coordinación de la sección VIII de **Oncología Médica. Rozman C. Farreras - Rozman.** Medicina Interna. **XVII Edición 2016.** Elsevier España, S. L. ISBN: 978-84-9022-995-8. Pág. 1081-1118.
7. **Prat A,** Albanell J. Capitulo 138 Estrategia diagnóstica y terapéutica en oncología. Sección VIII de **Oncología Médica. Rozman C. Farreras - Rozman.** Medicina Interna. **XVII Edición 2016.** Elsevier España, S. L. ISBN: 978-84-9022-995-8. Vol. I, Pág. 1086-87.
8. Muñoz M, **Prat A,** Reguart N, Maurel J, Albanell J, Arance A, Capitulo 139. Tratamientos medicos en oncología. Sección VIII de **Oncología Médica. Rozman C. Farreras - Rozman.** Medicina Interna. **XVII Edición 2016.** Elsevier España, S. L. ISBN: 978-84-9022-995-8. Vol. I, Pág. 1087-94.
9. Muñoz M, **Prat A,** Grau JJ, Viñolas N, Reguart N, Vilar E, Maurel J, Mellado B, Arance A, Capitulo 140 . Estrategia diagnóstica y terapéutica en los principales tumores sólidos. Sección VIII de **Oncología Médica. Rozman C. Farreras - Rozman.** Medicina Interna. **XVII Edición 2016.** Elsevier España, S. L. ISBN: 978-84-9022-995-8. Vol. I, Pág. 1094-1114.

10. **Prat A, Albanell J. Vol I.** Capítulo 138. Estrategia diagnóstica y terapéutica en oncología. XVIII Edición 2016. Sección VIII Oncología Médica. **Rozman C. Farreras – Rozman. XVIII Edición 2016.** Medicina Interna. Elsevier Spain. ISBN: 978-84-9022-994-1.
11. **Muñoz M, Prat A, Reguart N, Maurel J, Albanell J, Arance A. Vol I.** Capítulo 139. Tratamientos médicos en oncología. Sección VIII Oncología Médica. **Rozman C. Farreras – Rozman. XVIII Edición 2016.** Medicina Interna. Elsevier Spain. ISBN: 978-84-9022-994-1.
12. **Muñoz M, Prat A, Grau JJ, Viñolas N, Reguart N, Vilar E, Maurel J, Mellado B, Arance A. Vol I.** Capítulo 140. Estrategia diagnóstica y terapéutica en los principales tumores sólidos. Sección VIII Oncología Médica. **Rozman C. Farreras – Rozman. XVIII Edición 2016.** Medicina Interna. Elsevier Spain. ISBN: 978-84-9022-994-1.
13. **Prat A, Cortes J.** Perfiles de expresión génica en cáncer de mama. Primera edición 2015. Editor: Transworld Editores. Barcelona, España. ISBN: 97884-941494-1-2. Pages: 243.
14. **Prat A.** Molecular Biology of Lung Cancer in Early Disease. In: Molecular Biology of Lung Cancer. Publisher: Ferrer Incode, 2008, Barcelona, España.
15. **Prat A, Del Campo JM.** Chemotherapy for epithelial ovarian cancer after platinum-sensitive and/or platinum-resistance recurrence. In: Highlights from ASCO 2008. Publisher: Permanyer Publications, 2008, Barcelona, Spain.
16. Ruiz I, **Prat A, Cortés J.** Targeted Therapies in Oncology/Hematology and Prophylactic Management of Infectious Diseases. First Edition, 2007. Publisher: Vall d'Hebron University Hospital Guidelines. Pages: 18.
17. **Prat A.** OncoQuest. First Edition, 2007. Publisher: Elsevier, Madrid, Spain. ISBN: 978-84-8086-292-9. Pages: 310.
18. Jimenez P, **Prat A.** Medical Oncology. First Edition, 2005. Publisher: Curso Intensivo MIR Asturias, Oviedo, Spain. Pages: 300.
19. **Prat A, Jimenez P.** Board Exams: 2,600 Multiple-Choice Questions. Primera edición, 2004. Editor: Curso Intensivo MIR Asturias, Oviedo, Spain. Pages: 600.

Experiencia en técnicas de laboratorio

- In vitro cell culture / transfection.
- In vivo tumor and normal tissue handling.
- Fluorescent activated cell sorting (FACS).
- Cell migration / invasion / mammosphere assays.
- Mouse handling (cell injection, treatment administration...).
- RNA/DNA purification.
- Gene Expression using Agilent Microarrays.
- Gene Expression using Nanostring.
- Gene Expression using Illumina RNAseq.
- Statistical Analyses using R Code 2.10, SPSS and Winstat.

Investigador principal (IP) y Co-IP en multi-centro y/o ensayos clínicos internacionales

24 ensayos clínicos como IP y **43** como Co-IP

Investigador Principal en Ensayos Clínicos

1. **PAMELA.** PAM50 HER2-Enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-Positive breast BREAST CANCER.
2. **PATRICIA.** A Phase II study of palbociclib and trastuzumab with or without letrozole in pretreated HER2-positive metastatic breast cancer patients
3. **CBYL719A2201.** Phase II randomized, double-blind Clinical Trial with placebo-controlled of letrozole with or without BYL719 or buparlisib for neoadjuvant treatment of postmenopausal

women with breast cancer ER positive and HER2 negative.

4. **ALTERNATIVE.** Phase III Clinical Trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an IA and versus lapatinib plus an IA as first or second line therapy in postmenopausal patients with metastatic breast cancer (MBC) HER2-positive and ER positive who have previously received trastuzumab and endocrine therapies.
5. **SANDPIPER.** Phase III randomized Clinical Trial, double-blind with placebo-controlled of tasisib and fulvestrant versus placebo and fulvestrant in postmenopausal women with ER-positive and HER2-negative breast cancer, locally advanced or metastatic, with recurrence or progression disease during or after treatment with an aromatase inhibitor.
6. **BI1280.4.** Phase Ib/II randomized Clinical Trial of BI 836845 in combination with exemestane and everolimus versus exemestane and everolimus in women with locally advanced or metastatic breast cancer.
7. **ARRAY (MILO).** Recurrent/persistent low grade serous carcinomas ovary fallopian tube or primary peritoneum.
8. **CORAIL.** Phase III randomized Clinical Trial Of Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Patient with platinum-resistant ovarian cancer.
9. **SOLO3.** Open, multicenter, randomized, controlled phase III Clinical Trial to evaluate the efficacy and safety of olaparib monotherapy versus chemotherapy with a single agent of physician choice in the treatment of ovarian cancer relapsed platinum-sensitive in patients carrying the germinalesBRCA1 mutations study /2.
10. **ABBVIE.** A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
11. **GEICO1402R.** Study post-authorization retrospective and multicenter to analyze the effectiveness and safety of the combination of trabectedin and pegylated liposomal doxorubicin (DLP) for the treatment of patients with recurrent ovarian cancer, platinum-sensitive, according to the technical data sheet.
12. **EGF117165.** Phase II study, open, to evaluate biomarkers associated with the response to subsequent therapies in patients with metastatic HER2-positive who received treatment Trastuzumab in combination with Lapatinib or chemotherapy.
13. **METRIC:** Estudio pivotal aleatorizado y multicéntrico de CDX-011 (CR011-vcMMAE) en pacientes con cáncer de mama triple negativo metastásico con sobreexpresión de GPNMB.
14. **TVEC.** A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors.
15. **CBYL719Z2102:** A phase Ib dose-finding study of BYL719 plus everolimus and BYL719 plus everolimus plus exemestane in patients with advanced solid tumors, with dose-expansion cohorts in renal cell cancer (RCC), pancreatic neuroendocrine tumors (pNETs), and advanced breast cancer (BC) patients.
16. **PALLAS PALbociclib CoLLaborative Adjuvant Study:** A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
17. **PHERGain:** Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy.
18. **COMPLEEMENT-1:** An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.
19. **BGB324 BGBC007** A phase II multicenter study of BGB324 in combination with pembrolizumab

in patients with previously treated locally advanced and unresectable or metastatic TNBC or TN-IBC.

20. **MO39196 (IMPASSION):** A Phase III, Multicenter, Randomised, Double-blind, Placebo controlled study of atezolizumab (Anti-PD-L1 Antibody) in combination with paclitaxel compared with placebo with paclitaxel for patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer.
21. **AFT –38 (PATINA):** A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer.
22. **BYLieve.** Phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment.
23. **IMPASSION-1 MO39196.** A Phase III, Multicenter, randomised, double-blind, placebo-controlled study of atezolizumab (Anti-PD-L1 Antibody) in combination with paclitaxel compared with placebo with paclitaxel for patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer.
24. **CRONOS.** Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS.

Co-Investigador en Ensayos Clínicos

1. **XL147-001.** Phase I Dose-Escalation study of the safety and pharmacokinetics of XL147 administered orally daily to subjects with solid tumors.
2. **IMCL CP11-0602.** Phase II Multicenter, Open-label Study evaluating the efficacy and safety of IMC-11F8, a potent fully human IgG1 monoclonal antibody to EGFR, in combination with 5-FU/FA and oxaliplatin (modified FOLFOX-6) in patients with treatment-naïve locally-advanced or metastatic colorectal cancer.
3. **EudraCT Nr: 2006-006370-25.** Phase 2, Randomized, Open Label, Multicenter study of intradermal IMA901 Plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.
4. **C0328T07.** Phase II Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in combination with mitoxantrone versus mitoxantrone in subjects with metastatic hormone-refractory prostate cancer.
5. **EORTC 30986.** Randomised Phase II/III study assessing gemcitabine with carboplatin and methotrexate with carboplatin and vinblastine in previously untreated patients with urothelial cancer ineligible for cisplatin based chemotherapy.
6. **A4021011.** Phase II Study of CP-751,871 (monoclonal antibody against the IGF1R) in Combination with Docetaxel and Prednisone in Hormone Refractory Prostate Cancer.
7. **WO20024.** Study of Pertuzumab in Combination with Tarceva (Erlotinib) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
8. **CA183-002.** First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy.
9. **CEPO906A.** Phase I/II Dose Escalation Trial of EPO906 every 3 Weeks in Patients with Non-small cell lung cancer (NSCLC).
10. **BO17705.** Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients with Metastatic Renal Cell Cancer with Nephrectomy.

11. **AVADO trial, BO17708.** Phase III Study of Avastin (Bevacizumab) in Combination with Docetaxel in Women with HER2 Negative Metastatic Breast Cancer.
12. **BO17931.** Study to Evaluate the Effect of the Combination of Pertuzumab with Carboplatin-Based Standard Chemotherapy in Patients with Recurrent Ovarian Cancer.
13. **ARD6122; AVE0005.** VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer (EOC).
14. **EGF104334.** Study Of Lapatinib versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer.
15. **E7389-G000-301.** E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine Therapy.
16. **BO17929.** Study of Omnitarg (Pertuzumab) in combination with herceptin in patients with metastatic breast cancer.
17. **A8641020.** Phase II clinical Trial of Single-agent PF-03084014 in patients with advanced triple-negative breast cancer with or without genomic alterations in notch receptors.
18. **OPTIHERHEART.** Phase II Multicenter, single-arm clinical trials to evaluate the safety of liposomal doxorubicin (Myocet®), paclitaxel, trastuzumab and pertuzumab as neoadjuvant therapy in patients with HER2 positive breast cancer prospective.
19. **TNACITY.** Phase II/III, multicenter, open, randomized nab®-Weekly combined paclitaxel with gemcitabine or carboplatin, compared with gemcitabine/carboplatin as first-line therapy in patients with metastatic breast cancer, ER, PgR and HER2 NEGATIVE (triple negative).
20. **GEICAM/2010-04.** Phase I/II clinical trial of dasatinib in combination with trastuzumab and paclitaxel as first line treatment in patients with HER2 + MBC.
21. **BAY 88-8223/16298.** Phase II randomized clinical trial, double-blind, placebo-controlled dichloride radium-223 compared with placebo when its given to patients with breast cancer of negative metastatic HER2, positive for hormone receptors and with bone metastases treated with hormone therapy base.
22. **BAY 17096.** Phase II Randomized, Double-blind, Placebo-controlled Clinical trial of radium-223 dichloride compared to placebo when administered with everolimus exemstano ER +.
23. **ETNA** Neoadjuvant chemotherapy with nab-paclitaxel in womwn with HER2 negative high-risk breast cancer.
24. **RXPONDER.** Randomized Phase III clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with Recurrence Score (RS) of 25 or less.
25. **KATHERINE.** Open, multicenter and randomized phase III Clinical Trial to assess the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with breast cancer primary HER2-positive morbidly presence of residual tumor in the breast or lymph node Axillary after preoperative treatment.
26. **PEARL.** Palbociclib + QT after progression on aromatase inhibitors Non steroidus.
27. **CHANG-HER.** Phase III clinical trial for analyzing patient preference for the use of trastuzumab SC vs IV in patients with breast cancer.
28. **PENELOPEb.** Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.
29. **BELLE3.** Progresion to Everolimus+ Exemestano.
30. **MOMALEESA-3.** Estudio aleatorizado, doble ciego, controlado con placebo de ribociclib en combinación con fulvestrant para el tratamiento de mujeres postmenopáusicas con cáncer de mama avanzado con receptor hormonal positivo, HER2-negativo que no han recibido o que sólo han recibido una línea de tratamiento endocrino previa.
31. **B3271002.** Phase 3, Randomized, Double-Blind Study of PF-05280014 Plus Paclitaxel Versus

Trastuzumab Plus Paclitaxel For The First Line Treatment of Patients With HER2-Positive Metastatic Breast Cancer.

32. **CEL-CMM-2013-01.** TUDDi in metastatic breast cancer patients treated with second line chemotherapy in monotherapy.
33. **ULTIMATE.** A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant.
34. **EMBRACA Estudio de fase III.** Aleatorizado, paralelo, con 2 brazos y multicéntrico sobre Talazoparib (BMN 673) en comparación con la elección del médico en pacientes con mutaciones en la línea germinal de BRCA con cáncer de mama localmente avanzado y/o metastásico, que han recibido quimioterapia previa para la enfermedad metastásica.
35. **MONARCHE.** A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with standard adjuvant endocrine therapy vs standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR positive, HER2 negative, Breast Cancer.
36. **SYD985.002.** A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer.
37. **HER2Climb.** Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Ca.
38. **MERUS-MCLA-128.** Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC.
39. **KELLY.** A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes.
40. **POSEIDON.** Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alone in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment.
41. **LUCY.** A phase III b single-arm, open label multicentre study of olaparib monotherapy in the treatment of HER2-ve metastatic breast cancer patients with germline BRCA 1/2 mutations.
42. **GEICAM/2015-06-COMET A.** A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer.
43. **IPATUNITY-CO400216.** A double-blind, placebo-controlled, randomized phase III study of ipatasertib in combination with paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-ALTERED, Locally advanced or metastatic, triple-negative breast cancer or hormone receptor-positive, HER2-Negative breast cancer.